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Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy that 
results from the unregulated growth of B-cell and T-cell lymphoid progenitors. Despite 
the implementation of risk-stratification and improved multi-agent therapeutic regimens, 
20% of pediatric and 50% of adult patients fail to achieve remission and end up 
relapsing. NT5C2 (5’ cytosolic nucleotidase II) is the most frequently mutated gene 
specifically found in relapsed ALL. NT5C2 mutations are present in 20% of relapsed T-
ALLs and 3-10% of relapsed B-ALLs and present as heterozygous gain of function 
alleles exhibiting increased nucleotidase activity. As NT5C2 can dephosphorylate and 
inactivate the cytotoxic metabolites generated by 6-mercaptopurine, a chemotherapy 
used in the treatment of ALL, these NT5C2 activating mutations can contribute to 
thiopurine chemotherapy resistance (Tzoneva, Perez-Garcia et al. 2013). 
 
Here we perform an extensive structure-function study to understand how relapse-
associated NT5C2 mutations result in increased nucleotidase activity and contribute to 
chemotherapy resistance in ALL. Crystallization of 15 NT5C2 WT and mutant structures 
as well as enzymatic, structural modeling, and genetic screens identified three regulatory 
mechanisms of NT5C2, which are disrupted by these gain of function alleles. Class I 
NT5C2 mutations lock the protein in an active configuration through stabilization of the 
helixA region, which allows for substrate processing and catalysis. Class II NT5C2 
mutations disrupt an intramolecular switch off domain involving the arm region and the 
intermonomeric positively charged pocket. And a single C-terminus truncating mutant 
creates a third class of mutations, which show increased nucleotidase activity due to the 
loss of the C-terminus blockade against allosteric activation. These studies provide new 
insight into the regulatory controls that mediate NT5C2 activity providing a framework for 
the development of targeted inhibitors for the treatment of relapsed ALL. 
 
In addition to looking at relapse associated NT5C2 mutations on a structural level, we 
also explored how NT5C2 mutations shape the clonal architecture and evolutionary 
dynamics during tumor initiation and disease progression in ALL. To formally address 
these questions, we developed a murine NOTCH1-driven T-ALL with conditional knock-
in of the Nt5c2R367Q mutation, the most recurrent mutation found in relapsed ALL, from 
the endogenous locus. Using this model, we confirmed that Nt5c2+/R367Q lymphoblasts 
show increased resistance to 6-MP in vitro and in vivo. We also found that Nt5c2+/R367Q 
mutant lymphoblasts exhibit impaired cell fitness and decreased leukemia initiating cell 
capacity. Metabolomic profiling and guanosine rescue experiments show that this 
decrease in cell fitness is due to excess clearance of purine metabolites out of the cell 
as a result of deregulated Nt5c2 nucleotidase activity. However, in the context of 6-MP 
therapy, Nt5c2+/R367Q mutant cells are positively selected for in mixed population studies 
in vitro and in vivo. These results identify a clear selective advantage for NT5C2 mutant 
cells in the context of 6-MP chemotherapy. In addition, NT5C2 mutant chemoresistant 
cells show collateral sensitivity to inhibition of inosine monophosphate dehydrogenase 
(IMPDH) with mizoribine, which further disrupts guanosine production pointing to a 
potentially selective therapy against NT5C2 mutant cells. 
 
We also show here the initial development of a small molecule NT5C2 inhibitor for the 
treatment of relapsed ALL. Using a malachite green based NT5C2 nucleotidase assay, 
we performed a small molecule high throughput assay and identified HTP_2 as a lead 
compound with low micromolar inhibitory activity against NT5C2 R367Q mutant 
recombinant protein. HTP_2 can reverse 6-MP resistance in Nt5c2+/R367Q mouse 
lymphoblasts and NT5C2 R29Q mutant expressing human cell lines. Interestingly, 
HTP_2 treatment also results in increased sensitivity to 6-MP therapy in NT5C2 wild-
type cells, suggesting a role for wild-type NT5C2 activity in the clearance of 6-MP and 
supporting a potential therapeutic use for NT5C2 inhibitors in potentiating the effects of 
6-MP based chemotherapy in NT5C2 wild-type cells as well. NT5C2 knockdown cells 
and Nt5c2 knockout mice show no apparent toxicities suggesting that systemic inhibition 
of NT5C2 could be fairly well tolerated. In all, this work presents a framework for the 
development of a high affinity NT5C2 inhibitor for the reversal of 6-MP resistance in 
relapsed ALL patients. 
 
These studies presented here address the role of NT5C2 mutant proteins as drivers of 
resistance and as therapeutic targets in relapsed ALL. Improved understanding of the 
molecular mechanisms responsible for increased NT5C2 nucleotidase activity and on 
the process of clonal evolution during disease progression provide important insight into 
the mechanism driving ALL resistance and relapse. The identification of IMPDH 
inhibition as a collateral vulnerability in NT5C2 mutant ALL cells and the development of 
a first-in-class NT5C2 inhibitor serve as framework for the development of new 
combination therapies aimed at curtailing the emergence of these thiopurine-resistant 
relapse driving clones in ALL.  
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Chapter 1: Introduction 
 
 






Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy of 
immature lymphoid cells in the bone marrow and blood. Leukemia was first described by 
Rudolf Virchow and John Hughes Bennet independently in 1845 (Kampen 2012). Upon 
realizing that his patients had more white blood cells than red cells, Virchow named the 
phenomenon “weisses blut” in German (‘white blood’ in English) or “Leukemia” in Greek 
(Patlak 2002, Kampen 2012).  
 
Presenting morphology 
ALL patients commonly present in the clinic with neutropenia, anemia, 
thrombocytopenia, elevated white blood cell counts, diffuse infiltration of immature 
lymphoblasts in the bone marrow, and hematopoietic failure (Hunger and Mullighan 
2015). Infiltration of lymph nodes, spleen, and liver are common, and in the case of ALL 
tumors derived from T-cell progenitors (T-ALL) patients can present with mediastinal 
thymic masses. In addition, some patients show meningeal infiltration in the central 
nervous system at diagnosis. ALL patients commonly present with infections, easy 
bruising and fatigue as a result of low blood cell counts (Alvarnas, Brown et al. 2015, 
Terwilliger and Abdul-Hay 2017). Diagnosis is confirmed by the presence of 20% or 
more lymphoblasts in the bone marrow, which initiates further immunophenotyping, 
cytogenetic testing, and in some cases DNA-sequencing to further classify and treat the 




Acute lymphoblastic leukemia is a malignancy of both children and adults with about 
80% of cases occurring in pediatric patients and 20% of cases occurring in adults 
(Terwilliger and Abdul-Hay 2017, Siegel, Miller et al. 2018). In children, ALL is the most 
common cancer accounting for 26% of all cancers diagnosed before the age of 14 
(Ward, DeSantis et al. 2014). In the United States there are about 30 patients diagnosed 
with ALL per million people ages 20 and below, with the highest incidence between ages 
3 and 5 (Ries LAG Bethesda, MD, 1999.). There is a second peak of increased 
diagnosis for adults around 50 years of age. Overall, the age-adjusted incidence of ALL 
in the United States is 1.7 per 100,000 men and women per year as of 2015 (Paul, 
Kantarjian et al. 2016). Incidence of ALL also varies greatly depending on gender, race, 
and ethnicity. Hispanic and white children are at a higher risk of developing ALL than 
African American children, and ALL is much more frequent in boys than in girls (Lim, 
Bhatia et al. 2014, Hunger and Mullighan 2015, Siegel, Henley et al. 2017, Siegel, Miller 
et al. 2018). 
 
Genetic Landscape of ALL 
Genetic abnormalities commonly found in ALL include aneuploidy, chromosomal 
rearrangements, copy number alterations, and point mutations all of which work together 
in a coordinated multistep process contributing to lymphoid cell transformation (Harrison 
2009). Common pathways altered in ALL include but are not limited to, transcriptional 
regulation of lymphoid development and differentiation pathways, cell-cycle regulation, 
tumor suppressor pathways, growth factor signaling, RAS signaling, phosphatidylinositol 
3-kinase pathways, and JAK stat signaling (Ferrando, Neuberg et al. 2002, Mullighan, 
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Su et al. 2009, Mullighan, Zhang et al. 2009, Harvey, Mullighan et al. 2010, Zhang, 
Mullighan et al. 2011).  
 
ALL can be derived from B-precursor or T-precursor lymphoid progenitors. B-precursor 
ALL (B-ALL) accounts for 80-85% of all cases (Tasian and Hunger 2017). B-ALL and T-
ALL can be sub classified into different clinic-biological groups based on the presence of 
chromosomal alterations and genetic lesions associated with therapeutic response and 
prognosis (Table 1.1) (Vardiman, Thiele et al. 2009, Alvarnas, Brown et al. 2015, Arber, 















Hyperdiploidy            
(>50 chromosomes) -- 7% 25% 
Hypodiploidy             
(40-44 chromosomes) -- 2% 1% 









BCR-ABL1 25% 2-4% 
t(12;21)(p13;q22) ETV6-RUNX1 (TEL1-AML1) 2% 22% 







iAMP 21 RUNX1 - 2% 
Ikaroz IKZF1 50% 12-17% 
B-ALL 
and       
T-ALL 
t(v;11q23) KMT2A       (MLL) 10% 8% 
T-ALL 
t(1;14)(p32;q11) TAL-1 12% 7% 

















B- precursor acute lymphoblastic leukemia 
25% of pediatric and 7% of adult B-ALL patients show high hyperdiploidy (> 50 
chromosomes), which is commonly associated with a favorable prognosis. Conversely, 
1% of children and 2% of adults with B-ALL have hypodiploidy (<44 chromosomes), a 
feature associated with very poor prognosis (Nachman, Heerema et al. 2007, Holmfeldt, 
Wei et al. 2013).  
 
In addition to altered chromosome numbers, B-ALL is grouped based on the presence of 
recurrent oncogene-driving chromosomal translocations. The t(12;21)(p13;q22) 
translocation encoding the ETV6-RUNX1 (TEL1-AML1) fusion is the most common 
translocation in B-ALL present in 22% of pediatric and 2% of adult B-ALL patients and is 
associated with a good prognosis. The ETV6-RUNX1 fusion oncogene is a typical 
example of transcription factor fusion oncogene and is generated by the association of 
two hematopoietic transcription factors ETV6 (TEL1, translocation-Ets-leukemia) and 
RUNX1 (AML1, acute myeloid leukemia-1), which together deregulate the normal activity 
of RUNX1 and favor the development of B-precursor ALL (Morrow, Horton et al. 2004, 
Fischer, Schwieger et al. 2005). A second common translocation in B-ALL is the 
t(9;22)(q34;q11.2) rearrangement, or the Philadelphia chromosome, which is present in 
2-4% of pediatric and 25% of adult B-ALL cases. The Philadelphia chromosome 
encodes the BCR-ABL1 fusion protein, a deregulated and constitutively active tyrosine 
kinase, which drives increased cell proliferation, growth, and survival (Nagar, Hantschel 
et al. 2003). Another less common translocation found in B-ALL is the t(1:19)(q23;p13) 
TCF3-PBX1 (E2A-PBX1) encoding translocation, which is present in 6% of pediatric and 
3% of adult ALLs. TCF3-PBX1 encodes a chimeric transcription factor with increased 
transcriptional transactivation activity resulting in aberrant expression of PBX1 target 
genes (Hunger, Galili et al. 1991). Additionally, translocations involving the mixed-
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lineage leukemia gene (KMT2A) are common in B-ALL and some T-ALLs accounting for 
8% of pediatric and 10% of adult ALL cases. KMT2A, also known as MLL, encodes 
lysine methyltransferase 2A, a histone methyltransferase involved in the epigenetic 
regulation of gene expression via reading and writing of histone H3 K4 trimethylation, an 
active promoter-associated chromatin mark. KMT2A has been identified in over 70 
unique chromosomal translocations leading to numerous fusion proteins with a 
convergent mechanism of action (Meyer, Hofmann et al. 2013). KMT2A translocations 
are particularly common in infant leukemias and can be found in 75% of patients that 
present with ALL before the age of 1 and are generally associated with poor prognosis 
(Andersson, Ma et al. 2015). 
 
Advanced molecular cytogenetic studies have uncovered a wealth of chromosomal and 
gene alterations in ALL, many resulting in novel molecular categories. A recent example 
is the identification of a group of about 2% of pediatric B-ALLs showing an internal 
amplification (iAMP) of part of chromosome 21, which is commonly detected with 
fluorescent in situ hybridization (FISH) probes encompassing the RUNX1 gene 
(Harrison, Moorman et al. 2014). Leukemias harboring the rare Robertsonian 
translocation rob(15;21)(q10;q10) are particularly prone to develop this iAMP 21 subset 
of B-ALL (Li, Schwab et al. 2014). Another recently identified category of B-ALL is BCR-
ABL1-like B-ALL: BCR-ABL1-like or Ph-like ALLs have a gene expression signature 
related to that of BCR-ABL1 positive ALLs, but do not show the BCR-ABL1 (Philadelphia 
chromosome) translocation (Den Boer, van Slegtenhorst et al. 2009). Genetic alterations 
in Ph-like ALL are very diverse, but commonly involve signaling factors and result in 
constitutively active kinase activity recurrently involving ABL2, PDGFRB, NTRK3, TYK2, 




In addition, mutations in important lymphoid developmental genes are seen across the 
B-ALL spectrum. The two most frequently mutated B-cell development factor genes in B-
ALL are PAX5, presenting with mutations or deletions in 35% of pediatric cases and 
35% adult ALLs, and IKZF1, presenting with mutations in 12-17% of pediatric ALLs and 
50% adult cases.  IZKF1 mutations are commonly associated with the BCR-ABL1 
rearrangements (Kuiper, Schoenmakers et al. 2007, Mullighan, Goorha et al. 2007, 
Familiades, Bousquet et al. 2009). 
 
T- cell acute lymphoblastic leukemia 
Clinical and biological grouping of T-ALL corresponds to the presence of chromosomal 
rearrangements driving the expression of developmentally important transcription factor 
oncogenes associated with distinct stages of T-cell development (Ferrando, Neuberg et 
al. 2002, Belver and Ferrando 2016).  
 
TLX1 (HOX11) and TLX3 (HOX11L2) are HOX genes encoding developmental 
transcription factors that are commonly activated in early cortical T-ALLs with a 
CD1a+CD4+CD8+ immunophenotype. TLX1 activation is typically caused by the 
t(10;14)(q24;q11) rearrangement found in 5-10% of pediatric and 30% of adult T-ALLs.  
This translocation places TLX1 under control of enhancers in the T-cell Receptor (TCR) 
loci TCRα or TCRδ leading to high levels of TLX1 expression (Hatano, Roberts et al. 
1991, Kennedy, Gonzalez-Sarmiento et al. 1991, Ferrando, Neuberg et al. 2002, 
Ferrando, Neuberg et al. 2004). Similarly, the t(5;14)(q35;q32) rearrangement found in 
20-25% of pediatric and 5% of adult T-ALL cases places TLX3 under the regulatory 
control of the BCL11B locus leading to increased TLX3 expression and activity (Bernard, 
Busson-LeConiat et al. 2001).  
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In contrast, T-ALLs with elevated levels of TAL1 (T-cell acute lymphocytic protein 1), a 
basic helix-loop-helix (bHLH) transcription factor, are considered mature thymocyte 
stage T-ALLs presenting with a CD4+ CD8+ CD3+ immunophenotype (Ferrando, Neuberg 
et al. 2002). T-ALLs express increased levels of TAL1 through various mechanisms such 
as translocations placing TAL1 expression under the control of TCR loci, the focal 90 kb 
deletion (TAL1d) that relocates the TAL1 coding sequence to the nearby STIL locus, or 
somatic mutations upstream of TAL1 that generate a neoenhancer activated by 
mutation-generated MYB transcription factor binding sites (Begley, Aplan et al. 1989, 
Chen, Yang et al. 1990, Mansour, Abraham et al. 2014). In addition, TCR enhancer-
engaging activating translocations have been found to involve other TAL1-related bHLH 
transcription factors TAL2, LYL1, and BHLHB1 (Mellentin, Smith et al. 1989, Xia, Brown 
et al. 1991, Wang, Jani-Sait et al. 2000, Homminga, Vuerhard et al. 2012).  
 
Increased TAL1 expression is commonly found together with increased expression of 
LMO (LIM-only domain) genes LMO1 and LMO2, which form transcriptional complexes 
with TAL1 and other bHLH transcription factors (Larson, Lavenir et al. 1996, Ferrando, 
Neuberg et al. 2002). LMO1 and LMO2 are commonly misexpressed in T-ALL due to 
t(11;14)(p15;q11) and t(11;14)(p13;q11) TCR translocations respectively (McGuire, 
Hockett et al. 1989, Royer-Pokora, Loos et al. 1991).   
 
Finally, early T-cell precursor (ETP) ALL with a developmental arrest at the earliest 
stages of T-cell differentiation (CD4- CD8- cells) are closely related to hematopoietic 
stem cells and myeloid progenitors (Coustan-Smith, Mullighan et al. 2009) and account 
for 10-15% of childhood T-ALL and 40-50% of adult T-ALLs (Van Vlierberghe, Ambesi-
Impiombato et al. 2011).  ETP ALLs are are commonly associated with mutations that 
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activate oncogenic signaling (KRAS, FLT3, IL7R), alter epigenetic programs (DNMT3A, 
PHF6, EZH2, SUZ12) and disrupt important transcription factors implicated in lymphoid 
and T-cell development including RUNX1, GATA3, and ETV6 (Zhang, Ding et al. 2012).  
 
In addition to these major subgroups, T-ALLs harbor a number of genetic alterations that 
disrupt important T-cell developmental factors or cell cycle signaling pathways. The most 
prominent genetic alteration in T-ALLs is the loss of the tumor suppressors p16INK4A and 
p14ARF, which are encoded by the CDKN2A locus on chromosome 9. Chromosomal 
deletions in the CDKN2A locus can be found in >70% of T-ALLs (Hebert, Cayuela et al. 
1994, Ferrando, Neuberg et al. 2002). p16INK4A inhibits the progression of the cell cycle 
from the G1 to S phase and p14ARF inhibits MDM2, a negative regulator of p53.  
Therefore, these deletions allow cells to bypass signals which are critical for inducing 
cell cycle arrest and apoptosis in response to cellular stress (Kamijo, Weber et al. 1998). 
 
Additionally, NOTCH1 mutations are found in >50% of T-ALLs (Weng, Ferrando et al. 
2004). NOTCH1 is a class I transmembrane protein that functions as a ligand activated 
transcription factor. Upon extracellular ligand binding, NOTCH1 undergoes two 
proteolytic cleavages by ADAM 10 and gamma secretase that release the intracellular 
NOTCH1 (ICN) domain, which then enters the nucleus, complexes with other 
transcription factors and initiates transcriptional activity (Dumortier, Wilson et al. 2005). 
In hematopoietic cells, NOTCH1 is critical for early T-cell fate and thymocyte 
development (Radtke, Wilson et al. 1999, Wolfer, Wilson et al. 2002). NOTCH1 
mutations found in ALL disrupt the heterodimerization domain or C-terminal PEST 
domain leading to constitutive activation of NOTCH1 signaling (Weng, Ferrando et al. 
2004). NOTCH1 activity is similarly upregulated in another 8-30% of T-ALLs due to 
dominant negative mutations in FBXW7 (F-box and WD repeat domain containing 7), 
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which is responsible for the degradation of activated NOTCH1 (O'Neil, Grim et al. 2007, 
Thompson, Buonamici et al. 2007). Activated NOTCH1 signaling has been shown to 
contribute to leukemic cell growth directly via increased transcription of anabolic genes, 
protein translation, and nucleotide and amino acid metabolism as well as promoting cell 
growth by inducing the expression of the MYC oncogene (Palomero, Lim et al. 2006, 
Weng, Millholland et al. 2006).  
 
Germline predispositions: 
Although most genetic alterations identified in ALL occur as somatic mutations, a 
number of germline genetic alterations have been linked to increased ALL occurrence. 
Most notably, trisomy 21 (Down Syndrome) and TP53 mutations (Li-Fraumeni 
syndrome) are associated with an increased risk of ALL (Kleihues, Schauble et al. 1997, 
Malinge, Izraeli et al. 2009, Stieglitz and Loh 2013). Additionally, rare germline mutations 
in PAX5 (Shah, Schrader et al. 2013), ARID5B (Xu, Cheng et al. 2012), GATA3 (Perez-
Andreu, Roberts et al. 2013), IZKF1 (Churchman, Qian et al. 2018) and ETV6 
(Moriyama, Metzger et al. 2015) have been linked to increased risk of pre-B cell ALL 
occurrence. 
 
Current Therapy for ALL 
Before the introduction of combination chemotherapy, survival rates for T-ALL were only 
about 10% compared to 40% for patients diagnosed with B-ALL (Greaves, Janossy et al. 
1981). With the introduction of multiagent chemotherapy, survival rates for patients with 
T-ALL have drastically improved approaching 80-90% in children (Pui and Howard 2008, 
Tasian and Hunger 2017) and 60% in adults (Stock, Johnson et al. 2013). In addition to 
multi-agent chemotherapy approaches, ALL overall survival has improved due to the 
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integration of central nervous system (CNS)-directed treatment and reliance on risk-




Figure 1.1 – Improved overall survival of children with acute lymphoblastic leukemia 
treated in cooperative group trials in North America and landmark advances in the 
treatment of ALL. Adapted from Tasian and Hunger 2017 and Heikamp and Pui 2018. 
 
 
Upon diagnosis, patients are risk stratified based on age, white blood cell count, gender, 
the presence of bulky disease, T-cell lineage immunophenotype, and various 
chromosomal translocations (Nachman, Sather et al. 1998). For B-ALL, “standard risk’ is 
classified as age 1-9 years old or an initial white cell count less than 50,000 cells per 
cubic millimeter and “high risk” is classified as ages 10 and older or white blood cell 
counts greater than 50,000 cells per cubic millimeter (Smith, Arthur et al. 1996).  
Patients diagnosed before the age of 1 year fall into a different subgroup, often with a 
worse prognosis. Interestingly, age and white blood cell count are more important 
prognostic factors in B-ALL than in T-ALL (Pui, Yang et al. 2015). T-ALL risk stratification 
is largely based on CNS status, immunophenotype and early response to therapy 
(Schrappe, Valsecchi et al. 2011). In terms of genetic characteristics, high-risk cases 
include patients with Ph-like gene expression patterns, MLL rearrangements, 
intrachromosomal amplifications of chromosome 21, and hypodiploid B-ALLs and early 
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T-cell precursor T-ALLs. Low risk cases include hyperdiploidy and ETV6-RUNX1 fusions 
in B-ALL and NOTCH1 or FBXW7 mutations in T-ALL (Heikamp and Pui 2018). 
 
Although ALL is a highly heterogeneous disease and therapy is typically adapted for 
each patient, the standard of care therapy proceeds in three phases: (i) induction, (ii) 
consolidation, and (iii) maintenance. To combat central nervous system (CNS) positive 
leukemias, patients also receive intrathecal chemotherapy throughout treatment, but 
timing and schedule depend on the protocol being followed. 
 
Induction therapy is intended to induce a rapid depletion of leukemic blasts. This phase 
of treatment commonly lasts between four to six weeks and consists of a glucocorticoid 
(dexamethasone or prednisone), vincristine, aspariginase preparation, and optional 
therapy with an anthracycline (doxorubicin or daunorubicin) and intrathecal 
chemotherapy (Table 1.2) (Pui and Evans 2006, Conter, Arico et al. 2010, Gaynon, 
Angiolillo et al. 2010, Schmiegelow, Forestier et al. 2010). On average 95 % of patients 
achieve initial remission during induction therapy (Cooper and Brown 2015).  
 
A rapid response to initial chemotherapy is an important prognostic factor, thus minimal 
residual disease (MRD) levels are checked at multiple points throughout therapy to 
monitor leukemic burden. Patients who show slow responsiveness to induction therapy 
are placed on an induction intensification protocol, which greatly improves overall 
survival (Nachman, Sather et al. 1998). MRD is typically assessed by flow cytometry or 
quantitative PCR, but more recently is being assessed with next generation sequencing 
(NGS) which allows for enhanced sensitivity and specificity (Faham, Zheng et al. 2012, 
Wu, Sherwood et al. 2012). 
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Following remission after induction therapy, patients are treated for 2-9 months with 
consolidation therapy to eradicate any remaining blasts and prevent further leukemic 
development. Consolidation therapy incorporates a multitude of drugs different from 
those used in induction therapy to maximize synergistic drug combinations and minimize 
therapy resistance. This phase consists of intensive therapy followed by a brief low 
intensity maintenance-like treatment followed by a delayed intensification regimen 
(Tubergen, Gilchrist et al. 1993). Consolidation therapy consists of a mixture of high-
dose methotrexate with folinic acid rescue, 6-mercaptopurine (6-MP), aspariginase, 
dexamethasone and vincristine. Cyclophosphamide and cytarabine are sometimes 
included for high-risk patients as well (Cooper and Brown 2015, Hunger and Mullighan 
2015, Heikamp and Pui 2018).  
 
After consolidation therapy, patients are continuously treated with a low-intensity anti-
metabolite based maintenance therapy for 18-30 months. Maintenance therapy consists 
of daily oral 6-mercaptopurine or 6-thioguanine as well as weekly oral methotrexate. 
Some protocols also incorporate 5-7 day pulses of glucocorticoids and vincristine 
(Hunger and Mullighan 2015).   
 
Allogeneic hematopoietic stem cell transplants (HSCT) in first remission are sometimes 
used in patients who fail to achieve remission or present with a very high risk of relapse 
or treatment failure, but there is not a well defined protocol yet for these cases (Cooper 




Table 1.2 - Chemotherapeutics used in the treatment of acute lymphoblastic leukemia 
 
Drug Name Type of Drug Mechanism of Action 
Prednisone, 
Dexamethasone Glucocorticoid 
Glucocorticoids bind to the glucocorticoid 
receptor in the cytoplasm and induce 
localization to the nucleus leading to cell cycle 
arrest and apoptosis (Inaba and Pui 2010) 
Vincristine Antimitotic 
Interacts with beta-tubulin and prevents the 
formation of spindle microtubules disrupting 
mitosis and cell division (Gidding, Kellie et al. 
1999) 
PEG asparaginase, 
Erwinia asparaginase Aspariginase 
Naturally occurring enzyme that depletes 
serum of asparagine (Muller and Boos 1998) 
Daunorubicin, 
Doxorubicin Anthracycline 
DNA intercalating agent (Tacar, Sriamornsak 
et al. 2013) 
Cyclophosphamide Alkylating agent 
Nitrogen mustard prodrug that induces 
intrastrand DNA crosslinks upon hepatic 
processing (Emadi, Jones et al. 2009) 
6-mercaptopurine Thiopurine 6-thioguanine nucleotides incorporate into 
DNA resulting in DNA base pair mismatch and 
subsequent apoptosis (Karran 2006) 6-thioguanine Thiopurine 
Methotrexate Folate analogue 
Methotrexate inhibits dihydrofolate reductase 
blocking de novo purine biosynthesis (Longo-
Sorbello and Bertino 2001) 
Cytarabine Pyrimidine analogue 
Cytosine analogue with an arabinose sugar 
incorporates into DNA and stalls DNA 
replication (Kufe, Spriggs et al. 1984) 
 
 
Thiopurine based maintenance therapy and germline toxicities 
It was first observed in the early 1950s that combination treatment with methotrexate 
(MTX) and 6-mercaptopurine (6-MP) could induce temporary remissions in childhood 
leukemia (Farber and Diamond 1948, Burchenal, Murphy et al. 1953). Overtime and with 
numerous trials, this idea has now been elaborated to show that long term remission of 
pediatric ALL is significantly improved when patients receive post-remission 
maintenance therapy consisting of 6-MP and MTX treatment (Frei, Karon et al. 1965). 
 
Although this therapy is very well established, the mechanisms for why prolonged 
thiopurine treatment improves ALL patient outcome are still not fully understood. Yet, 
multiple studies have shown that patients with higher dose intensity of 6-MP have better 
event free survival (Relling, Hancock et al. 1999). As maintenance therapy relies on daily 
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oral 6-MP administered by the patient or caregiver, compliance and therapy adherence 
is difficult to ensure over the 2-3 year timeline. Patients who drop below 95% 6-MP 
adherence are 2.5 fold more likely to relapse suggesting that 6-MP maintenance efficacy 
depends on chronic and continuous exposure to the drug over a long period of time 
(Bhatia, Landier et al. 2012). 
 
6-MP is processed and activated by enzymes in the purine biosynthesis pathway into 2’-
deoxy-6-thioguanosine triphosphate (thio dGTP) and is subsequently incorporated into 
DNA (Figure 1.2) (Elion 1989). The cytotoxicity of 6-MP and 6-TG treatment has a 
delayed effect as cytotoxicity is enacted through the post-replicative mismatch repair 
system. Thio dGTP leads to equal incorporation of cytosine and thymidine on the 
opposite strand upon DNA replication leading to DNA mismatches and subsequent 
mismatch repair dependent cell death (Swann, Waters et al. 1996, Waters and Swann 
1997, Karran 2006). Although the majority of 6-MP is incorporate into DNA, a portion of 
6-MP, which is converted to thioIMP, is also thiomethylated by TPMT (thiopurine S-
methyltransferase) to MeTIMP (methylthioIMP), which inhibits purine de novo 
biosynthesis. Although this does not appear to play a major role in 6-MP mediated 
cytotoxicity as Tpmt-/- knockout mice show similar rates of de novo purine biosynthesis 






Figure 1.2 – Purine and thiopurine metabolism. NT5C2 dephosphorylates endogenous and 
thiopurine generated 6-hydroxypurine monophosphates before they are exported out of the cell. 
Abbreviations: pyrophosphate synthetase 1 gene (PRPS1), phosphoribosyl pyrophosphate 
(PRPP), 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), 6-mercaptopurine (6-MP), 
Methyl 6-MP (Me6-MP), xanthine oxidase (XO), Methyl 6-thioguanine (Me6-TG), hypoxanthine-
guanine phosphoribosyltransferase (HGPRT), Nudix hydrolase 15 (NUDT15), inosine 
monophosphate (IMP), xanthine monophosphate (XMP), guanosine monophosphate (GMP), 
guanosine triphosphate (GTP), deoxy GTP (dGTP), Cytosolic 5’ nucleotidase II (NT5C2), inosine 
monophosphate dehydrogenase (IMPDH), guanosine monophosphate synthase (GMPS), 
thiopurine methyltransferase (TPMT), methyl thioIMP (MeTIMP) 
 
 
In addition to being converted into active cytotoxic metabolites, 6-MP is also inactivated 
by enzymes in the purine biosynthesis pathway creating a delicate balance between 
cytotoxic and inactive 6-MP metabolites. A number of toxicities have been observed due 
to germline mutations in these inactivating enzymes leading to inaccurate thiopurine 
dosing and sometimes fatal thiopurine toxicity. For example, 1 in 300 people inherit 
TPMT deficiency as an autosomal recessive trait. TPMT is an enzyme that catalyzes the 
S-methylation of 6-MP, decreasing the amount of thioguanine nucleotide production and 
incorporation into DNA (Figure 1.2) (Evans, Horner et al. 1991, McLeod, Krynetski et al. 
2000). Additionally, loss of function variants in NUDT15 (nudix hydrolase 15) are found 
in Asian populations and are associated with thiopurine toxicity. NUDT15 is responsible 
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for dephosphorylating thio-dGTP preventing its incorporation into DNA and thus 
minimizing the toxicity of thiopurines (Figure 1.2) (Moriyama, Nishii et al. 2016). 
Pretreatment screening for loss of function mutations in these critical thiopurine 
metabolizing enzymes is now standard of care to prevent thiopurine toxicity. Taking 
these mutations into account, maintenance therapy is continually adjusted on a patient-
to-patient case to achieve target levels of myelosuppresion. Patients who tolerate initial 
6-MP doses and are not dose escalated have a poorer outcome, thus continued 
monitoring and adjustment is necessary to provide effective maintenance therapy dosing 
(Relling, Hancock et al. 1999). 
 
Relapsed acute lymphoblastic leukemia 
Despite improved outcomes following initial therapy, overall survival of patients with 
primary resistant ALL who fail to achieve a complete remission and relapse remains 
poor. Approximately 20% of pediatric and 50% of adult patients fail to achieve remission 
and die as a result of disease progression (Nguyen, Devidas et al. 2008, Raetz and 
Bhatla 2012).   
 
The time of relapse after therapy starts, immunophenotype of relapse, and the site of 
relapse are all important prognostic factors upon relapsing (Raetz and Bhatla 2012).  
Patients that relapse after therapy have a much better prognosis than those patients that 
relapse while on therapy. Additionally, patients with MRD positivity above 0.01% 
following induction therapy have a much higher risk of relapse (Borowitz, Wood et al. 
2015). In addition, patients who relapse at extramedullary sites have a better prognosis 
than those who relapse in the bone marrow (Nguyen, Devidas et al. 2008).  
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Upon relapse, patients are treated with reinduction therapy, similar to that of induction 
therapy, in an attempt to induce a second remission so the patient can eventually 
receive a hematopoietic cell transplant. Reinduction therapy consists of the same drugs 
used in induction therapy but they are commonly given at increased doses or on 
alternate schedules (Cooper and Brown 2015, Pierro, Hogan et al. 2017). Patients who 
relapse within the testis tend to receive more intensive reinduction chemotherapy and 
testicular radiation to improve remission likelihood (Wofford, Smith et al. 1992). Patients 
who relapse within the CNS are treated with dexamethasone, which bypasses the blood 
brain barrier, low dose cranial radiation, and intensive chemotherapy administered via 
lumbar punctures or Ommaya ventricular reservoirs to ensure delivery to the CNS 
(Barredo, Devidas et al. 2006, Larson 2018). 
 
Although the implementation of risk stratification and multi-agent chemotherapy has 
greatly improved the outcomes of patients treated with initial therapy over the past few 
decades, recent studies comparing outcomes of relapse ALL patients from 1988-94 and 
1995-2002 have shown no improvement in relapsed patient survival (Nguyen, Devidas 
et al. 2008). Thus new therapeutic regimens and improved understanding of ALL at 
relapse are desperately needed for the improved treatment and survival of patients with 
relapsed ALL. 
 
Genetic alterations in relapsed acute lymphoblastic leukemia 
Leukemia-initiating cells capable of self-renewal (Cox, Diamanti et al. 2009, Gerby, 
Clappier et al. 2011), protective microenvironment safe-haven niches (Konopleva, 
Konoplev et al. 2002, Hawkins, Duarte et al. 2016) and clonal evolution (Mullighan, 
Phillips et al. 2008, Ma, Edmonson et al. 2015, Oshima, Khiabanian et al. 2016) with 
acquisition of secondary genetic alterations driving chemotherapy resistance (Mullighan, 
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Zhang et al. 2011, Meyer, Wang et al. 2013, Tzoneva, Perez-Garcia et al. 2013, Li, Li et 
al. 2015, Ma, Edmonson et al. 2015, Malinowska-Ozdowy, Frech et al. 2015, Oshima, 





Figure 1.3 – Branched clonal evolution of relapsed leukemia. (a) Branched evolution scheme. 




Recent genomic analyses of matched diagnostic and relapsed patient samples have 
greatly improved our understanding of the clonal evolution of relapsed ALL. These 
studies have shown that ALL displays branched evolution where relapse clones emerge 
from ancestral clones sharing some, but not all, genetic alterations with the diagnostic 
sample (Figure 1.3). It is postulated that multi-agent chemotherapy treatment drives this 
clonal evolution by suppressing prominent clones at diagnosis and simultaneously 
allowing for the emergence of new clones harboring resistance driving mutations (Figure 
1.3) (Mullighan, Phillips et al. 2008, Ma, Edmonson et al. 2015, Oshima, Khiabanian et 
al. 2016). Most relapsed ALL samples preserve key genetic features from diagnosis, 
such as translocations and aneuploidy, but acquire additional genetic mutations and 
copy number alterations upon relapse. Interestingly, the frequency of somatic mutations 
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in ALL at diagnosis and relapse is fairly low averaging 20 or less non-silent mutations 






Figure 1.4. – Common genetic alterations implicated in therapy resistance and relapse in 
ALL. Adapted from Bhojwani and Pui 2013. 
 
 
In particular, genes regulating cell cycle progression, lymphoid development, DNA 
repair, transcription regulation, and nucleotide metabolism have been found implicated in 
relapsed ALL and are summarized in Figure 1.4 (Bhojwani and Pui 2013). Some of 
these relapse specific genetic alterations have been directly associated with specific 
resistance to certain chemotherapies. For example, mutations in CREBBP (CREB 
binding protein), a transcriptional co-activator and histone acetyltransferase (HAT), are 
found in 20% of relapsed ALL samples and have been linked with glucocorticoid 
resistance. These truncating and loss of function mutations disrupt histone acetylation 
and thus transcriptional regulation of CREBBP targets, which include glucocorticoid 
responsive genes (Mullighan, Zhang et al. 2011). Additionally, mutations and deletions in 
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the NR3C1 gene, which encodes the glucocorticoid receptor, and deletions in the 
TBL1XR1 gene, which prevents repression of the glucocorticoid complex, have been 
associated with glucocorticoid resistance at relapse (Kuster, Grausenburger et al. 2011, 
Jones, Bhatla et al. 2014).  
 
A number of genes have also been implicated in thiopurine resistance. PRPS1 
(Pyrophosphate synthetase 1 gene) point mutations have been found in 7% of relapsed 
B-ALLs encoding gain of function PRPS1 mutants and have been associated with 
thiopurine resistance. PRPS1 gain of function mutations result in a build-up of 
hypoxanthine, which competes with 6-MP as a substrate for HPRT therefore decreasing 
6-MP conversion into thio-nucleotides and minimizing the cytotoxic effects of 6-MP (Li, Li 
et al. 2015). Decreased expression of MSH6 is also associated with 6-MP resistance 
due to the failure of MSH6 to recognize thioguanine nucleotide induced mismatches and 
initiate mismatch repair (Yang, Bhojwani et al. 2008, Evensen, Madhusoodhan et al. 
2018). NT5C2, cytosolic 5’ nucleotidase II, is by far the most prominent relapse ALL 
associated mutation accounting for 20% of relapse T-ALL and 3-10% of relapse B-ALL 
cases. NT5C2 activating mutations act as gain of function alleles leading to increased 
processing of thiopurine metabolites and decreased cytotoxicity of these 
chemotherapies causing overt thiopurine chemotherapy resistance (Meyer, Wang et al. 
2013, Tzoneva, Perez-Garcia et al. 2013). 
 
New therapeutics for the treatment of ALL  
With the identification of numerous genetic alterations present in diagnosis and relapsed 
ALL, a multitude of targeted therapeutics have been developed and implemented in 
clinical trials to attempt to improve patient survival. A summary of active clinical trials 
involving new therapies can be found in Table 1.3.   
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Table 1.3 – Active recruiting and non-recruiting clinical trials as of November 2018 





NCT00390793 Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. 
NCT01044069 
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With 
Autologous T Cells Genetically Targeted to the B Cell Specific Antigen 
CD19 
NCT01683279 A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia 
NCT01860937 
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in 
Pediatric and Young Adult Patients With Relapsed B-Cell Acute 
Lymphoblastic Leukemia 
NCT02420717 Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) 
NCT02458014 Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease 
NCT02494882 
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in 
Remission Induction Therapy in Newly Diagnosed Philadelphia 
Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 
Years or Older 
NCT02767934 Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia 
NCT02819804 Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia 
NCT02935543 CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL 
NCT02981628 Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia 
NCT02997761 Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia 
NCT03104491 Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia 
NCT03147612 
Low-Intensity Chemotherapy and Ponatinib in Treating Participants With 
Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute 
Lymphoblastic Leukemia 
NCT03241940 
CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in 
Treating Children or Young Adults With Recurrent or Refractory CD19 
Positive B Acute Lymphoblastic Leukemia 
NCT03263572 
Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome 
(Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic 
Leukemia (ALL) 
NCT03472573 Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia 
NCT03573700 Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia 




One of the most dramatic effects in overall survival has been seen with the development 
of tyrosine kinase inhibitors (TKIs) for the treatment of BCR-ABL1 positive ALLs 
(Wassmann, Pfeifer et al. 2006, Arico, Schrappe et al. 2010). The first TKI implemented 
in the treatment of Ph-positive ALL was Imatinib mesylate which led to complete 
remission rates >90% (Daver, Thomas et al. 2015). Imatinib works as a competitive 
inhibitor at the ATP-binding site of the ABL1 kinase, inhibiting phosphorylation and 
activation of downstream targets (Druker, Talpaz et al. 2001). Unfortunately, as imatinib 
has been implemented in the clinic, some patients have developed resistances to 
therapy with T315I mutations in the kinase domain, which stabilize the active kinase 
formation and ultimately lead to relapse. To further combat these kinase driven 
diseases, other TKIs such as dasatinib and ponatinib have been developed (Shah, Tran 
et al. 2004, Ravandi, O'Brien et al. 2015). Dasatinib is a promiscuous tyrosine kinase 
inhibitor known to target ABL1 as well as other Src family kinases (Zhang and Meier 
2006). In contrast Ponatinib has been specifically developed to reduce the emergence of 
T315I resistant clones and has improved complete remission rates to 98% (Jabbour, 
Kantarjian et al. 2015, Sasaki, Jabbour et al. 2016). Additionally, dissection of the 
genetic makeup of Ph-like ALL has identified chromosomal rearrangements resulting in 
non BCR-ABL1 gene fusions involving ABL1, ABL2, CSF1R, and PDGFRB (Pui, 
Roberts et al. 2017). As dasatinib targets a number of tyrosine kinases such as these, 
specific Ph-like ALLs similarly benefit from treatment with dasatinib (Zhang and Meier 
2006, Pui, Roberts et al. 2017). Some Ph-like ALLs have also been found to have EPOR 
and JAK2 rearrangements which contribute to increased JAK-STAT signaling making 
these ALLs candidates for treatment with JAK inhibitors (Roberts, Li et al. 2014). Initial 
experiments have confirmed increased cell death with the JAK inhibitor ruxolitinib and 
there are currently a number of ongoing clinical trials implementing ruxolitinib into 
therapy for Ph-like ALL patients. 
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In addition to targeted genetic treatments, immunotherapy has rapidly evolved in the 
treatment of acute lymphoblastic leukemia (Figure 1.5). In particular, chimeric antigen 
receptor T-cells or CAR T-cells have rapidly evolved over the past decade. CAR T-cells 
are genetically modified autologous T lymphocytes engineered to express binding sites 
of specific antibodies to target and eliminate cancer cells. The most common CAR T-cell 
strategy used for the treatment of ALL consists of an extracellular immunoglobulin 
domain that recognizes CD19 and an intracellular signaling domain that activates the T-
cell to kill CD19 expressing B-ALL leukemic cells. Unlike chemotherapies, CAR T-cells 
persist in the patient for much longer and thus have lasting affects (Sabatino, Hu et al. 
2016). The first clinical trial implementing CAR T-cells in the treatment of relapsed ALL 
induced complete remission in 93% of patients (Maude, Frey et al. 2014). This CAR T-
cell therapy, Tisagenlecleucel (formerly CRL019), was designated as a “breakthrough 
therapy” in 2017 by the FDA and was approved for therapy in patients with relapsed B-
ALL (O'Leary, Lu et al. 2018). As some patients have relapsed due to lack of persistence 
of CAR T-cells and emergence of CD19 negative leukemias, researchers are currently 
implementing a multitude of strategies to improve CAR T-cell efficacy (Maude, Frey et al. 
2014, Gardner, Wu et al. 2016). These improvements include CAR T-cells targeting 
other antigens such as CD22, or tandem CAR T-cells that recognize CD19 and CD22 
(Schneider, Xiong et al. 2017, Fry, Shah et al. 2018).  
 
Although CAR T-cell therapeutics are an incredible new development for the treatment 
of B-ALL, they are not always an option as at least two weeks is needed to harvest and 
engineer T-cells from the patient before they are ready to use leading to a delay in 
therapy that is not always the best option for the patient. In these cases, monoclonal 
antibodies are a good alternative and have recently been implemented in the treatment 
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of ALL. One example in particular is the use of rituximab, a chimeric CD20 targeting 
antibody that induces complement-mediated cytotoxicity, which has been used 
extensively in the treatment of non-Hodgkins lymphoma (Cerny, Borisch et al. 2002). B-
ALLs expressing high levels of CD20 were shown to have a worse prognosis and thus 
rituximab was added to clinical trials for these patients. Addition of rituximab to the 
treatment of newly diagnosed Ph-negative positive ALL has improved the 3-year 
complete remission duration to 70% (Thomas, O'Brien et al. 2010).  
 
In addition to CD20 expression, many B-ALLs express CD19. As a result, 
Blinatumomab, a bispecific T-cell engager (BiTE) antibody construct that steers CD3-
positive effector T-cells to CD19-positive leukemia cells has recently been tested in the 
treatment of relapsed and refractory B-cell precursor ALL. Blinatumomab has shown 
particular success in inducing MRD negativity in 78% of patients with positive MRD 
following initial therapy after just one cycle of treatment. These results lead 
blinatumomab to be approved for the treatment of patients with positive MRD by the 
FDA in March 2018 (Gokbuget, Dombret et al. 2018, Jabbour, Pui et al. 2018). 
 
In addition to expressing CD19 and CD20, 90% of precursor B-ALLs express the cell-
surface glycoprotein CD22, and thus CD22 has emerged as an attractive therapeutic 
target for the treatment of B-ALLs (Piccaluga, Arpinati et al. 2011, Shah, Stevenson et 
al. 2015). Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 monoclonal 
antibody linked to the cytotoxic compound calicheamicin that has recently been added to 
trials to improve B-ALL therapeutic regimens (DiJoseph, Armellino et al. 2004). Upon 
binding to CD22, inotuzumab ozogamicin is internalized and calcheamicin is released to 
bind to DNA and induce double strand breaks thus inducing apoptosis (Zein, Sinha et al. 
1988, Hanna, Ong et al. 1996, Kantarjian, Vandendries et al. 2016). Following success 
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in inducing complete remission and improving MRD negativity in patients with relapsed 
and refractory B-ALL, Inotuzumab ozogamicin or Besponsa was recently approved in 
2017 by the FDA for the treatment of adults with relapsed or refractory B-ALL 
(Kantarjian, Thomas et al. 2013, DeAngelo, Stock et al. 2017, Lamb 2017). 
 
Most immunotherapies are targeted at B-cells as they have clear antigens to target, yet it 
has proven difficult to identify a unique marker of T-ALL that is not present on normal T 
lymphocytes. The only monoclonal antibody developed for T-ALL, alemtuzumab, an anti-
CD25 antibody, has shown limited success. In one study, alemtuzumab induced one 
complete remission out of 13 patients treated and was associated with increased toxicity 
(Angiolillo, Yu et al. 2009). Preclinical studies using CD5-targeted CAR T-cells to target 
T-cell leukemias have been fairly successful but have not yet made the move into clinical 
settings (Mamonkin, Rouce et al. 2015, Chen, Wada et al. 2017). 
 
 
Figure 1.5 – Novel molecular, epigenetic and immunotherapeutic approaches to target 
relapsed and refractory disease. Adapted from Heikamp and Pui 2018. 
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Physiologic role of NT5C2 
NT5C2 (5’ cytosolic nucleotidase II), also known as cN-II or high Km 5’-nucleotidase, is 
one of seven mammalian 5’ nucleotidases that dephosphorylates ribo and 
deoxyribonucleoside monophosphates. The seven nucleotidases vary in cellular 
localization, substrate preference and tissue specific expression, but all function to 
dephosphorylate nucleoside monophosphates to counterbalance the activity of 
nucleoside kinases as a way to regulate nucleotide pools within the cell (Table 1.4) 
(Bianchi and Spychala 2003, Hunsucker, Mitchell et al. 2005).   
 
 
Table 1.4 – 5’-nucleotidase family member gene names and preferred substrate. Adapted 







size Natural Substrate 
Ecto-5'-nucleotidase 
(eN) NT5E 574 aa 
broad: purine, pyrimidine, deoxy-and 
ribonuceloside monophosphates 
    Cytosolic 5'-nucleotidase 
IA (cN-IA) NT5C1B 368 aa AMP, dTMP, dCMP, dGMP, dAMP, dIMP 
    Cytosolic 5'-nucleotidase 
IB(cN-IB) NT5C1B 550 aa AMP 
    Cytosolic 5'-nucleotidae 
II (cN-II) NT5C2 561 aa 
6-hydroxy purines: IMP, dIMP, GMP, dGMP, 
XMP 
    Cytosolic 5'-nucleotidae 
III (cN-III) NT5C3 285 aa 
Pyrimidine monophosphates: CMP, UMP, 
dUMP, dCMP, dTMP  
    Cytosolic 5′(3′)-
deoxyribonucleotidase 
(cdN) 
NT5C 201 aa 
2′ and 3′ monophosphates: 3′-dUMP, 3′-dTMP, 
3′-UMP and 2′-UMP; lower activity with 5′-dIMP, 
5′-dUMP, 5′-dCMP, 5′-dTMP and 5′-dAMP 
    Mitochondrial 5′(3′)-
deoxyribonucleotidase 
(mdN) 
NT5M 228 aa 
pyrimidine monophosphates with thymine or 
uracil bases: 5′-dUMP, 5′-dTMP, 3′-dTMP and 5′-






NT5C2 is a ubiquitously expressed cytosolic nucleotidase that preferentially 
dephosphorylates the 6-hydroxypurine monophosphates inosine monophosphate (IMP), 
xanthine monophosphate (XMP), and guanosine monophosphate (GMP) as well as their 
deoxyribose forms dIMP and dGMP and with low efficiency adenosine monophosphate 
(AMP) into their respective purines allowing them to be exported from the cell (Itoh, 
Mitsui et al. 1967, Spychala, Madrid-Marina et al. 1988, Tozzi, Camici et al. 1991, Pesi, 
Turriani et al. 1994, Banditelli, Baiocchi et al. 1996, Allegrini, Pesi et al. 1997, 
Hunsucker, Mitchell et al. 2005) (Figure 1.6). In addition to its nucleotidase activity, 
NT5C2 also acts as a phosphotransferase to donate phosphates to acceptors such as 




Figure 1.6 - Purine Metabolism. Abbreviations: Adenosine deaminase (ADA), Adenosine kinase 
(AdK), Adenylate kinase (AK), Adenine phosphoribosyltransferase (APRT), deoxyguanosine 
kinase (dGK),guanylate kinase (GUK), hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT), inosine monophosphate dehydrogenase (IMPDH), nucleoside diphosphate kinase 
(NDPK), purine nucleoside phophorylase (PNP), ribonucleotidase reductase (RR), guanosine 




NT5C2 protein and structure 
Structurally, NT5C2 is a member of the haloacid dehalogenase (HAD) superfamily of 
Mg2+-dependent intracellular 5’-nucleotidases, which characteristically have an α/β-
Rossman-like domain and a smaller 4-helix bundle domain (Koonin and Tatusov 1994). 
NT5C2 was first purified from chicken liver in 1967 (Itoh, Mitsui et al. 1967) and has now 
been extensively investigated in many vertebrates (Bretonnet, Jordheim et al. 2005).  
NT5C2 is a 561 amino acid protein and migrates to about ~57kDa as measured on an 
SDS-polyacrylamide gel.  
 
NT5C2 is a homotetramer that functions as a dimer of dimers, with the dimer being the 
smallest functional unit with enzymatic activity (Spychala, Madrid-Marina et al. 1988, 
Wallden and Nordlund 2011) and is regulated by allosteric activators ATP, dATP, 
diadenosine tetraphosphate (Ap4A), and 2,3-bispho-sphoglycerate (BPG) (Pinto, 
Canales et al. 1986, Bontemps, Van den Berghe et al. 1988, Spychala, Madrid-Marina et 
al. 1988, Marques, Teixeira et al. 1998) (Figure 1.7). The physiologic activator of NT5C2 
is not known, but some groups suspect Ap4A due to its ability to activate NT5C2 at lower 
concentrations than other activators and that Ap4A levels increase upon apoptosis, 
which may trigger purine catabolism and recycling for use by other cells (Pinto, Canales 






Figure 1.7- Tetrameric structure of active NT5C2 D52N 537X with IMP, Mg2+ and ATP 
bound. Adapted from Wallden and Nordlund 2011. 
 
 
The allosteric binding site (also referred to as effector site 1) of NT5C2 is located close 
to the subunit interface, with the adenosines of two ATP molecules binding back-to-back 
to each subunit of the dimer with a Mg2+ ion coordinated between the two phosphate 
moieties (Figure 1.7). The adenosine moiety forms hydrogen bonds with Gln453, 
Asn154, and is stacked between Phe354 and Ile152 (Figure 1.8). The substrate, IMP, 
binds within the active site with the nucleoside stacked between Phe157, His209 and 
Tyr210 forming electrostatic interactions with Asp206 and Arg202 (Figure 1.8). A second 




Figure 1.8 - Schematic diagrams of allosteric and active sites of NT5C2. (a) Allosteric site 
with activator, ATP, and Mg2+ bound. Residues marked with * are from the neighboring monomer 






Mechanistically, the 5’-nucleotidase activity of NT5C2 proceeds via formation of a 
phosphoenzyme intermediate mediated by three highly conserved HAD motifs in the 
α/β-Rossman-like domain in the catalytic center (Figure 1.9) (Collet, Stroobant et al. 
1998, Allegrini, Scaloni et al. 2001). For NT5C2, Motif I, DXDX(V/T)(L/V/I), is integral to 
the reaction mechanism. The first Asp (Asp52 in NT5C2) of motif I makes a nucleophilic 
attack on the phosphate of the substrate, while the second Asp (Asp54 in NT5C2) 
donates a proton to the departing nucleoside. Motif II is a (S/T) residue (Thr249 in 
NT5C2) which stabilizes the phosphoenzyme intermediate along with the Lys (Lys292 in 
NT5C2) of motif III, K(Xx)D(X0-4)D. The additional negatively charged residues in motif III 
(Asp351 and Asp356 in NT5C2) interact with the metallic cation, Mg2+, which is essential 
for catalytic activity (Allegrini, Scaloni et al. 2001, Allegrini, Scaloni et al. 2004, 
Bretonnet, Jordheim et al. 2005). NT5C2 is also known to possess a 
phosphotransferase activity, but the mechanism for this has not yet been elucidated 




Figure 1.9 – Conserved HAD motif alignment in intracellular 5’-nucleotidase family 




Comparison of the basal (apo) and active (allosteric effector bound) structures of NT5C2 
revealed a role of the Gly355-Gln364 region in the allosteric activation of the enzyme. 
Upon allosteric activator binding, this region (helixA) becomes organized into an alpha 
helix and is stabilized by electrostatic interactions between Lys362 and the phosphate 
groups of the allosteric activator. This conformational change induces a rotation of 
Phe354 moving it out of the active site, allowing Asp356 to move in and trigger 
conformational changes in His352 and Lys292 of motif III, thereby transitioning the 
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enzyme to its active state, allowing for substrate binding and catalysis (Figure 1.10) 
(Wallden and Nordlund 2011).  
 
 
Figure 1.10- Mechanism of activation of NT5C2. (Left) Active site of apo inactive NT5C2 D52N 
537X with disorganizes residues represented by a dotted line. (Right) Active, helix A, 
configuration of NT5C2 D52N 537X. Upon addition of activator (ATP), Mg2+, and substrate 
(IMP), Gly355-Glu364 becomes organized into an alpha helical configuration allowing allosteric 




Additionally, NT5C2 has a striking 13 acidic-residue long C-terminus that is very well 
conserved in mammals which may play a role in the regulation of the enzyme. 
Experiments with C-terminus truncated recombinant protein have suggested that this 
acidic stretch may be important for the formation and stability of the tetrameric structure 
(Spychala, Chen et al. 1999). Additionally experiments under oxidative conditions with 
recombinant NT5C2 protein identified a Cys175-Cys547 disulfide bond that might play a 
role in enzyme regulation depending on redox states of the cell (Allegrini, Scaloni et al. 
2004). Due to its acidic nature, it is suspected that the C-terminus of NT5C2 will bind in 
one of three positively charged regions (i) K(25)KYRR, (ii) K(359)SKKRQ, or (iii) 
Q(420)RRIKK (Spychala, Chen et al. 1999). As of yet, all published structures have 
been solved with C-terminus truncations due to solubility issues thus the regulatory 
capacity of this element is not yet known.  
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NT5C2 in relapsed leukemia  
Using whole exome sequencing of matched diagnosis, remission, and relapse samples, 
we and other groups identified an abundance of mutations in NT5C2 present in relapsed 
ALL patient samples (Meyer, Wang et al. 2013, Tzoneva, Perez-Garcia et al. 2013).  
Mutations in NT5C2 occur in 20% of relapsed T-ALL and 3-10% of relapsed early 
precursor B-ALL cases and are particularly common amongst early relapse patients 
accounting for 35-45% of these cases (Meyer, Wang et al. 2013, Tzoneva, Perez-Garcia 
et al. 2013, Ma, Edmonson et al. 2015, Tzoneva, Dieck et al. 2018). Recently, NT5C2 
mutations have also been identified in acute promyelocytic leukemia (APL) relapse 
samples from patients who have been treated with 6-MP (Lehmann-Che, Bally et al. 
2018). So far in the literature, our group and others have reported 32 independent 
NT5C2 mutant alleles consisting of 27 single amino acid substitutions, four in frame indel 
mutations and a C-terminal truncating mutation (Figure 1.11) (Meyer, Wang et al. 2013, 
Tzoneva, Perez-Garcia et al. 2013, Kunz, Rausch et al. 2015, Ma, Edmonson et al. 
2015, Oshima, Khiabanian et al. 2016, Richter-Pechanska, Kunz et al. 2017, Dieck, 
Tzoneva et al. 2018, Lehmann-Che, Bally et al. 2018, Tzoneva, Dieck et al. 2018). All 
NT5C2 relapse associated mutations present as heterozygous mutations and are only 
found in relapse samples. Extensive deep sequencing efforts have failed to detect 
NT5C2 mutations at the time of diagnosis, or at least at the level of detection available 










NT5C2 in health and disease 
As NT5C2 regulates purine metabolism and levels within the cell, NT5C2 expression 
and activity has been implicated in a number of human malignancies and diseases. Most 
notably, familial germline loss of function NT5C2 mutations have been identified in 
spastic paraplegia (SPG45) (Novarino, Fenstermaker et al. 2014, Darvish, Azcona et al. 
2017). Spastic paraplegia is a neurodegenerative disease resulting in upper motor 
neuron degeneration and lower limb spasticity. Researchers have suggested that 
homozygous loss of NT5C2 function obstructs the development of central white matter 
structures in the brain leading to this devastating disease (Elsaid, Ibrahim et al. 2017). 
Additionally, in genome wide association studies, schizophrenia risk alleles have been 
associated with altered NT5C2 expression (Duarte, Troakes et al. 2016, Hauberg, Holm-
Nielsen et al. 2016). Increased NT5C2 activity levels have also been associated with 
Lesch-Nyhan syndrome, an X-linked deficiency of the purine salvage enzyme 
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hypoxanthine-guanine phosphoribosyltransferase (HGPRT) (Pesi, Micheli et al. 2000). 
NT5C2 was found to dephosphorylate 5'-amino-4-imidazolecarboxamide riboside 5'-
monophosphate (ZMP), a byproduct that accumulates in Lesch-Nyhan syndrome, into Z-
riboside, which promotes apoptosis of neuroblastoma cell lines in culture. Thus it is 
postulated that increased NT5C2 activity in Lesch-Nyhan syndrome contributes to 
neurologic impairment in this disease as well. 
 
In the context of chemotherapy, NT5C2 can also dephosphorylate and inactivate the 
cytotoxic thiopurine monophosphate nucleotides 6-thioinosine monophosphate (6-tIMP), 
6-thioxanthine monophosphate (6-tXMP) and 6-thioguanosine monophosphate (6-tGMP) 
which are generated by the incorporation of 6-thioguanine (6-TG) and 6-mercaptopurine 
(6-MP), two thiopurine nucleoside analogs used in the treatment of acute lymphoblastic 
leukemia, into the salvage pathway of purine biosynthesis (Figure 1.2) (Brouwer, Vogels-
Mentink et al. 2005). Thus, NT5C2 mutations have been identified in relapsed ALL 
patient samples following thiopurine based maintenance therapy. Additionally, increased 
expression of NT5C2 is correlated with worse disease-free survival in acute myeloid 
leukemia (Galmarini, Cros et al. 2005) and increased NT5C2 activity has also been 
associated with resistance to 2-chlorodeoxyadenosine (2-CdA) treatment in patients with 
hairy cell leukemia (HCL) and in refractory chronic lymphocytic leukemia (CLL) 
(Kawasaki, Carrera et al. 1993).  
 
III. NT5C2 inhibitors 
As NT5C2 plays a crucial role not only in regulating endogenous purine levels in the cell, 
but also in the efficacy of thiopurine therapy within the cell, NT5C2 is a relevant clinical 
target for developing therapeutics to decrease therapy resistance and regulate purine 
catabolism in patients with altered nucleotide metabolism. 
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Small molecule drug screening  
Ideally, the first step in drug development is identifying a clear, druggable, target. In 
terms of screening, it is best to have a target that the biologic response can be 
measured in vitro and in vivo (Hughes, Rees et al. 2011). With these parameters, 
chemical library screening has become a major component of drug design. In current 
research trends, there are four common compound screening strategies: (i) Virtual 
library screening (ii) high throughput screening of natural and synthetic chemical libraries 
with no prior chemotype knowledge, (iii) screening of fragment based chemical libraries 
and (iv) screening for physiologic activity with follow up mechanism of action studies. 
 
Virtual screening, which originated in the 1970s, is based around using computational 
models and algorithms to identify potential bioactive molecules (Shoichet 2004, 
Schneider 2010). Virtual screening relies on in silico interrogation of a crystal structure 
with a library of chemical compounds in attempts to identify ligands that bind to 
targetable pockets. Although virtual screening is a fairly cost effective method of 
screening chemicals, it relies heavily on assumptions of binding energies in an aqueous 
environment and sampling of various conformations of flexible compounds and thus 
results in fairly high rates of false-negative and false-positive predictions (Shoichet 
2004). 
 
In recent years, high throughput large library screening of natural compounds and 
synthetically designed compounds has become the standard for identifying novel 
therapeutics (Mayr and Bojanic 2009, Connor, Beckmann et al. 2012, Lachance, Wetzel 
et al. 2012). These screens typically proceed with a large initial screen of hundreds of 
thousands of compounds followed by secondary synthesis and verification of top hits, 
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testing for dose dependent activity in the screening assay, and finally secondary assay 
analyses to avoid off-target compounds that directly interfere with screening assay 
(Figure 1.12). These high throughput based library screens are particularly important 
when no prior knowledge is know about the chemotype likely to show activity against the 
target of interest and provide an unbiased approach to drug design. If virtual screening 
has been done or if previous lead compounds have been identified, screening of more 
focused libraries in a similar manner is particularly useful for a more knowledge-based 
screening library. These more targeted library screens are normally used and designed 
to parse out structure-activity relationships of the lead compound or to improve medicinal 





Figure 1.12 – Overview of drug discovery screening assays. Adapted from Hughes 
et al 2011. 
 
 
In contrast to high throughput screens, fragment-based drug discovery (FBDD) 
screening consists of screening smaller libraries of very small molecular weight 
compounds at high concentrations. FBBD relies on low affinity interactions and allows 
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for screening of low-complexity and diverse chemicals to use as building blocks in the 
development of a more potent inhibitor (Hajduk and Greer 2007).   
 
In addition to these targeted chemical library screens against recombinant protein, some 
screens are also performed in a cellular or organism based model to retain endogenous 
protein function (Swinney and Anthony 2011). These screens come with the advantage 
of maintaining a physiologic setting for drug activity, but require follow up studies to 
identify the direct target of the compound of interest and have the potential for 
unacknowledged off-target effects (Schenone, Dancik et al. 2013).  
 
Importantly, as more and more academic and industry groups perform large-scale 
compound activity screens, chemical databases cataloguing compounds and their 
bioactivity such as ChEMBL (Gaulton, Hersey et al. 2017) and PubChem (Wang, Bryant 
et al. 2017) have been developed to aid researchers as they move through the drug 
development pipeline. In addition to these useful tools and resources for improved small 
molecule designs, a number of rules and guidelines have been established for 
developing inhibitor screens and ideal chemical qualities for new drugs: 
 
High throughput screen assay development 
The majority of chemical screening assays rely on robust activity based screens on 
recombinant protein or in cellular based systems. Most assays used routinely in basic 
lab settings need to be optimized and adapted for high throughput screening due to the 
large scale capacity of these screens. With increasingly large library sizes, researchers 
need to consider speed, efficiency, and low reagent consumption as well as ensuring the 
assay is robust, sensitive, reproducible and accurate in order to ensure quality results 
over a long period of time with batch and reagent variability. A lot of these parameters 
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are met with the use of high capacity 384 or 1536-well plates as well as robotics and 
automated liquid handling systems (Zhang, Chung et al. 1999, Hughes, Rees et al. 
2011). 
 
Most importantly, as most assays are run in singlet or duplicate to minimize reagent 
costs, the assay must be accurate and sensitive in its ability to identify a ‘hit’. This quality 
is assessed by the Z-score of the assay. As high throughput assays have a high level of 
variability including random instrumental and human-based error, the Z-score takes 
these factors into account to ensure accurate differential readings regardless of 
variability in the assay (Figure 1.13) (Zhang, Chung et al. 1999). To ensure a large 
enough separation of control and sample wells, the ideal high throughput assay should 
have a Z-score equal to or higher than 0.5. 
 
 
Figure 1.13 – Z-score for assessing high throughput assay variability and reliability. (Left) 
Illustration of the defined data variation band and separation band in an HTS assay. (Right) Z-
score formula. Adapted from Zhang et al 1999. 
 
 
In particular, for enzyme assays in high throughput conditions, additional parameters 
should be considered. In order to identify competitive inhibitors of an enzymatic reaction, 
it is essential to perform the assay under initial velocity conditions at or below the 
substrate Km of the reaction. Performing the assay at initial velocity minimizes chances 
of reaction saturation and ensures that the reverse enzymatic reaction does not take 
place and interfere with the final readout (Brooks, Geeganage et al. 2004).  
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Small molecule screen chemical guidelines 
With many chemical based screens, researchers have learned to design libraries around 
certain physiochemical properties to aid in a smoother transition from hit identification to 
use in pre-clinical and clinical settings. In 1997 Lipinski and colleagues established the 
Rule of Five to estimate solubility and permeability of chemical compounds used in drug 
discovery screens: poor absorption or permeation compounds have (i) greater than 5 H-
bonds, (ii) 10 H-bond acceptors, (iii) a molecular weigh over 500 or (iv) a calculated 
LogP (Partition-coefficient) greater than 5 and should not be included in chemical 
screens (Lipinski, Lombardo et al. 2001). In addition to considering these rules when 
designing libraries, chemists have also begun to avoid chemicals with known 
toxicophores or reactive groups, which may interfere with synthesis and lead 
optimization down the line (Gribbon and Sewing 2005). 
 
NT5C2 inhibitors updates and progress 
As NT5C2 activity and expression levels have been implicated in chemotherapy 
resistance, a number of groups have begun the process of developing NT5C2 inhibitors 
for the treatment of these patients.  
 
Virtual screening of small a targeted ribonucleoside phosphonates library with follow up 
enzymatic assays identified two β-hydroxyphosphonate analogues which inhibited 
NT5C2 activity at low millimolar concentrations isolating a chemotype for further 
improvement studies (Gallier, Lallemand et al. 2011). Follow up studies with screening of 
32 analogues based on these two lead compounds identified two slightly more potent 
analogues (Figure 1.14): These studies showed that only modest modifications in the 
sugar were tolerated and that nucleobase modifications were possible but ultimately 
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showed no increase in inhibitory capacity. Of note these lead β-hydroxyphosphonate 
compounds are too polar to bypass the cell membranes and thus require further prodrug 
like modifications before use in preclinical models (Meurillon, Marton et al. 2014). 
Additionally, in silico screening of freely available chemical databases yielded an 
anthraquinone derivative (AdiS) that was shown to block nucleotidase activity by binding 
to the allosteric site (Figure 1.14). AdiS showed cytotoxicity in a number of human cell 
lines at very high micromolar concentrations highlighting the need for further optimization 




Figure 1.14 – NT5C2 inhibitory compounds identified in the literature. Adapted from 
Meurillon et al 2014 and Jordheim et al 2013. 
 
 
These studies have made great strides in identifying chemical compounds that may bind 
to and inhibit NT5C2 activity, but further medicinal chemistry is needed in these lead 
compounds to improve their potency, cytotoxicity, and cell accessibility. Additional high 
throughput screens and drug development strategies may highlight additional 







β-hydroxyphosphonate anlalogues  Anthraquinone derivative  
AdiS R=Na 
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IV. Specific Aims 
 
Acute lymphoblastic leukemia is the leading cause of cancer in children and 
adolescents. Although outcomes for these patients has drastically improved over the 
past 50 years, still 20% of these patients fail to achieve a complete remission, relapse, 
and succumb to the disease. NT5C2 has been identified as the most recurrently mutated 
gene at relapse. There is a clear need to better understand how these NT5C2 mutations 
drive clonal evolution and chemotherapy resistance in relapsed ALL in order to better 
treat these patients and improve overall survival. Thus, my central goal was to perform 
structure-function and genetic studies to better understand the role of these variants in 
relapsed ALL and to identify new therapeutics to curtail the emergence of these 
mutations in relapsed ALL. 
 
Towards this goal, I proposed the following aims: 
 
 
Aim 1: Perform an in-depth structure-function analysis of NT5C2 relapse associated 
mutations. 
 
Aim 2: Understand the role of NT5C2 mutations in the clonal evolution of chemotherapy 
resistant relapse. 
 
Aim 3: Therapeutically target NT5C2 mutant leukemias.  
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Chapter 2: Structure and Mechanisms of NT5C2 Mutations 
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SUMMARY
Activating mutations in the cytosolic 50-nucleotidase II gene NT5C2 drive resistance to 6-mercaptopurine in
acute lymphoblastic leukemia. Here we demonstrate that constitutively active NT5C2 mutations K359Q and
L375F reconfigure the catalytic center for substrate access and catalysis in the absence of allosteric acti-
vator. In contrast, most relapse-associated mutations, which involve the arm segment and residues along
the surface of the inter-monomeric cavity, disrupt a built-in switch-off mechanism responsible for turning
off NT5C2. In addition, we show that the C-terminal acidic tail lost in the Q523X mutation functions to restrain
NT5C2 activation. These results uncover dynamic mechanisms of enzyme regulation targeted by chemo-
therapy resistance-driving NT5C2 mutations, with important implications for the development of NT5C2 in-
hibitor therapies.
INTRODUCTION
NT5C2 is a highly conserved and ubiquitously expressed cyto-
solic nucleotidase involved in the maintenance of intracellular
nucleotide pool homeostasis by promoting the clearance of
excess purine nucleotides from cells (Allegrini et al., 1997; Bandi-
telli et al., 1996; Hunsucker et al., 2005; Itoh et al., 1967; Pesi
et al., 1994; Spychala et al., 1988; Tozzi et al., 1991). NT5C2 pref-
erentially dephosphorylates the 6-hydroxypurine monophos-
phates inosine monophosphate (IMP), guanosine monophos-
phate (GMP), and xanthosine monophosphate, as well as the
deoxyribose forms of IMP and GMP (dIMP and dGMP), facili-
tating the export of the resulting purine nucleosides out of the
cell (Hunsucker et al., 2005). The importance of this activity for
cell homeostasis is highlightedby theassociation of loss-of-func-
tion mutations in NT5C2 with hereditary spastic paraplegia in
Significance
Gain-of-functionNT5C2mutations are highly prevalent in high-risk early relapse leukemiamaking NT5C2 themost prevalent
therapeutic target in relapsed acute lymphoblastic leukemia. Here we identify distinct mechanisms of NT5C2 regulation tar-
geted by relapse leukemia-associated NT5C2mutations. These results support a critical role of negative regulators of allo-
steric activation in the control of NT5C2 activity pointing to the allosteric effector site as a potential therapeutic target for the
development of NT5C2 inhibitors.
136 Cancer Cell 34, 136–147, July 9, 2018 ª 2018 Elsevier Inc.
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humans (Novarino et al., 2014). Yet, perhaps the most prominent
role of NT5C2 in human disease results from the capacity of this
enzyme to dephosphorylate and inactivate cytotoxic thiopurine
monophosphate nucleotides––6-thioinosine monophosphate,
6-thioxanthosine monophosphate, and 6-thioguanosine mono-
phosphate—generated by the incorporation of 6-thioguanine
(6-TG) and 6-mercaptopurine (6-MP), two thiopurine nucleoside
analogs used in the treatment of lymphoblastic leukemia, into
the salvage pathway of purine biosynthesis (Brouwer et al.,
2005). In this context, somatic gain-of-function mutations in
NT5C2 encoding proteins with increased nucleotidase activity
drive selective resistance to chemotherapy with 6-MP and
6-TGandare recurrently present in acute lymphoblastic leukemia
(ALL) samples at relapse, with a prevalence as high as 35%–45%
in early relapse ALL cases progressing under 6-MP chemo-
therapy (Ma et al., 2015; Meyer et al., 2013; Tzoneva et al.,
2013, 2018).
Structurally, NT5C2 is a member of the haloacid dehalogenase
(HAD) superfamily of Mg2+-dependent intracellular 50-nucleotid-
ases (KooninandTatusov,1994) and functionsasahomotetramer
made up of a dimer of two tightly associated dimers (Wallden
et al., 2007). Mechanistically, the 50-nucleotidase activity of
NT5C2 proceeds via formation of a phosphoenzyme intermediate
mediated by three conserved HAD motifs in the catalytic center
(Allegrini et al., 2001; Collet et al., 1998). Motif I, DXDX(V/T) (L/V),
is most integral to the reaction mechanism, in which the first
Asp (Asp52 in NT5C2) makes a nucleophilic attack on the phos-
phate of the substrate and the second Asp (Asp54 in NT5C2) do-
nates a proton to the departing nucleoside. Motif II is a (S/T)
residue (Thr249 in NT5C2) which stabilizes the phosphoenzyme
intermediate, and motif III, K(Xx)D(X0-4)D, contains a highly
conserved Lys (Lys292 in NT5C2), which also contributes to the
stabilization of the intermediate by countering some of the nega-
tive charges. In addition, motif III contains Asp351 and Asp356
in NT5C2, which interact with an essential Mg2+ ion involved in
the catalysis. Moreover, Asp54 in motif I also helps to coordinate
theMg2+ ion, while Met53 and Thr56 (motif I) are important for the
correct orientation of all Asp residues. These elements define the
structural components required for the catalytic activity ofNT5C2.
NT5C2 functions as a dimer of dimers, with the dimer being the
smallest functional unit with enzymatic activity (Spychala et al.,
1988; Wallden and Nordlund, 2011) and is regulated by allosteric
activators with ATP, dATP, and diadenosine tetraphosphate
(Ap4A) as the most likely activators at physiological concentra-
tions (Marques et al., 1998; Pinto et al., 1986; Spychala et al.,
1988). The effector binding site of NT5C2 is located close to
the subunit interface, with two ATP molecules binding back-to-
back to each subunit of the dimer. Comparison of the basal
(apo) and active (allosteric effector bound) structures of NT5C2
revealed a role of the Gly355-Glu364 region in the allosteric acti-
vation of the enzyme. This segment (helix A) is disordered in the
apo inactive form of the enzyme and adopts an ordered a helix
conformation in the effector-bound activated state. This confor-
mational change facilitates substrate binding and catalysis by
inducing a rotation of Phe354 out of the active site and bymoving
Asp356 into the catalytic center (Wallden and Nordlund, 2011).
The relevance of helix A in the activation of NT5C2 is supported
by modeling studies implicating local conformational changes in
this region as responsible for the increased nucleotidase activity
of a strongly activating NT5C2 mutation mapping to this site
(NT5C2 p.K359Q) (Tzoneva et al., 2013). Yet, the majority of
NT5C2 mutations found in relapse ALL are located outside of
this helix A region, suggesting that additional regulatory ele-
mentsmay be involved in the control of NT5C2 activity. However,
these mutations show an apparent random spatial distribution in
the structure of the enzyme and their mechanisms of action
remain to be established.
RESULTS
Functional Heterogeneity of NT5C2 Mutations in
Relapsed ALL
To gain further insight on the role and mechanisms of NT5C2
in resistance to 6-MP chemotherapy we compiled allelic
data on 643 relapsed ALL cases along with previously
published data (Kunz et al., 2015; Ma et al., 2015; Meyer et al.,
2013; Oshima et al., 2016; Richter-Pechanska et al., 2017;
Tzoneva et al., 2013, 2018) identifying in all 32 independent
NT5C2 mutant alleles consisting of 27 single amino acid substi-
tutions, four in-frame indel mutations (p. Asp396_Ala400del,
p.Lys404delinsLysAsp, p. Ser408_Asp415del, and p.Ser445_
Arg446delinsPhe_Gln) and a C-terminal truncating mutation
(p.Gln523*) (Figure 1A; Table S1) under the supervission of the
Columbia University Institutional Review Board. Gain-of-func-
tion mutations resulting in increased enzymatic activity typically
cluster in defined protein domains involved in enzyme regulation
(Gao et al., 2017; Tamborero et al., 2013). In this context, we
identified recurrent relapsed leukemia-associated NT5C2 muta-
tions involving Arg39, Arg238, Arg367, Leu375, Asp407, and
Pro414 supporting a potentially important role of these residues
in the control of NT5C2 activity. However, each of these recur-
rent mutations show inexplicit functional features and none of
them are located in the catalytic regulatory helix A region.
To functionally explore the role of NT5C2mutations asdrivers of
increased nucleotidase activity and thiopurine resistance, we
tested their activity and response toATPallosteric activation (Mar-
ques et al., 1998; Pinto et al., 1986; Spychala et al., 1988) in in vitro
nucleotidase assays. These analyses revealed distinct patterns of
enzymatic activity and responses to ATP. Purified recombinant
NT5C2 K359Q and NT5C2 L375F (class I mutations) showed
markedly increased basal nucleotidase activity with reduced
response to allosteric activation (!1.5-fold increase over basal at
0.3 mM ATP), below that observed in wild-type (WT) recombinant
NT5C2 (2.6-fold over basal at 0.3mMATP) (Figure 1B). In contrast,
most relapse-associated activatingNT5C2 alleles (R39Q, R238W,
R367Q, D407A, S408R, S445F, and R478S) (class II mutations)
showed increased nucleotidase activitywith retained or increased
dynamic response to ATP allosteric regulation (2.3- to 4.6-fold
over basal at 0.3 mM ATP) (Figure 1C). Finally, a C-terminal trun-
catedmutantprotein,NT5C2Q523X,showednucleotidaseactivity
levels similar to thoseof theWTNT5C2 inbasal conditionsbutwas
hyper-responsive (6.5-fold over basal at 0.3 mMATP) to allosteric
activation (class III mutation) (Figure 1D).
NT5C2 Structure and Activation-Associated
Conformational Changes
To investigate the molecular basis mediating the heteroge-
neous patterns of activity of NT5C2 activating mutations, we
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determined crystal structures of the basal and active states of
relapse-associated mutants and WT full-length human NT5C2
proteins at up to 1.8 A˚ resolution (Figures S1A–S1D; Tables
S2 and S3). The structure of the full-length human NT5C2 mono-
mer revealed a HAD core (residues 30–372 and 435–478) with
three extensions consisting of the N-terminal (residues 1–29),
helical arm (residues 373–434), and C-terminal (residues 479–
561) regions (Figures 2A–2F). Moreover, analysis of the struc-
tures of WT human NT5C2 in the basal (Apo) and the activated
(Pi bound in the effector site) state show marked conformational
and functional changes in the monomer (Figures 2A and 2B),
dimer (Figures 2C and 2D), and tetramer (Figures 2E and 2F)
of the enzyme upon activation, which were selectively altered
by each class of NT5C2 mutations. Moreover, analysis of the
buried surface area at the interface of two different (strong
and weak) dimers, forming the NT5C2 tetramer showed that
the strong dimer in each basal structure appears to bury twice
as much area at its dimer interface compared with its active
counterpart, supporting that the NT5C2 dimer and tetramer
adopt a more open configuration upon allosteric activation (Fig-
ures S1E and S1F; Table S4).
Mechanism of NT5C2 Class I Mutations
In agreement with previous studies (Wallden and Nordlund,


















































































   
561IIIIII













































































































































Figure 1. Distribution and Activity Profile of
NT5C2Mutations in Human-Relapsed Acute
Lymphoblastic Leukemia
(A) Graphical representation of relapse-associated
mutations in B-ALL (black) and T-ALL (red). HAD
core motifs are shown in black rectangles with
roman numerals.
(B–D) In vitro nucleotidase assays assessing the
enzymatic activity of class I (B), class II (C), and
class III (D) NT5C2 mutations in the presence of
increased concentrations of ATP represented as
specific activity (top) and specific activity relative
to no ATP (bottom). Data in (B–D) are shown as
mean ± SD. See also Table S1.
NT5C2 change from a loop structure
to a helix (helix A) upon activation.
This conformational change is triggered
by electrostatic interactions between
Lys362 and the phosphate moieties of
the ATP effector and mediates the activa-
tion of the enzyme by moving Phe354
out of and Asp356 into the active site,
enabling it for substrate binding and
catalysis (Figure S2) (Wallden and Nor-
dlund, 2011). Of note, this active structure
is stabilized by ionic interactions between
Lys361 in helix A and Asp459, which
is also positioned between Arg39 and
Arg367 (Figure S2). Notably, analysis of
the crystal structures of NT5C2 K359Q
(Figure 3A) and NT5C2 L375F (Figures
3B and 3C), showed that this mechanism
is hijacked by these class I NT5C2 mu-
tants, which adopt an active conformation even without ATP or
Pi bound in the effector site. Thus, and consistent with modeling
analyses (Tzoneva et al., 2013), in NT5C2 K359Q, a mutation
located within the helix A region of NT5C2, the Gln359 side chain
contacts both the backbone and the side chain of Phe354,
thereby promoting the formation of an active helix A configura-
tion (Figure 3A). In addition, the presence of Gln at position 359
alters the neighboring network of interactions between Lys361
and Asp459 by abolishing one of two hydrogen bonds between
Arg367 and Asp459, thereby allowing for increased stabilization
of helix A (Figure 3A). Notably, the helix A region in the second
class I mutant protein NT5C2 L375F is also organized in an active
helical conformation in the absence of ATP or Pi (Figure 3B), as
observed previously (Hnizda et al., 2016, 2018). Yet, the specific
mechanisms driving this active conformation were not directly
apparent as Leu375 is located away from the helix A region (Fig-
ure 3C). Mechanistically, detailed inspection of the NT5C2 L375F
full-length structure revealed that the extra bulk of the Phe side
chain forces a shift of !1 A˚ in the Ca position of L375F and dis-
places the underlying helical arm (Figure 3C). As a result, Arg98,
which makes two salt bridges with Glu373, and one hydrogen
bond with the backbone of Asn154 in basal and active WT
NT5C2 and NT5C2 K359Q, makes only one salt bridge with
Glu374 in NT5C2 L375F, which, in turn, favors the interaction
of Phe450 with Ile353 and an active conformation of helix A
138 Cancer Cell 34, 136–147, July 9, 2018
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(Figure 3B). In addition, the Phe side chain introduced by the
L375F mutation also engages in enhanced interactions with hy-
drophobic residues Phe36, Leu379, Phe441, Tyr461, and His486
from the neighboring NT5C2 subunit through favorable p-stack-
ing (Figure 3C). These results demonstrate that an active confor-
mational state of the helix A region in the absence of allosteric
modulator mediates the gain-of-function properties of NT5C2
K359Q and NT5C2 L375F class I mutants.
Although the underlying mechanisms mediating the increased
activity of non-class I NT5C2 mutant proteins did not became
directly apparent in the analyses of the conformational changes
in the helix A segment, it did not escape our attention that activa-
tion-associated changes in NT5C2 also involve shifts in the posi-
tion of the helical arm and the C-terminal segments (Figures 2A–
2F). We hypothesized that despite their distant location from the
catalytic site, these elements could also have a regulatory role
with potentially important implications for understanding the
mechanisms of action of class II and class III NT5C2 mutant
proteins.
Mechanism of NT5C2 Class II Mutations
Close inspection of the distribution of class II NT5C2 mutations
revealed a group of NT5C2 alleles (R39Q, R238W/L/G/Q,
R367Q, S445F_R446Q, and R478S) located in a positively
charged pocket at the interface of the tightly associated dimer
(Figures 2A–2D and S3A), while a second group of class II muta-
tions (K404N, 404-405insD, D407A/Y/E/H, S408R, P414S/A, and
D415G) locate in the tip region of the arm segment (Figures 2A–
2D). Notably, all class II NT5C2 mutant variants characterized in
our enzymatic assays localize in these two regions. Based on
this observation we proposed that class II mutants located in
the positively charged pocket region (R39Q, R367Q, S445F,
R238W, and R478S) and loop segment (D407A and S408R)
could share a common mechanism of action. Consistently, the
crystal structures (Table S2) of a recurrent mutation (R238W)
involving the R238 residue located in the protein surface adja-
cent to the entrance of the inter-subunit pocket (Figure S3B),
the structure of a representative allele (D407A) involving the
D407 residue in the tip region of the arm segment (Figure S3C),
Figure 2. Crystal Structure of Basal and Activated WT Human NT5C2
(A) A Ribbon diagram of the basal structure of the full-lengthWTNT5C2, displaying the HAD domain (cyan) and its three extensions: N-terminal segment (orange),
arm region (pink), and C-terminal segment (marine). The mutation sites are depicted as red solid spheres for Ca of each mutated amino acid. The phosphate
(yellow for phosphorus) ions are depicted as stick models and labeled as Pi. The N and C termini amino acids (L24 and D552), and the termini amino acids (T510
and P541) of the disordered region in the C segment are also labeled.
(B) A ribbon diagram of the active structure of NT5C2 WT, in which the allosteric helix A (aA) is shown in dark purple. The N and C termini amino acids (S4 and
S488), and the termini amino acids (L402 and R421) of the disordered region in the arm segment are also labeled.
(C and D) Ribbon and surface (for subunit B) depictions of basal (C) and active (D) dimers of WT.
(E and F) Ribbon diagrams of the basal (E) and active (F) WT tetramers, respectively. Solid blue oval and blue arrows represent crystallographic 2-fold, while solid
red arrow represents non-crystallographic 2-fold. See also Figure S1 and Tables S2, S3, and S4.
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and that of two recurrent class II pocket mutations (R39Q and
R367Q) involving basic amino acids at the bottom of the posi-
tively charged inter-subunit pocket (Figure S3D), showed a com-
mon conformation in which the helix A region adopted an active
structure similar to that ofWTNT5C2 in the presence of allosteric
activator (Figures 4A–4D). These results support that the posi-
tively charged pocket and the tip of the arm segment could
form a single functional unit.
In considering the potential mechanism mediating the effects
of NT5C2 class II mutants it is worth noting that NT5C2 activation
results in dynamic configuration changes of the tip region of the
arm segment. Specifically, the loop at the tip of the helical arm
segment of NT5C2 establishes intimate contacts with the other
monomer in the basal structure, yet these contacts are lost
upon activation, with the helical arm pivoting away from the other
monomer and the tip region becoming disordered upon allo-
steric activation, supporting a role for this element in NT5C2
regulation (Figures 2A–2F).
To evaluate the regulatory capacity of the tip of the helical arm
segment we performed a CRISPR/Cas9 gain-of-function screen.
While CRISPR/Cas9-induced frameshifts and in-frame indels
targeting critical enzymatic domains are likely to be loss-of-func-
tion, in-frame alleles involving negative regulatory domains can
produce protein variants with increased enzymatic activity (Do-
novan et al., 2017; Ipsaro et al., 2017). Such gain-of-function al-
leles are selectable in functional screens by their capacity to
confer resistance to specific inhibitors (Donovan et al., 2017; Ip-
saro et al., 2017). Here we aimed to test the potential role of the
tip region of the arm segment as a potential negative regulator of
NT5C2 activity following this strategy. Toward this goal we ex-
pressed Cas9 and gRNAs targeting two sites in the Nt5c2 locus
at codons H405 and I416 in the tip segment of the arm domain in
mouse leukemia lymphoblast cells and then selected potential
gain-of-function CRISPR-directed non-homologous end joining
generated mutations resulting in increased NT5C2 nucleotidase
activity for their capacity to confer resistance to 6-MP (Fig-
ure S4A). Deep sequencing analysis of CRISPR/Cas9-induced
mutations treated with 6-MP revealed a positive selection of
Nt5c2 in-frame indels and point mutations compared with
vehicle-treated controls (Figures 5A and 5B). Characterization
of a selection of positively selected in-frame alleles demon-
strated gain-of-function effects with increased nucleotidase ac-
tivity (Figure S4B; Table S5). Consistently, extended targeted
mutation analysis of the tip region of the arm segment of
NT5C2 in relapsed ALL patient samples identified an in-frame
NT5C2 deletion removing much of this element (delS408-D415)
(Figure S4C). Notably, this mutation behaved as a class II gain-
of-function allele in enzymatic assays and conferred resistance
to 6-MP chemotherapy when expressed in ALL cell lines (Figures
S4D and S4E). In all, these results support that local disruption of
the tip region of the arm segment of NT5C2 leads to deregulated
enzymatic activity, and point to this segment as a negative reg-
ulatory element disrupted by a subset of class II NT5C2 muta-
tions in relapsed ALL.
Should the tip of the arm segment and the positively charged
inter-monomeric pocket targeted by class II NT5C2 mutations
form a bipartite regulatory unit, then we predicted that these
two regions could physically interact. In support of this possibil-
ity, the tip region of the arm segment of NT5C2 (Ser408) contacts
the neighbor subunit (Arg238) in the absence of allosteric acti-
vator, which places Asp407, a recurrently mutated residue in
the tip region, at the entrance of the positively charged dimer
interface (Figure S4F). Moreover, molecular modeling analyses
of the arm segment of NT5C2 revealed that, following allosteric
stimulation, the NT5C2 Glu401-Asp415 segment can invade
the positively charged inter-subunit pocket, which opens up
upon activation (Figures 5C and S4G). Notably, the Asp407 res-
idue targeted by recurrent mutations in the arm segment plays
an important role in this transition by interacting with positively
charged residues along the surface of the inter-subunit pocket
(Figure S4G). Markedly, the most favorable (lowest potential
energy) conformation for Asp407 in the activated state of
NT5C2 places this residue interacting via hydrogen bonding
with Lys361 on the helix A segment of the neighboring protomer
(Figure S4H). This contact, in turn, would destabilize the interac-
tion between Lys361 and Asp459 responsible for maintaining the
enzyme in the activated state (Figure 5D) and return NT5C2 to its
basal inactive conformation. Based on these results we propose
that class II mutations would disrupt the dynamic movement of
the tip region of the arm domain through this inter-monomeric
cavity (Figure S4).
To formally test this model, we blocked the dynamic move-
ment of the tip region of the arm segment loop containing
Asp407 in WT NT5C2 using two independent antibodies against
this element and tested the effects of this perturbation in NT5C2
activity. In these experiments, incubation ofWT NT5C2 recombi-
nant protein with tip region antibodies resulted in increased
NT5C2 nucleotidase activity in basal conditions and, upon
Figure 3. Crystal Structures of Class I
NT5C2 Mutants
(A) Structure overlay of the active full-length
WT NT5C2 (gray for Ca atoms) and the constitu-
tively active K359Q NT5C2-537X (K359Q-537X)
(color), in which the interaction between K359Q
and F354 is shown. The hydrogen bonds are shown
in red dashed lines and black, the latter of which is
present only in the structure of WT.
(B) Structure overlay of L375F (color) with the active
WT (gray). The residues affected by the L375F
mutation are shown with stick models and colored
accordingly.
(C) Structure overlay of WT (gray) and the constitutively active full-length NT5C2 L375F (L375F) (color), shows the mutation site L375F at the base of the arm
extension. The hydrophobic residues surrounding L375F are shown as stick models and labeled. See also Figure S2.
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allosteric activation, phenocopying the effect of class II muta-
tions (Figure 5E). Importantly, the activating effect of these
NT5C2 antibodies was reversed by pre-incubation with a tip re-
gion peptide (Figure 5E). In all, these results identify a dynamic
switch-off NT5C2 auto-regulatory mechanism mediated by the
interplay of the tip of the arm segment and the positively charged
inter-monomeric pocket targeted by class II relapsed-associ-
ated NT5C2 mutations.
Mechanism of the Class III NT5C2 Q523X Mutation
Distinct from class I and class II mutations, the Q523XC-terminal
truncating mutant shows nucleotidase activity levels similar to
that of WT NT5C2 but a more dynamic response to allosteric
activation, in support of a third mechanism of NT5C2 regulation
(Figure 6A). Of note, the C-terminal region of NT5C2 is highly
conserved in vertebrates and contains a stretch of acidic resi-
dues at its end (Figure 6B). Moreover, this segment undergoes
major conformation changes in the context of NT5C2 activation,
suggesting a regulatory role for this region (Figures 2A–2F).
In the absence of an allosteric regulator, the C-terminal
segment of one NT5C2 subunit (residues 479–510 and 537–
553) folds over the base of the arm segment of the neighboring
protomer so that the acidic C-terminal tail introduces itself
into the positively charged inter-subunit pocket promoting a
compact dimer and a tightly associated NT5C2 tetramer confor-
mation (Figures 6C, 6D, and S5A). Of note, this tightly closed
conformation is released in the allosterically activated structure
of NT5C2 in which the C-terminal is no longer visible at the dimer
interface and is also displaced from the surface of the neigh-
boring subunit by the N-terminal segment (Figure S5B). These
results support that the acidic tail of NT5C2 may provide a hin-
drance toward NT5C2 activation by stabilizing the closed inac-
tive conformation of the enzyme. To functionally evaluate the
role of the C-terminal segment of NT5C2 and its interaction
with the positively charged inter-subunit pocket in the control
of NT5C2 activation we tested the effects of incubating WT
NT5C2 protein with polyclonal antibodies recognizing the C-ter-
minal acidic tail in nucleotidase assays. In these experiments
two independent antibodies recognizing the C-terminal acidic
tail of NT5C2 induced increased enzymatic activity in response
to allosteric activation (Figure 6E). Moreover, the activating ef-
fect of these antibodies was reversed by pre-incubation with a
NT5C2 C-terminal tail blocking peptide, indicating that disrupt-
ing the interaction of the C-terminal acidic tail of NT5C2 with the
positively charged inter-subunit pocket by antibody binding can
reproduce the effects of the class III NT5C2 Q523X mutation
(Figure 6E). Finally, and as predicted by this model, the apo
crystal structure of NT5C2 Q523X (Table S2) revealed a dimer
structure more open than that present in the apo form of
NT5C2 full-length crystals (Table S4), and its active structure
showed a helix A conformation similar to that of active WT
NT5C2 (Figures 6F and S1). In heterozygous NT5C2 mutant
cells, both homotypic and heterotypic dimers should be present
(Figure S5C). In cells harboring the NT5C2 Q523X mutant allele,
homotypic (Q523X/Q523X or WT/WT) and heterotypic (WT/
Q523X) dimers can be combined in six different tetramer config-
urations (WT/WT + WT/WT; WT/WT + WT/Q523X; WT/Q523X +
WT/Q523X; Q523X/Q523X + Q523X/WT; Q523X/Q523X + WT/
WT; and Q523X/Q523X + Q523X/Q523X). In this context we pre-
dict that the ‘‘opening’’ effect of the Q523X truncating mutation
would be most prominent in homotypic mutant dimer (Q523X/
Q523X) containing tetramers compared with complexes con-
taining heterotypic (WT/Q523X) protein pairs. Yet, in all, our re-
sults support that loss of the C-terminal tail of NT5C2 in the
Q523X class III mutation decreases the threshold for allosteric
NT5C2 activation by promoting a more relaxed dimer and
tetramer configuration.
DISCUSSION
Detailed functional understanding of the action of biological mol-
ecules involved in disease is essential for the development of
rational therapeutic strategies, yet deciphering the underlying
role of dynamic components based on structural information re-
mains a daunting task. The structural and biochemical studies of
NT5C2 presented here provide significant insights into the mode
Figure 4. Crystal Structure of NT5C2 Class II Mutations
(A) Structure overlay of the basal full-length NT5C2 R367Q (R367Q) (color) and the basal full-length WT NT5C2 (gray for Ca atoms), displaying the side chains of
important residues near effector binding site.
(B) Structure overlay of the basal full-length NT5C2 R39Q (color) and the basal WTNT5C2 (gray for C atoms), displaying the side chains of important residues near
effector binding site. A salt bridge between R367 (in cyan) and D551 (in marine) from the C-terminal segment is shown with a red dashed line.
(C) Structure overlay of the active R367Q (color) and the active WT (gray), showing the mutant R367Q does not form a hydrogen bond with D459. The two
phosphate ions, present in the active WT are depicted as stick models.
(D) Structure overlay of the active full-length NT5C2 R39Q (R39Q) (color) and the active WT (gray). ATP and Mg2+ ion, present in the R39Q structure, are depicted
as a stick model and a dark green solid sphere, respectively. The hydrogen bonds in the R39Q structure are shown as red dash lines, while the black dash lines
represent the hydrogen bonds in the active WT structure. See also Figure S3.
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of action and regulation of this nucleotidase, elucidating specific
mechanisms responsible for stabilizing the basal inactive config-
uration of the enzyme, for triggering allosteric activation, and for
returning the enzyme to its basal inactive state. Most critically,
these findings shed light on the mechanisms of activating muta-
tions in NT5C2 responsible for driving resistance to 6-MP
chemotherapy in relapsed ALL, setting the stage for the develop-
ment of small-molecule NT5C2 inhibitors for the reversal of
chemotherapy resistance in human leukemia.
Enzymatic analyses of recombinant proteins representative of
NT5C2 mutations distributed in different regions of the protein
in basal conditions and in response to allosteric activation
confirmed the gain-of-function nature of relapse-associated
NT5C2 alleles. Yet, these analyses revealed diversity in the enzy-
matic properties of these mutations. We distinguished three
groups ofmutations based on their enzymatic profile. Class I mu-
tations encompass alleles K359Q and L375F, which show a
strong increase in nucleotidase activity in the absence of
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Figure 5. Functional Characterization and Modeling of the Arm Segment Region Targeted by Class II NT5C2 Mutations
(A and B) Graphical representation of mutations selected for in murine leukemic cells infected with a gRNA targeting H405 (A) or I416 (B) after treatment with
vehicle or 2 mM 6-MP.
(C) Modeling analysis of the top 20 preferred conformations of the flexible arm segment in the inactive and allosterically activated NT5C2.
(D) A close-up view of the proposed interaction between Asp407 and Lys361 causing disruption of the a helix stabilizing the Asp459-Lys361 interaction.
(E) Western blot showing the specificity of antibodies generated against the tip region of the arm domain for NT5C2 (left) and in vitro nucleotidase assays of
purified WT NT5C2 recombinant protein incubated with two unique arm segment antibodies or the arm segment peptide in the presence of increasing doses of
ATP (right). Data in (E) are shown as mean ± SD. The p values were calculated using two-tailed Student’s t test, **p < 0.001, ***p < 0.0001. See also Figure S4 and
Table S5.
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Human  KPPNLFPLAP QEITHCHDED DDEEEEEEEE 
Rhesus  KPPNLFPLAP QEITHCHDED DDEEEEEEEE 
Opossum  KPPNLFPLAP QEITHCHDED DDEEEEEEEE
Dog  KPPNLFPLAP QEITHCHDED DDEEEEEEEE 
Mouse  KPPNLFPLAP QEITHCHDED DDEEEEEEE. 
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Figure 6. Functional Characterization of the NT5C2 C Terminus and Class III Mutation
(A) In vitro nucleotidase assays assessing the enzymatic activity of class III NT5C2 Q523X mutation in the presence of increased concentrations of ATP.
(B) Protein sequence alignment of the C-terminal of NT5C2 in vertebrate species.
(C) Basal structure of the full-length NT5C2 R39Q (R39Q), displaying the interactions of predominantly acidic region of the C-terminal segment with the positively
charged residues at the dimer interface. Red dashed lines depict hydrogen bonds. The side chains of residues that are involved in polar interactions are shown by
stick models. The side chain of R39Q is colored with light magenta, while others are colored accordingly.
(D) A surface potential depiction of the dimer interface in the basal structure of the full-length R39Q (R39Q). The acidic tail of the protomer A is shown with a stick
model in which several acidic residues are labeled.
(E) Western blot showing the specificity of antibodies generated against the C terminus of NT5C2 (top) and in vitro nucleotidase assays of WT NT5C2-purified
recombinant protein incubated with two unique C terminus targeted antibodies or the C terminus peptide in the presence of increasing doses of ATP (bottom).
(legend continued on next page)
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allosteric activation. Class II alleles, which account for >95% of
relapse-associated NT5C2 mutations, show increased levels of
nucleotidase activity in basal conditions, yet their enzymatic
activity is still dynamically increased in response to allosteric
effector. Finally, the class III group of NT5C2mutations is defined
by the C-terminal truncating NT5C2 Q523X allele, which shows
nucleotidase activity similar to that of WT NT5C2 in basal condi-
tions but is hyper-responsive to allosteric activation.
Two distinct selection pressures influence the clonal evolution
of NT5C2 mutations in ALL. In the absence of 6-MP chemo-
therapy, depletion of the intracellular nucleoside pool as a result
of increased activity of this enzyme normally involved in purine
degradation, can negatively impact the growth of NT5C2 gain-
of-function bearing leukemia clones (Tzoneva et al., 2018). How-
ever, increased clearance of thiopurine metabolites during 6-MP
therapy confers a selective advantage to cells harboring
activating NT5C2 alleles. Class II NT5C2 mutations, by far the
most prevalent group in relapsed ALL, balance these two
opposing selective pressures by conferring increased nucleo-
tidase activity, yet retaining control by allosteric regulation. It is
possible that the rare, yet stronger, class I alleles are less
frequently found because of a higher fitness cost in the absence
of 6-MP chemotherapy, and that weaker class III NT5C2 muta-
tions are poorly selected as result of a more limited capacity to
confer resistance to 6-MP.
NT5C2 is kept in an inactive state in the absence of allosteric
activators binding to the effector site. This inactive basal confor-
mation is secured by the C-terminal acidic tail, which inserts it-
self in between the two NT5C2 dimer subunits establishing mul-
tiple interactions with positively charged residues. In this, the
C-terminal segment of NT5C2 functions as a fastener securing
a tight closed inactive configuration of the enzyme. As a result,
NT5C2must undergo structural rearrangement in order to switch
to an active configuration. This transition to an active state, in-
volves the organization of the N-terminal segment of the protein
in a helical configuration. This displaces the C terminus from the
surface of the neighboring subunit and removes it from the inter-
monomeric space, now favoring a more open dimer conforma-
tion. In addition, binding of ATP to the effector site induces allo-
steric activation by inducing the helical conformation of the helix
A segment, which reconfigures the catalytic center for substrate
accessibility and catalysis. Yet, the transition to an activated
state is coupled with a mechanism that returns the enzyme
back to its inactive basal configuration. As the inter-subunit
space opens, Asp407 in the tip segment of the arm domain is
mobilized from its location next to the opening of this cavity
and is pulled into the inter-monomeric space via interactions
with multiple positively charged residues lining the surface of
this pocket. In this way, the negatively charged Asp407 ulti-
mately reaches and destabilizes the helix A segment, located
at the bottom of the inter-subunit pocket. In this, a mechanistic
parallel can be seen between NT5C2 and Marvin Minsky’s ‘‘ulti-
mate machine’’ design, a self-inactivating device consisting of a
box with a switch which, when turned ‘‘on,’’ activates a lever that
appears from inside the box and turns the switch back ‘‘off.’’
Activating gain-of-function mutations driving oncogenic trans-
formation involving multiple different mechanisms are recur-
rently found in human cancer. Mutations in the PEST domains
of MYC (Salghetti et al., 1999) and NOTCH1 (Weng et al.,
2004) result in increased protein stability via disruption of degron
motifs responsible for protein turnover via proteasomal degrada-
tion. Activating mutations in RAS signaling factors lock these
proteins in their active GTP-bound configuration by interfering
with their intrinsic GTPase activity (Scheffzek et al., 1997). In
addition, kinase oncoproteins are frequently activated by muta-
tions that interfere with intramolecular interactions responsible
for keeping them inactive in basal conditions. For example,
lymphoma-associated activating mutations involving the SH2
domain and the C-terminal region of FYN kinase disrupt the
inhibitory interaction of these elements induced by CSK phos-
phorylation of the FYN C-terminal region Y531 (Palomero et al.,
2014). At other times, activating mutations favor activation by
interfering with allosteric inhibitory feedback mechanisms, as is
the case in PFK1 mutations, which drive increased glycolytic ac-
tivity in some tumor cells (Webb et al., 2015). In this regard, and
of relevance to 6-MP resistance, activating mutations in PRPS1
found in leukemia interfere with allosteric feedback inhibition of
this enzyme by purine metabolites resulting in increased nucleo-
tide biosynthesis and consequent inhibition of 6-MP activation
(Li et al., 2015). Some aspects of NT5C2 activation by relapsed
leukemia-associated mutations, such as the disruption of intra-
molecular interactions responsible for maintaining the enzyme
in an inactive configuration (class III mutations), or the mimicry
of the effects of allosteric regulation with the catalytic center
(class Imutations), relate to some of those found in other proteins
with cancer-associated activating mutations. Yet, to our knowl-
edge, the dynamic switch-off of the activated helix A mediated
by the tip region of the arm domain and the positively charged in-
ter-monomeric unit targeted by class II mutations represents a
self-regulatory mechanism distinct from those present in other
enzymes harboring gain-of-function mutations.
Large-scale cancer-sequencing efforts have uncovered a
complex landscape of somatic mutations associated with malig-
nant transformation (Cancer Genome Atlas Research Network
et al., 2013). However, the interpretation of individual mutations
can be challenging in the absence of mechanistic information,
thus highlighting the need for in-depth functional analyses.
This imperative is particularly pressing in the case of muta-
tions potentially driving clinically relevant phenotypes such as
response or resistance to therapy. The results reported here
demonstrate a functional and structural diversity of leukemia-
associated NT5C2 mutations and provide a framework for the
functional interpretation of these genetic lesions in the clinic.
Thus, mutations involving the tip segment of the arm region
and residues located in the inter-subunit space, particularly
those involving positively charged residues, and truncating
(F) Structure overlay of the basal NT5C2 Q523X (Q523X) (ribbon) and the basal full-length NT5C2 R39Q (R39Q) (surface), showing the lack of the C terminus
(marine) in Q523X results in a more open tetramer as compared with that of R39Q.
Data in (A and E) are shown as mean ± SD. The p values were calculated using two-tailed Student’s t test, *p < 0.05, **p < 0.001, ***p < 0.0001. See also
Figure S5.
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mutations involving the C-terminal segment of NT5C2, should
be considered highly likely activating alleles. Finally, the
dependence of NT5C2 class II and class III mutant proteins,
which encompasses >95% of relapse-associated NT5C2
mutations, on allosteric activation points to the allosteric effector
site as a potentially attractive target for the design of small-mole-
cule NT5C2 inhibitors for the reversal of 6-MP resistance in
relapsed ALL.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
NT5C2 arm region antibody Covance CG111 and CG112
NT5C2 C-terminus antibody Covance CG109 and CG110
6x His Epitope Tag Antibody (HisH8) Thermo Fisher Scientific Cat# MA1-21315, RRID:AB_557403
DYKDDDDK Tag Antibody Cell Signaling Technology Cat # 2368S, RRID:AB_2217020
Anti-HA High Affinity Roche Cat# 11867431001, RRID:AB_390919
Bacterial and Virus Strains
Rosetta 2(DE3) Escherichia coli Millipore Sigma Cat# 71397-4
Chemicals, Peptides, and Recombinant Proteins
6-Mercaptopurine monohydrate Fisher Scientific Cat# AC226520050
Adenosine 50-triphosphate disodium salt hydrate Sigma Aldrich Cat# A3377
JetPEI Polyplus Cat # 101-10N
Polybrene Infection/Transfection Reagent Fisher Scientific Cat# NC9515805
Doxycycline Clontech Cat# 631311
IPTG Life Technologies Cat# 15529019
Lysozyme from chicken egg white Sigma Aldrich Cat# L3790-10X1ML
Imidazole Sigma Aldrich Cat# I2399-100G
TCEP Sigma Aldrich Cat# 646547-10X1ML
Critical Commercial Assays
QuikChange II XL Site-Directed Mutagenesis Kit Agilent Technologies Cat # 200522
Cell Proliferation Kit I Sigma Aldrich Cat# 11465007001
DNEasy Blood & Tissue Kit Qiagen Cat# 69506
MiSeq Reagent Kit v2 (500 cycle) Illumina Inc. Cat# MS-102-2003
50-NT Enzymatic Test Kit Diazyme Laboratories Cat# DZ123A-K
5’-NT Control Set Diazyme Laboratories Cat# DZ123A-CON
NextSeq 500 Mid Output Kit (300 cycles) Illumina Inc. Cat # FC-404-1003
Deposited Data
Coordinates of NT5C2 WT 537X (Basal) This paper PDB: 6DDC
Coordinates of NT5C2 R367Q 537X (Basal) This paper PDB: 6DDB
Coordinates of NT5C2 Q523X (Basal) This paper PDB: 6DDL
Coordinates of NT5C2 WT (Basal) This paper PDB: 6DDO
Coordinates of NT5C2 R367Q (Basal) This paper PDB: 6DDK
Coordinates of NT5C2 R39Q (Basal) This paper PDB: 6DDQ
Coordinates of NT5C2 L375F 537X (Active) This paper PDB: 6DDX
Coordinates of NT5C2 K359Q 537X (Active) This paper PDB: 6DDY
Coordinates of NT5C2 R367Q 537X (Active) This paper PDB: 6DDH
Coordinates of NT5C2 R238W 537X (Active) This paper PDB: 6DDZ
Coordinates of NT5C2 D407A 537X (Active) This paper PDB: 6DD3
Coordinates of NT5C2 Q523X (Active) This paper PDB: 6DE0
Coordinates of NT5C2 WT (Active) This paper PDB: 6DE1
Coordinates of NT5C2 L375F (Active) This paper PDB: 6DE2
Coordinates of NT5C2 R39Q (Active) This paper PDB: 6DE3
Experimental Models: Cell Lines
Human: HEK293T ATCC ATCC # CRL-3216, RRID:CVCL_0063
Human: JURKAT ATCC ATCC # TIB-152TM, RRID:CVCL_0367
Human: JURKAT-TET3G Clontech Cat# 631181
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled according to institutional rules
by the Lead Contact, Adolfo Ferrando (af2196@columbia.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Samples
DNAs from leukemic ALL blasts at relapse were provided by the Department of Pediatric Oncology/Hematology at the Charite´-
Universit€atsmedizin Berlin in Berlin, Germany. Informed consent was obtained at study entry and samples were collected under
the supervision of local Institutional Review Boards for participating institutions (Charite´-Universit€atsmedizin and Columbia Univer-
sity Medical Center) and analyzed under the supervision of the Columbia University Medical Center Institutional Review Board.
Mice
We maintained all animals in specific pathogen-free facilities at the Irving Cancer Research Center at Columbia University Medical
Campus. The Columbia University Institutional Animal Care and Use Committee (IACUC) approved all animal procedures. To
generate NOTCH1-induced T-ALL tumors in mice, we performed retroviral transduction of bone marrow cells (C57BL/6) enriched
in Lineage negative cells isolated using magnetic beads (Lineage Cell Depletion Kit, Miltenyi Biotec) with retroviruses expressing
Continued
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Plasmid: pLOC-NT5C2 Open Biosystems
Plasmid: pET28aLIC Cheryl Arrowsmith Addgene Cat #26094
Plasmid: pL-CRISPR.efs.gfp Heckl et al., 2014 Addgene Cat #57818
Plasmid: pLVXTRE3GZsGreen1 Clontech Cat# 631361






Chimera Suite Pettersen et al., 2004 N/A
I-TASSER Roy et al., 2010 N/A
Modeller Software Suite Eswar et al., 2008 N/A
SAVI Trifonov et al., 2013 N/A
Burrows–Wheeler Aligner (BWA aln) Li and Durbin, 2009 N/A
SnpEFF Cingolani et al., 2012 N/A
Other
Ni Sepharose 6 Fast Flow GE Healthcare Cat# 17-5318-01
COLUMN PD 10 VWR Cat# 95017-001
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an activated form of the NOTCH1 oncogene (DE-NOTCH1) (Schroeter et al., 1998) and the red fluorescent protein (RFP) and trans-
planted them via intravenous injection into lethally irradiated isogenic recipients (6-8 week old C57BL/6 females, Jackson Labs) as
previously described (Herranz et al., 2014, 2015).
Cell Culture
We performed cell culture in a humidified atmosphere at 37!C under 5% CO2. We purchased 293T cells for viral production from
American Type Culture Collection and grew them in DMEMmedia supplemented with 10% fetal bovine serum (FBS), 100 Uml–1 peni-
cillin G and 100 mg ml–1 streptomycin for up to two weeks. We purchased JURKAT TET3G cells from Clontech and cultured them in
RPMI-1640 media supplemented with 10% tet-approved FBS, 100 U ml–1 penicillin G and 100 mg ml–1 streptomycin. Cell lines were
regularly authenticated and tested for mycoplasma contamination. We cultured DE-NOTCH1 driven mouse leukemic cells in
OptiMEM media supplemented with 10% FBS, 100 U ml–1 penicillin G, 100 mg ml–1 streptomycin, 55 mM b-mercaptoethanol and
10 ng ml-1 mouse IL7.
METHOD DETAILS
Drugs
We purchased 6-mercaptopurine (6-MP) and ATP from Sigma-Aldrich. For in vitro assays we dissolved 6-MP in DMSO and ATP in
Reagent 2 of the 50-NT Enzymatic Test Kit (Diazyme).
Site-Directed Mutagenesis
We generated the NT5C2 mutations by site-directed mutagenesis on the mammalian expression pLOC-NT5C2 vector (Open Bio-
systems) using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions.
Plasmids and Vectors
We obtained the pET28aLIC (Plasmid #26094) and pL-CRISPR.efs.gfp (plasmid # 57818) plasmids from Addgene and the
pLVXTRE3GZsGreen1 vector from Clontech. We amplified the coding sequence of the NT5C2 cDNA from pLOC-NT5C2 (Tzoneva
et al., 2013) and cloned it into the pET28aLIC vector using In-fusion cloning using the In-Fusion HD Cloning Kit (Clonetch) following
manufacturer guidelines. We cloned the NT5C2 S408-D415 loop deletion mutation into the pET28aLIC and pLVXTRE3GZsgreen1
vector using Gibson Assembly using the Gibson Assembly Master Mix (New England Biolabs) following manufacturer guidelines.
We cloned a truncated active form of NOTCH1DE-NOTCH1 (Schroeter et al., 1998) into the pMSCV-pBabeMCS-IRES-RFP retroviral
vector (Addgene plasmid # 33337).We generated lentiviral vectors expressing CAS9 and gRNAs targeting the arm segment ofmouse
Nt5c2 by cloning the corresponding gRNA oligonucleotides (Sigma-Aldrich) into pL-CRISPR.efs.gfp as reported (Shalem
et al., 2014).
Retroviral and Lentiviral Production and Infection
We transfected lentiviral plasmids together with gag-pol (pCMV DR8.91) and V-SVG (pMD.G VSVG) expressing vectors into 293T
cells using JetPEI transfection reagent (Polyplus). We collected viral supernatants after 48 h and used them to infect JURKAT
Tet-On human cell lines by spinoculation with 4 mg mL-1 Polybrene Infection/Transfection Reagent (Fisher Scientific). We selected
infected human cell lines with 1 mg ml-1 puromycin (Sigma Aldrich) for 5 days.
In Vitro Cell Viability and Chemotherapy Response Assays
We analyzed chemotherapy responses of human leukemia cell lines expressing wild-type NT5C2 or NT5C2 S408-D415 deletion
following 72-hour incubation with increasing concentrations of 6-mercaptopurine by measurement of the metabolic reduction of
the tetrazolium salt MTT using the Cell Proliferation Kit I (Roche) following the manufacturer’s instructions. We analyzed human
cell lines with inducible expression of wild-type or mutant NT5C2 after 48 hours of doxycycline treatment (1 mg ml-1).
CRISPR Guided Generation and 6-MP Selection of Arm Domain Mutant NT5C2 Lymphoblasts
We generated NOTCH1-induced mouse T-ALL tumors via retroviral transduction of mouse hematopoietic progenitors with lentiviral
particles expressing a constitutively active truncated NOTCH1 allele (DE-NOTCH1) as before (Herranz et al., 2014; Herranz et al.;
Schnell et al., 2015). We infected DE-NOTCH1 mouse lymphoblasts with lentivirus particles expressing CAS9 and gRNAs targeting
Nt5c2 at codons H405 or I416, or with CAS9 only control lentiviral particles. We sorted infected cells based on GFP expression using
a SONY SH800S cell sorter (SONY). We treated sorted gRNA expressing cells with 2 mM 6-MP or DMSO control for 72 hours.
Following 6-MP treatment, cells were washed and placed in fresh media. Upon complete recovery from treatment, cells were har-
vested and DNA was isolated using DNEasy Blood &Tissue Kit (Qiagen).
Deep Sequencing
CRISPR Mutagenesis Deep Sequencing
We amplified by PCR genomic DNA sequences encompassing exon16 of mouse Nt5c2 from 50 ng of genomic DNA extracted from
mouse NOTCH1-induced T-ALL lymphoblast cells with primers designed according to Fluidigm recommendations and containing





Fluidigm-specific adapter sequences at the 5’ ends.Webarcoded the resulting amplified PCRproducts using Illumina –Fluidigm spe-
cific barcodes so that each sample carried a unique barcode. We pooled all indexed amplicons and quantified the resulting library
with Qbit and BioANalyzer analysis. To increase library diversity we spiked the library with 50% PhiX genomic library and sequenced
in a MiSeq instrument to generate 2x251 bp paired end reads.
We combined each read pair into a single sequence by finding the optimal alignment allowing up to 0 mismatches and without
gaps.We alignedmerged pairs as single-end reads to themousemm10 genome build using BWA (Li and Durbin, 2009).We classified
non-synonymous SNPEFF (Cingolani et al., 2012) variant calls as either in-frame and point mutations (disruptive inframe deletion,
disruptive inframe insertion, inframe deletion, inframe insertion, missense variant, and inframe insertion and splice region variant)
or frameshift (disruptive inframe deletion and splice region variant, frameshift variant, frameshift variant and splice acceptor variant
and splice region variant and intron variant, frameshift variant and splice donor variant and splice region variant and intron variant,
frameshift variant and splice region variant, frameshift variant and stop gained, inframe deletion and splice region variant, splice
acceptor variant and inframe deletion and splice region variant and intron variant, stop gained and disruptive inframe insertion,
stop gained and inframe insertion, stop gained), and relative counts over the total reads of each class were compared across
samples.
Patient Sample Deep Sequencing
We identified NT5C2 variants that differed from the reference genome in targeted resequencing data, containing the NT5C2 gene,
generated using the Access Array system from Fluidigm and analyzed them by paired-end sequencing (23 150 bp) in a NextSeq500
instrument (Illumina) using the SAVI algorithm (Trifonov et al., 2013).
Recombinant Protein Production and Purification
For 5’-nucleotidase assays in the absence and presence of allosteric activators we cloned, expressed and purified recombinant wild-
type and mutant NT5C2 proteins as previously described (Tzoneva et al., 2013). Briefly, we cloned full-length complementary DNA
constructs encoding wild-type or mutant NT5C2 with an N-terminal hexahistidine (His6) tag in the pET28a-LIC expression vector. We
expressed recombinant proteins from Rosetta 2(DE3) Escherichia coli cells by induction with 0.5 mM isopropyl-b-D-thiogalactopyr-
anoside for 3 h at 37!C. We harvested cells and lysed them in lysis buffer (50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10%
glycerol, 5 mM b-mercaptoethanol, 1% Triton X-100, 0.5 mg ml"1 lysozyme and 20 mM imidazole) supplemented with Complete
EDTA-free protease inhibitor (Roche). We purified His6-tagged NT5C2 proteins by binding them to nickel-Sepharose beads and
eluting them with 50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol, 5 mM b-mercaptoethanol and 300 mM imidazole.
We removed imidazole by buffer exchange using PD-10 desalting columns (GE Healthcare). We assessed protein expression and
purity by SDS-PAGE and Coomassie staining.
For X-ray crystallography analyses we cloned full-length (561 amino acids) or C-terminally truncated (amino acids 1-536) comple-
mentary DNA constructs encoding wild-type or mutant NT5C2 with an N-terminal hexahistidine (His6) tag in the pET28a-LIC expres-
sion vector. We expressed recombinant proteins from Rosetta 2(DE3) Escherichia coli cells by induction with 0.5 mM isopropyl-b-D-
thiogalactopyranoside overnight at 16!C.We resuspended harvested cells in lysis buffer (50 mM sodium phosphate pH 7.4, 500 mM
sodium chloride, 10% glycerol, 0.5 mM TCEP, 20 mM imidazole) supplemented with Complete EDTA-free protease inhibitor (Roche)
and lysed cells by sonication. We purified recombinant proteins using an A¨KTA fast protein liquid chromatography system (GE
Healthcare) using a 2-step protocol adapted from one previously described (Wallden et al., 2007). We first performed affinity chro-
matography using a 1 ml Ni2+-charged His-Trap HP column (GE Healthcare) equilibrated in lysis buffer. We eluted NT5C2 proteins
from the His-Trap column in a step-wise method with elution buffer (lysis buffer with 500mM imidazole) by first setting the buffer ratio
to 25%elution buffer for 8 column volumes and then switching to a linear gradient to 100%elution buffer over 10 column volumes.We
pooled NT5C2-containing fractions and purified further by size exclusion chromatography using a HiLoad 16/60 Superdex 200 gel
filtration column (GE Healthcare) equilibrated in 50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol and 0.5 mM TCEP.
We assessed protein expression and purity by SDS-PAGE and Coomassie staining and concentrated protein samples to 4-9 mg/ml.
For 5’-nucleotidase assays of NT5C2 proteins incubated with arm region or C-terminal polyclonal antibodies in presence or
absence of their corresponding specific blocking peptides, we expressed proteins as described for standard 5’-nucleotidase assays
(Tzoneva et al., 2013). We purified His6-tagged NT5C2 proteins in a 2-step process. First we bound proteins to nickel-Sepharose
beads and eluted them with 50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol, 5 mM b-mercaptoethanol and
300mM imidazole. We then further purified NT5C2 protein eluates by size exclusion using a HiLoad 16/60 Superdex 200 gel filtration
column (GE Healthcare) equilibrated in 50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol and 0.5 mM TCEP.
50-Nucleotidase Assays
We assessed 50-NT activity of purified recombinant wild-type and mutant NT5C2 proteins using the 50-NT Enzymatic Test Kit (Dia-
zyme) according to themanufacturer’s instructions as described previously (Tzoneva et al., 2013). We calculated 50-NT activity levels
using a calibrator of known 50-NT activity as standard. We performed assays in triplicate in an Infinite M200 Tecan plate reader.
For assayswith allosteric activators ATP,was dissolved directly in Reagent 2 of the test kit (containing the substrate IMP) andmade
serial dilutions to achieve a range of concentrations. For assays with antibodies and peptides (custom-generated by Covance), both
antibodies and peptides were resuspended in phosphate buffered saline (PBS) and all corresponding samples and controls were
diluted with PBS accordingly. We performed statistical analysis by Student’s t-test.




293T cells transfected with FLAG-tagged wild-type NT5C2 and HA-tagged NT5C2 R367Q were collected in lysis buffer (50 mM Tris-
HCl, 150 mM NaCl, 1 mM EDTA, 5%Glycerol, 5 mM b-ME, 0.1% Triton). We incubated cell lysates with EZview! Red ANTI-FLAG"
M2Affinity Gel cloneM2 beads (Sigma) or EZview!Red Anti-HA Affinity Gel beads (Sigma) for 2 hours at 4!C. Following four washes
with lysis buffer and onewash with PBS, we boiled the beads in 2x SDS-loading buffer, separated them by SDS PAGE and transfered
them to a nitrocellulose membrane for western blot analysis. We detected Flag-tagged proteins by immunoblot with a DYKDDDDK
Tag Antibody (Cell Signaling Technology Cat # 2368) and HA-tagged proteins with an Anti-HA High Affinity antibody (Roche Cat
#11867431001).
Antibody Generation
We generated rabbit polyclonal antisera directed against Keyhole Limpet Hemocyanin-conjugated NT5C2 peptides corresponding
to the tip of the arm segment (E399-I414) or the C-terminus segment (Q542-E561) of the wild-type NT5C2 protein. Specific immu-
noglobulins were purified from rabbit sera by positive affinity purification using the corresponding immobilized peptide columns
(Covance).
Structural Modeling Analyses
Computational modeling analyses and images were generated using Chimera suite (Pettersen et al., 2004). Additional modeling was
conducted using Modeller (Eswar et al., 2008) and I-TASSER webserver (Roy et al., 2010). Tip region of the arm domain models were
built, refined and scored usingModeller Software suite (Eswar et al., 2008; Fiser et al., 2000). Topmodels for figures were selected by
ranking 5,000 iterations by DOPE score as described elsewhere (Fiser et al., 2000). All secondary structure prediction was conducted
using the PredictProtein platform and webserver (Rost et al., 2004). Path prediction and molecular dynamics of NT5C2 models were
predicted using UCSF Chimera software (Pettersen et al., 2004). Electrostatics of NT5C2 molecular surfaces were investigated with
APBS and PDB2PQR software packages. PDB2PQR submission was run with a PARSE force field, optimal hydrogen bonding
network. PROPKA was utilized to assign protonation states for each structure at their respective crystallization pH (Unni et al.,
2011). Charge mapping method utilized was cubic Bspline discretization. Mobile ions were not included and Poisson-Boltzmann
was run with linearized (lpbe) setting. Supplementary electrostatics analysis and visualization was conducted through use of the
Columbic surface coloring algorithm provided in Chimera software package (Pettersen et al., 2004).
Crystallization and Structure Determination
All crystals of the human NT5C2 were grown using the microbatch under oil method. In all cases, 1-4 ml of the protein solution was
mixed with 1-2 ml of the precipitant solution. The truncated wild-type (WT-537X) and its corresponding mutants were grown at 18!C,
whereas all of the full-length wild-type NT5C2 and its corresponding mutants were grown at 4!C for the first week, and then trans-
ferred to 18!C for the next 3 weeks. All protein samples contain a mutation at position 52 (D52N), and the protein concentration
ranges from 3-12 mg/ml in a buffer consisting of 50 mM Na3PO4 (pH 7.4), 100 mM NaCl, 10% glycerol, and 0.5 mM TCEP. Beam
lines X4C of the National Synchrotron Light Source (NSLS), BL14-1 and BL12-2 of Stanford National Accelerator Laboratory
(SLAC), BL501 and BL502 of Berkeley Advanced Light Source (ALS), and SER-CAT of Advance Photon Source (APS) were used
for collecting a single-wavelength native data set for each of fifteen crystal structures presented in this study. All of the diffraction
images were processed with the HKL2000 package (Otwinowski and Minor, 1997). For the sake of clarity, the crystallization exper-
iments are described below in two parts for basal and active forms of NT5C2. All of the chemicals for crystallization purposes were
purchased from Sigma-Aldrich and the paraffin oil for micro batch method was purchased from Hampton Inc.
Crystallization of the Basal Forms of NT5C2
A: Crystallization of the Basal WT-537X, R367Q-537X, and Q523X
The basal form ofWT-537Xwas crystallized using a crystallization reagent comprising 100mMsodiumacetate trihydrate (pH 4.6) and
2 M ammonium sulfate. In contrast, R367Q-537X was crystallized using a crystallization reagent comprising sodium acetate trihy-
drate (pH 4.6) and 30% (v/v) 2-Methyl-2, 4-pentanediol (MPD), 20 mM calcium chloride dihydrate, and 5 mM MnCl2. The crystals
of the basal form of Q523Xwere obtained bymicroseedingmethod using crystals of the basal formof the full-length R39Q (see below)
and using the same crystallization condition as that for R367Q-537X, except MnCl2 was not added into the crystallization mixture. All
crystals were cryoprotected by supplementing the crystallization solution with 20% (v/v) glycerol and flash-freezing in liquid nitrogen
for data collection at 100 K. Crystals of the three basal forms WT-537X, R367Q-537X and Q523X diffracted X-rays to 2.91 A˚, 2.80 A˚,
and 2.26 A˚ resolution respectively, and they belong to space group C2, and there are two protomers in the asymmetric unit (ASU) of
the crystals.
The structure of the active form of WT-537X NT5C2 in complex with ATP, Mg2+, and IMP (PDB id: 2XCW) was used as a search
model to determine the structure of the basal form of WT-537X NT5C2 using the molecular replacement method with the program
COMO (Jogl et al., 2001). The entire loop at the tip of the arm segment and four additional residues (489-492) of the C-terminal
segment were manually built with the program XtalView (McRee, 1999). Most stages of the structure refinement were performed us-
ing CNS 1.3 (Schroder et al., 2010), and PHENIX was used at the final stage of refinement for this and other structures reported in
this study (Adams et al., 2010). Crystal structure of the basal R367Q-537X was subsequently determined using the basal structure
of WT-537X using a similar methodology.
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B: Crystallization of the Basal Full-Length WT, R567Q, and R39Q
The basal forms of the three full-length enzymes,WT, R367Q, and R39Q, were crystallized using a crystallization condition consisting
of 100 mM HEPES (pH 7.5), 10% (w/v) PEG 3350, and 200 mM L-proline. Whereas crystals of the full-length R367Q (R367Q) were
grown without microseeding, those of the full-length WT (WT) and R39Q (R39Q) were obtained by microseeding method. A few large
crystals of R367Qwere used as seeds for growing crystals of R39Q,while seeds fromR39Qcrystals were used for growing crystals of
WT. All crystals were cryoprotected by supplementing the crystallization solution with 20% (v/v) ethylene glycol and flash-freezing in
liquid nitrogen for data collection at 100 K. Crystals of WT, R367Q, and R39Q, respectively, diffracted X-rays to 2.48 A˚, 2.50 A˚, 2.31 A˚
resolution, and they all belong to space groupC2221 with two protomers in ASU of each crystal. These structures were subsequently
determined using the structure of basal form of WT-537X as the search model in the molecular replacement method. These struc-
tures revealed mostly ordered C-terminal segment, which was reported for the first time in this study.
Crystallization of the Active Form of NT5C2
A: Crystallization of the Active Forms of L375F-537X, K359Q-537X, R367Q-537X, R238W-537X, D407A-537X,
and Q523X
Crystals of L375F-537Xwere grown using the crystallization cocktail consisting of 1.8M ammonium citrate tribasic (pH 7), while those
of K359Q-537X were grown in presence of ATP, Mg2+, and IMP and by using the crystallization cocktail comprising 0.1 M HEPES
(pH 7.5), 20% (w/v) PEG 1000, and 0.1 M ammonium bromide. In both cases, the structures were in active form, and in the latter
case no detectable electron density was observed for ATP, Mg2+ or IMP. The crystals, respectively, diffracted X-rays to 2.9 A˚ and
1.8 A˚ resolution. Crystals of R367Q-537X were grown in presence of ATP, Mg2+, and IMP using the crystallization reagent consisting
of 0.1 M HEPES (pH 7.5), 20% (w/v) PEG 1000, and 0.1 M ammonium nitrate. Crystals diffracted X-ray to resolution 2.35 A˚. Whereas
IMP has well-defined electron density, there is no interpretable electron density for ATP or Mg2+.
Crystals of R238W-537X were grown in presence of ATP, Mg2+, and IMP using the crystallization cocktail consisting of 35% (w/v)
tascimate (pH 7). Clear electron density was observed for both ATP and Mg2+ ion. Seeds from crystals of the full-length L375F (see
below), in complex with ATP and Mg2+, were used to grow crystals of D407A-537X in presence of ATP, Mg2+, and IMP using the
crystallization reagent consisting of 2M ammonium sulfate and 5% (v/v) 2-proponal. A similar methodology was used to grow crystals
of Q523X in presence of ATP, Mg2+, and IMP. No electron density was detected for ATP, Mg2+, or IMP in either structure of D407A-
537X or 537X. All crystals were cryoprotected by supplementing the crystallization solution with 20% (v/v) glycerol and flash-freezing
in liquid nitrogen for data collection at 100 K. Crystals of R238W-537X, D407A-537X, and 537X diffracted X-rays to 1.97 A˚. 1.98 A˚, and
2.05 A˚ resolution, respectively. All crystals of the active form of NT5C2-537X, wild-type and mutant, belong to space group I222 with
one protomer in ASU.
B: Crystallization of Active Form of Three Full-Length Proteins: WT, L375F, and R39Q
The full lengthWT (WT) enzyme in presence of ATP, Mg2+, and IMPwas crystallized using seeds from crystals of the full length L375F
(see below) and the crystallization reagent comprising 0.1MHEPES (pH 7.5), and 20% (w/v) PEG 1000, and 0.1M ammonium nitrate.
The full length L375F (L375F) was crystallized in presence of ATP, Mg2+, and IMP, and by using a crystallization reagent consisting of
2M ammonium sulfate and 5% (v/v) 2-proponal. The full length R39Q (R39Q) was crystallized in presence of ATP, Mg2+, IMP, and by
using the crystallization reagent consisting of 100 mM HEPES (pH 7.5) and 12% (w/v) PEG 3350. While crystals of WT were cryopro-
tected by supplementing the crystallization solution with 20% (v/v) glycerol, those of L375F and R39Q were cryoprotected with 20%
(v/v) ethylene glycol and all the crystals were flash-frozen in liquid nitrogen for data collection at 100 K.
Whereas neither ATP, Mg2+ion nor IMP was observed in the structure of WT, there were well-defined electron densities for both
ATP and Mg2+ion in the structures of L375F and R39Q. Crystals of the full length active forms of NT5C2, WT, L375F, and R39Q, dif-
fracted X-ray to 2.15 A˚. 2.10 A˚, and 3.06 A˚ resolution, respectively.
All nine structures of the active form of NT5C2 belong to space group I222 with one protomer in ASU. The data quality and refine-
ment statistics are shown in Table S2.
QUANTIFICATION AND STATISTICAL ANALYSIS
We performed statistical analysis by Student’s t-test. We considered results with P < 0.05 as statistically significant.
DATA AND SOFTWARE AVAILABILITY
The atomic coordinates reported in this paper are deposited in PDB:6DDC, 6DDB, 6DDL, 6DDO, 6DDK, 6DDQ, 6DDX, 6DDY, 6DDH,
6DDZ, 6DD3, 6DE0, 6DE1, 6DE2, 6DE3.






Table S1. Related to Figure 1 NT5C2 mutations identified in relapsed ALL patient samples. 
 Sample ID Diagnosis Exon Predicted amino acid change Reported in 
Relapse T-ALL B63 T-ALL 15 D407Y This paper 
Relapse T-ALL B63 T-ALL 2 R39Q This paper 
Relapse B-ALL 1 B-ALL 13 R367Q This paper 
Relapse B-ALL 2 B-ALL 13 R367Q This paper 
Relapse B-ALL 3 B-ALL 13 R367Q This paper 
Relapse B-ALL 284 B-ALL 15 K404N This paper 
Relapse B-ALL 4 B-ALL 15 D407Y This paper 
Relapse B-ALL 240 B-ALL 15 P414S This paper 
Relapse B-ALL 5 B-ALL 9 R238L This paper 
Relapse B-ALL 6 B-ALL 15 P414S This paper 
Relapse B-ALL 7 B-ALL 15 del_S408_D415 This paper 
Relapse B-ALL 326 B-ALL 13 R367Q This paper 
Relapse B-ALL 8 B-ALL 9 R238L This paper 
Relapse B-ALL 9 B-ALL 13 R367Q This paper 
Relapse B-ALL 396 B-ALL 15 D407H This paper 
Relapse B-ALL 396 B-ALL 15 D415G This paper 
Relapse B-ALL 403 B-ALL 9 R238W This paper 
Relapse B-ALL 403 B-ALL 13 R367Q This paper 
Relapse B-ALL 371 B-ALL 13 R367Q This paper 
Relapse B-ALL 377 B-ALL 13 R367Q This paper 
Relapse B-ALL 376 B-ALL 13 D384N This paper 
Relapse B-ALL 265 B-ALL 2 R39Q This paper 
Relapse B-ALL 427 B-ALL 2 R39Q This paper 
Relapse B-ALL 304 B-ALL 16 V454M This paper 
Relapse B-ALL 287 B-ALL 9 R238W This paper 
Relapse B-ALL 315 B-ALL 9 R238W This paper 
Relapse B-ALL 10 B-ALL 13 R367Q This paper 
Relapse B-ALL 11 B-ALL 13 R367Q This paper 
Relapse B-ALL 234 B-ALL 13 R367Q This paper 
Relapse B-ALL 12 B-ALL 13 R367Q This paper 
Relapse B-ALL 243 B-ALL 13 R367Q This paper 
Relapse B-ALL 244 B-ALL 13 R367Q This paper 
Relapse T-ALL 4 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL 11 T-ALL 13 K359Q Tzoneva et al. 2013 
Relapse T-ALL 17 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL 17 T-ALL 9 R238L Tzoneva et al. 2013 
Relapse T-ALL 22 T-ALL 9 R238W Tzoneva et al. 2013 
Relapse T-ALL 29 T-ALL 11 R291W Tzoneva et al. 2013 
Relapse T-ALL 35 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL 37 T-ALL 15 D407A Tzoneva et al. 2013 
Relapse T-ALL 30 T-ALL 17 Q523* Tzoneva et al. 2013 
Relapse pre-B ALL 16 pre-B ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B11 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B15 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B30 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B37 T-ALL 13 R367Q Tzoneva et al. 2013 




Relapse T-ALL B44 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B48 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B52 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B53 T-ALL 13 R367Q Tzoneva et al. 2013 
Relapse T-ALL B9 T-ALL 9 R238W Tzoneva et al. 2013 
Relapse T-ALL B29 T-ALL 9 R238W Tzoneva et al. 2013 
Relapse T-ALL B64 T-ALL 9 R238W Tzoneva et al. 2013 
Relapse T-ALL B9 T-ALL 13 L375F Tzoneva et al. 2013 
Relapse T-ALL B64 T-ALL 13 L375F Tzoneva et al. 2013 
T-ALL C4 T-ALL 13 R367Q Tzoneva et al. 2018 
T-ALL C5 T-ALL 9 R238W Tzoneva et al. 2018 
T-ALL C7 T-ALL 13 R367Q Tzoneva et al. 2018 
T-ALL C10 T-ALL 9 R238W Tzoneva et al. 2018 
T-ALL C11 T-ALL 13 R367Q Tzoneva et al. 2018 
T-ALL C14 T-ALL 15 D407E Tzoneva et al. 2018 
T-ALL C17 T-ALL 13 R367Q Tzoneva et al. 2018 
T-ALL C18 T-ALL 13 R367Q Tzoneva et al. 2018 
T-ALL C20 T-ALL 13 R367Q Tzoneva et al. 2018 
T-ALL N1 T-ALL 13 R367Q Tzoneva et al. 2018 
SJBALL192 B-ALL 15 P414A Tzoneva et al. 2018 
SJBALL192 B-ALL 2 R39Q Tzoneva et al. 2018 
SJTALL001 T-ALL 2 R39Q Tzoneva et al. 2018 
n/a B-ALL 9 R238W Meyer et al. 2013 
n/a B-ALL 9 R238W Meyer et al. 2013 
n/a B-ALL 9 R238W Meyer et al. 2013 
n/a B-ALL 13 R367Q Meyer et al. 2013 
n/a B-ALL 15 K404ins Meyer et al. 2013 
n/a B-ALL 15 S408R Meyer et al. 2013 
n/a B-ALL 16 S445F Meyer et al. 2013 
PANTSM B-ALL 2 R39Q Ma et al. 2015 
PAPAGK B-ALL 9 R238G Ma et al. 2015 
PAPJIB B-ALL 13 R367Q Ma et al. 2015 
PAPJIB B-ALL 9 R238Q Ma et al. 2015 
PAPSPG B-ALL 9 R238W Ma et al. 2015 
PAPSPN B-ALL 15 S408R Ma et al. 2015 
PAPZNK B-ALL 13 R367Q Ma et al. 2015 
PAPZNK B-ALL 13 S360P Ma et al. 2015 
PARFTR B-ALL 9 R238G Ma et al. 2015 
PARFTR B-ALL 2 R39Q Ma et al. 2015 
PARFTR B-ALL 9 R238W Ma et al. 2015 
PARFTR B-ALL 13 R367Q Ma et al. 2015 
PARJZZ B-ALL 13 R367Q Ma et al. 2015 
PASKAY B-ALL 13 R367Q Ma et al. 2015 
11 T-ALL 13 R367Q Richter-Pechanska et al. 2017 
11 T-ALL 15 P414S Richter-Pechanska et al. 2017 
15 T-ALL 13 R367Q Richter-Pechanska et al. 2017 
23 T-ALL 14 396_400del Richter-Pechanska et al. 2017 
24 T-ALL 9 R238W Richter-Pechanska et al. 2017 
76 T-ALL 17 T489M Richter-Pechanska et al. 2017 
29 T-ALL 9 R238W Richter-Pechanska et al. 2017 




30 T-ALL 13 R367Q Richter-Pechanska et al. 2017 
37 T-ALL 13 R367Q Richter-Pechanska et al. 2017 
39 T-ALL 13 R367Q Richter-Pechanska et al. 2017 
78 T-ALL 9 R238G Richter-Pechanska et al. 2017 
44 T-ALL 13 R367Q Richter-Pechanska et al. 2017 
48 T-ALL 13 R367Q Richter-Pechanska et al. 2017 
48 T-ALL 2 R39Q Richter-Pechanska et al. 2017 
59 T-ALL 7 R195Q Richter-Pechanska et al. 2017 
63 T-ALL 15 D407Y Richter-Pechanska et al. 2017 
64 T-ALL 9 R238W Richter-Pechanska et al. 2017 
64 T-ALL 13 L375F Richter-Pechanska et al. 2017 
5376 T-ALL 2 R34Q Richter-Pechanska et al. 2017 
S20 T-ALL 17 P533L Richter-Pechanska et al. 2017 
A61 T-ALL 13 R367Q Kunz et al. 2015 
T92 T-ALL 15 D407Y Kunz et al. 2015 
S00285 T-ALL 13 R367Q Kunz et al. 2015 
S00456 T-ALL 15 P414S Kunz et al. 2015 
S00207 T-ALL 13 R367Q Kunz et al. 2015 
T92 T-ALL 13 R367Q Kunz et al. 2015 
19 T-ALL 16 R478S Oshima et al. 2016 
19 T-ALL 13 R367Q Oshima et al. 2016 
29 T-ALL 13 K359Q Oshima et al. 2016 
41 
B-precursor 








Figure S1. Related to Figure 2 Structural overlay and buried surface area of basal and active 
monomers and tetramers. (A) An overlay of 5 basal NT5C2 monomers: cyan, orange, yellow, 
green, and magenta for CD atoms of the full-length WT (WT), R367Q-537X, Q523X, the full-
length R367Q (R367Q) and the full-length R39Q (R39Q), respectively. Phosphates (yellow for 
phosphate) and Mg2+ ions are depicted as stick models and solid dark-green spheres, 
respectively. (B) An overlay of 5 basal NT5C2 tetramers. The color schemes are the same as 
(A) and Mn2+ ions are shown with solid purple spheres. (C) An overlay of 9 active NT5C2 
monomers: cyan, blue, orange, yellow, salmon, grey, purple, green, magenta, for CD atoms of 
WT, L375F, R39Q, Q523X, K359Q-537X, L375F-537X, R367Q-537X, D407A-537X and 
R238W-537X, respectively. ATP (black and yellow for C and P atoms), IMP (purple for C atoms) 
are represented as stick models and a Mg2+ ion as a solid dark-green sphere. (D) An overlay of 
9 active NT5C2 tetramers. Color schemes are as in (C). (E) Cartoon representation of the 
strong dimer in the full-length WT basal structure, in which the buried surface area at the dimer 
interface is depicted with wheat color. (F) Cartoon representation of the strong dimer in the full-
length WT active structure, in which the buried surface area at the dimer interface is depicted 






Table S2. Related to Figure 2. Data collection and refinement statistics. 
NT5C2 WT-537X R367Q-537X Q523X WT R367Q 
State Basal Basal Basal Basal Basal 
Ligands Pi, Mg2+ Pi, Mn2+ Pi Pi Pi 
Data collection      
Space group C2 C2 C2 C2221 C2221 
Cell dimensions      











DEJ  (q) 90, 116.2, 
90 













Rmerge (%) 11.5 
(58.1) 
9.1 (38.7) 12.1 (53.7) 12.2 (55.1) 13.1 (55.4) 
CC1/2 0.94 
(0.80) 
0.98 (0.93) 0.95 (0.86) 0.96 (0.98) 0.97 (0.93) 
I/VI 8.9 (1.9) 24.4 (5.7) 21.4 (3.2) 19.7 (2.4) 20.4 (4.3) 
Completeness (%) 96.6 
(96.5) 
98.9 (98.2) 99.9 (100) 100 (100) 100 (100) 
Redundancy 3.2 (2.9) 6.1 (6.1) 7.5 (7.1) 7.4 (7.5) 12.5 (12.6) 













No. reflections 30,410 
(1,227) 
34,385 (1220) 67,084 (2,003) 46,552 
(1,395) 
44,609 (1,987) 












No. atoms      
Protein 7,741 7,624 7,630 8,160 8,030 
Ligand/ion 22 22 20 20 10 
Water 279 168 677 550 516 
B-factors      
Protein 43.0 42.0 34.6 33.6 31.6 
Ligand/ion 35.2 42.5 40.9 26.4 16.4 
Water 31.5 35.6 41.2 34.1 33.1 
RMSD      
Bond lengths (Å) 0.008 0.009 0.007 0.002 0.007 
Bond angles (º) 1.0 1.2 0.9 0.5 0.9 





NT5C2 R39Q L375F-537X K359Q-537X  R367Q-537X  R238W-537X  
State Basal Active Active Active Active 
Ligands Pi, EDO Pi Pi, GOL IMP ATP, Mg2+, Pi, 
GOL 
Data collection      
Space group C2221 I222 I222 I222 I222 
Cell dimensions      










DEJ  (q)  90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 










Rmerge (%) 11.3 (56.2) 9.6 (39.6) 7.4 (51.0) 8.9 (47.6) 7.6 (58.8) 
CC1/2 0.98 (0.93) 0.99 (0.97) 0.98 (0.92) 0.98 (0.89) 0.98 (0.88) 
I/VI 16.2 (4.0) 23.9 (4.4) 44.1 (2.7) 28.0 (4.0) 30.9 (2.9) 
Completeness 
(%) 
99.9 (100) 98.8 (100) 99.4 (100) 100 (99.9) 99.8 (100) 
Redundancy 13.7 (13.8) 7.0 (7.0) 13.3 (13.5) 7.4 (6.8) 10.1 (6.6) 
Refinement      














69,296 (1817) 32,292 (1,239) 54,413 (1,622) 










No. atoms      
Protein 8,158 3,859 3,780 3,863 3,856 
Ligand/ion 28 5 29 23 51 
Water 782 26 346 127 340 
B-factors      
Protein 32.4 51.6 35.1 37.7 28.5 
Ligand/ion 37.2 78.1 49.2 62.6 58.1 
Water 40.3 41.4 45.8 45.4 33.5 
RMSD      
Bond lengths (Å)  0.007 0.008 0.007 0.008 0.007 
Bond angles (º) 0.9 1.1 1.0 1.0 1.0 






NT5C2 D407A-537X Q523X WT L375F R39Q 
State Active Active Active Active Active 
Ligands Pi, GOL Pi, GOL Pi, GOL ATP, Mg2+, Pi, 
EDO 
ATP, Mg2+, Pi 
Data collection      
Space group I222 I222 I222 I222 I222 
Cell dimensions      










DEJ  (q) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 










Rmerge (%) 9.1 (53.4) 6.7 (42.7) 5.7 (24.5) 9.7 (55.0) 14.5 (49.8) 
CC1/2 0.98 (0.95) 0.98 (0.94) 0.99 (0.98) 0.98 (0.95) 0.96 (0.86) 
I/VI 25.1 (3.6) 36.6 (4.3) 43.1 (8.5) 35.2 (4.9) 9.8 (2.9) 
Completeness 
(%) 
99.9 (100) 100 (100) 100 (100) 100 (100) 99.2 (99.9) 
Redundancy 12.1 (11.8) 7.4 (7.4) 7.4 (7.4) 14.7 (14.8) 4.7 (4.7) 
Refinement      










No. reflections 52,385 (1,558) 47,644 (1,455) 40,999 (1,233) 44,471 (1,304) 14,798 (1,077) 










No. atoms      
Protein 3,837 3,784 3,809 3,848 3,846 
 Ligand/ion 32 26 26 48 38 
Water 445 356 284 439 77 
B-factors      
Protein 29.1 33.3 31.6 30.4 50.7 
Ligand/ion 45.9 55.1 44.8 32.8 46.5 
Water 26.2 39.6 43.2 29.4 36.2 
RMSD      
Bond lengths (Å)  0.006 0.006 0.007 0.006 0.007 
Bond angles (º) 0.8 0.8 1.0 0.8 1.0 
PDB code 6DD3 6DE0 6DE1 6DE2 6DE3 
*Highest resolution shell is shown in parenthesis. Pi, EDO, and GOL represent phosphate ion, 






Table S4. Related to Figure 2. Buried surface area (Å2) in the basal versus active state. 
Basal Strong dimer Weak dimer 
WT-537X 9,783 1,799 
R367Q-537X 8,438 1,973 
Q523X 9,783 1,757 
WT 14,469 2,423 
R367Q 14,625 2,500 
R39Q 15,699 2,512 
Active Strong dimer Weak dimer 
K359Q-537X 3,783 1,728 
L375F-537X 4,442 1,719 
R367Q-537X 4,057 1,693 
D407A-537X 4,414 1,767 
R238W-537X 4,052 1,651 
Q523X 3,825 1,739 
WT 4,187 1,852 
L375F 4,184 1,710 






Figure S2. Related to Figure 3. Topology of the helix A (αA) region in basal vs active form of 
the full-length WT structures. A close-up view of helix A region (deep purple) in activated full-
length wild-type NT5C2 as compared with that of basal structure (grey). The side chain of 
important residues on and near the helix A region are shown with stick models, and the Red 
dash lines represent H-bonds. Phosphate ions (Pi) and the metal ion are also shown. The stick 
model of ATP from the active structure of the full-length R39Q NT5C2 (R39Q) is also shown as 






Figure S3. Related to Figure 4 Electrostatic Surface visualization of NT5C2 and close-up view 
of R238W mutation site and structural overlay of active NT5C2 D407A-537X and the full-length 
wild-type NT5C2 (WT). (A) Electrostatics comparison between apo (left) and active (right) wild-
type NT5C2. Ambient Surface Representation of active NT5C2 with Adaptive Poisson-
Boltzmann Solver values mapped and color-coded representing negativity (red) and positivity 
(blue).  Scale shown is normalized to -10kT/e-10kT/e.  (B) Structural overlay of NT5C2 R238W-
537X (colored) and WT (grey). The side chains R238 (grey) and R238W (light magenta) and the 
residues surrounding are shown with stick models, labeled and colored accordingly. A 
hydrophobic tryptophan residue at position 238 is a much better fit for the local hydrophobic 
pocket comprising a number of hydrophobic residues (L234, L235, L469, F473, M19, L24). 
Substitution of R238 with Trp results in displacement of Cα of Met19 and Phe473 by ~1.5 Å, yet 
this has little effect in the overall conformation of the enzyme. (C) A Ribbon diagram showing 
the superposition of the active D407A-537X (colored) and WT (grey). The helix A (αA, deep 
purple), HAD domain and the three segments are colored and labeled for the structure of 
D407A. Phosphate ions are shown with stick models and labeled. (D) A close-up view of αA, 
depicting the essential hydrogen bonds (red dash lines) between D459 with the three basic 







Figure S4. Related to Figure 5. Functional characterization of the NT5C2 arm region. (A) 
Schematic representation of CRISPR/CAS9 screen to identify gain-of-function NT5C2 alleles 
with inframe indels in the arm region of NT5C2.  (B) In vitro nucleotidase assays of recombinant 
protein of inframe indel NT5C2 mutants identified as gain of function alleles in the 
CRISPR/Cas9 screen compared to NT5C2 wild-type protein. (C) Chromatogram of Relapse B-
ALL 7 patient sample sanger sequencing of NT5C2 exon 15 showing the NT5C2 p.S408-




infected with doxycycline inducible wild-type or NT5C2 S408-D415 deletion expressing 
lentiviruses to increasing doses of 6-MP. (E) In vitro nucleotidase assays of NT5C2 S408-D415 
deletion purified recombinant protein compared to NT5C2 wild-type. (F) Interaction of the tip 
region of the arm segment from one protomer with R238 of another protomer at the dimer 
interface. A close-up view of the hydrogen bonding network of the residues at the tip of the arm 
segment (pink) in subunits A and the side chain of R238 in subunit B. The red dashlines depict 
hydrogen bonds. (G) Utilizing molecular dynamics morphing between top ranked conformations 
in active NT5C2, the path of Asp407 was assessed for interactions. Dynamic register of 
electrostatic potential of different predicted conformations of Asp407 in the arm region reveals a 
distinct positive track into the inter-monomer cavity. Displayed residues are depicted in spherical 
atomic surface and colored by charge (blue=positive, red=negative, green=neutral).  All atoms 
revealed show distance potential for electrostatic interaction with Asp407 as it passes through 
highest DOPE scoring models.  Atoms reveal a positive track through which Asp407 and other 
loop residues may bind in a fleeting stepwise fashion (shown with red arrow). (H) Lowest energy 
prediction conformation of arm region showing interactions between Lys361 and Asp407 













Figure S5. Related to Figure 6.  The location of the C-terminal and N-terminal segments in the 
basal structure of the full-length R39Q and hetero-tetramer analysis. (A) A Ribbon diagram 
displaying the C-terminal segment (marine) of the full-length R39Q (R39Q) (cyan for CD atoms) 
from subunit A (cyan), which wraps around the base of the arm segment (pink) of subunit B 
(yellow), where the acidic tail of the subunit A interacts with the positively-charged amino acids 
at the dimer interface. The arm segment of both subunit A and B is shown in pink, while the C-
terminal segment of subunit A is colored marine and is also represented by surface so as to 
accentuate its location. Residues 511-535 of the C-terminal segment are disordered. (B) A 
Ribbon diagram showing an overlay of the active ATP-bound full-length R39Q dimer (orange for 
C atoms of the N segment and gray for the rest of CD atoms) and the basal structure of the 
same enzyme, in which subunits A and B are shown in cyan and yellow, respectively. The C-
segment of subunit B of the basal structure is colored in marine. The N-segment and the C-
segment of the active and the basal structures are also depicted as transparent orange and 
marine surfaces, respectively. (C) Mutant-wild-type NT5C2 complex detection via Flag and HA 
immunoprecipitations from 293T cells expressing Flag-tagged NT5C2 wild-type and HA-tagged 
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Clonal evolution mechanisms in NT5C2 mutant-
relapsed acute lymphoblastic leukaemia
Gannie Tzoneva1†*, Chelsea L. Dieck1*, Koichi Oshima1, Alberto Ambesi-Impiombato1†, Marta Sánchez-Martín1, 
Chioma J. Madubata2, Hossein Khiabanian3, Jiangyan Yu4,5, Esme Waanders4, Ilaria Iacobucci6, Maria Luisa Sulis7, 
Motohiro Kato8, Katsuyoshi Koh8, Maddalena Paganin9, Giuseppe Basso9, Julie M. Gastier-Foster10,11,12,13,  
Mignon L. Loh14,15, Renate Kirschner-Schwabe16, Charles G. Mullighan6, Raul Rabadan2,17 & Adolfo A. Ferrando1,2,7,18
Relapsed acute lymphoblastic leukaemia (ALL) is associated 
with resistance to chemotherapy and poor prognosis1 . Gain-of-
function mutations in the 5′-nucleotidase, cytosolic II (NT5C2) 
gene induce resistance to 6-mercaptopurine and are selectively 
present in relapsed ALL2,3. Yet, the mechanisms involved in 
NT5C2 mutation-driven clonal evolution during the initiation 
of leukaemia, disease progression and relapse remain unknown. 
Here we use a conditional-and-inducible leukaemia model to 
demonstrate that expression of NT5C2(R367Q), a highly prevalent 
relapsed-ALL NT5C2 mutation, induces resistance to chemotherapy 
with 6-mercaptopurine at the cost of impaired leukaemia cell 
growth and leukaemia-initiating cell activity. The loss-of-fitness 
phenotype of NT5C2+/R367Q mutant cells is associated with excess 
export of purines to the extracellular space and depletion of the 
intracellular purine-nucleotide pool. Consequently, blocking 
guanosine synthesis by inhibition of inosine-5′-monophosphate 
dehydrogenase (IMPDH) induced increased cytotoxicity against 
NT5C2-mutant leukaemia lymphoblasts. These results identify the 
fitness cost of NT5C2 mutation and resistance to chemotherapy as 
key evolutionary drivers that shape clonal evolution in relapsed ALL 
and support a role for IMPDH inhibition in the treatment of ALL.
Improved support and intensified chemotherapy regimens have 
increased the overall survival rates of newly diagnosed paediatric 
ALL to over 80%1. However, the outcomes of patients with relapsed 
or refractory ALL remain poor, with cure rates of only about 40%1. 
Leukaemia-initiating cells capable of self-renewal4,5, protective 
microenvironment safe-haven niches6,7 and clonal evolution8–10 with 
acquisition of  secondary genetic alterations driving chemotherapy 
resistance2,3,9–13 have all been implicated as drivers of ALL disease 
progression and relapse. In this context, heterozygous  activating 
mutations in the NT5C2 nucleotidase gene are present in about 20% 
of relapsed  paediatric T-cell ALL (T-ALL) cases2 and 3–10% of relapsed 
B-precursor ALLs2,3. NT5C2 (Enzyme Commission (EC) number 
3.1.3.5) is a highly conserved and ubiquitously expressed enzyme 
responsible for catalysing the 5′ -dephosphorylation of the purine 
 nucleotides inosine monophosphate, xanthine monophosphate and 
guanosine monophosphate14. This activity controls the  intracellular 
 levels of 6-hydroxypurine monophosphate nucleotides via their 
dephosphorylation to nucleosides, which are subsequently exported 
out of the cell14,15. In addition, NT5C2 metabolizes and inactivates the 
active metabolites that mediate the cytotoxic activity of 6-mercaptopu-
rine (6-MP), a purine analogue chemotherapy drug that is broadly used 
in the treatment of ALL16 (Extended Data Fig. 1). Expression of gain-
of-function relapse-associated mutant forms of NT5C2 can therefore 
induce resistance to 6-MP in vitro2,3.
Genomic profiling of matched samples from the time of ALL diagnosis 
and after relapse supports the hypothesis that cellular competition 
and chemotherapy resistance work as dynamic evolutionary forces 
that shape the clonal architecture of ALL8–10. To test this hypothesis 
we generated a knock-in mouse model (Nt5c2+/co-R367Q) for condi-
tional expression of Nt5c2(R367Q) (Extended Data Fig. 2), the most 
 common NT5C2 mutation found in relapsed ALL2,3, and gene rated 
primary NOTCH1-induced Rosa26+/CreERT2Nt5c2+/co-R367Q T-ALL 
tumours17,18 (Extended Data Fig. 2) with conditional tamoxifen- 
inducible expression of Nt5c2(R367Q) (Fig. 1a and Extended Data 
Fig. 2). Treatment of isogenic Nt5c2 wild-type (Nt5c2+/co-R367Q, 
vehicle-treated) and Nt5c2+/R367Q mutant (Nt5c2+/co-R367Q, 4-hydroxy- 
tamoxifen-treated) leukaemia cells with increasing concentrations of 
6-MP showed overt resistance to thiopurine chemotherapy specifically 
in Nt5c2+/R367Q mutant cells (Fig. 1b). Moreover, Nt5c2+/R367Q mutant 
cells were positively selected in a dose-dependent manner over isogenic 
wild-type Nt5c2+/co-R367Q tumour cells under 6-MP treatment in vitro 
(Fig. 1c). Treatment of mice harbouring isogenic Nt5c2+/co-R367Q (vehicle 
treated, wild-type group) or Nt5c2+/R367Q (tamoxifen treated, mutant 
group) leukaemias with 6-MP produced a dose-dependent response in 
Nt5c2+/co-R367Q wild-type tumours and overt resistance with progres-
sion in Nt5c2+/R367Q mutant leukaemias (Fig. 1d, e and Extended Data 
Fig. 2g). Moreover, 6-MP treatment of mixed tumour populations of 
isogenic wild-type Nt5c2+/co-R367Q and mutant Nt5c2+/R367Q lympho-
blasts demonstrated positive selection in vivo of cells harbouring the 
Nt5c2(R367Q)-encoding mutant allele (Extended Data Fig. 2h). These 
results support a direct role for NT5C2(R367Q) as a driver of 6-MP 
resistance in vivo and are concordant with the strong association of 
NT5C2 mutations with early relapse and progression during 6-MP 
maintenance therapy in the clinic2,3.
Recent genomic studies of matched diagnostic and relapsed ALL 
samples support the hypothesis that relapsed leukaemia emerges from 
the expansion of pre-existing resistant populations present as minor 
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subclones at the time of diagnosis19. To evaluate further the role of 
NT5C2 as a driver of clonal progression and relapse in ALL, we used 
ultra-deep sequencing with unique-molecular-identifier barcoding 
(4,100× coverage) to analyse the presence of NT5C2 mutations in 
14 diagnostic DNA samples from cases showing acquired NT5C2 
mutations at relapse. Notably, these analyses (1:1,000 sensitivity) failed 
to detect the corresponding relapse-associated NT5C2 mutant allele 
at the time of diagnosis (Extended Data Table 1). NT5C2(R367Q) 
allele-specific quantitative PCR (qPCR) (n = 9) (1:1,000 sensitivity) 
yielded similar negative results (Extended Data Table 1). Moreover, in 
one case bearing the NT5C2(R39Q) mutation at the time of relapse, 
droplet PCR analysis (1:20,000 sensitivity) detected the presence of this 
mutation during complete remission 37 days prior to the emergence of 
clinical relapse (Extended Data Table 1). Before then, and at the time of 
diagnosis, the signal for this mutation (0.00064%) was below the estab-
lished sensitivity of the assay (0.005%). In a separate case we detected a 
NT5C2(P414A) mutation in first relapse and a second NT5C2(R39Q) 
variant in second relapse. In this patient, the NT5C2(P414A) muta-
tion was not detectable by droplet PCR analysis at the time of diagno-
sis, whereas the mutant allele encoding NT5C2(R39Q) was detected 
below the 0.005% detection threshold at 0.0024–0.0031% frequency. 
However, analysis of bone marrow at the time of first relapse detected 
a NT5C2(R39Q) subclonal population (0.0058%) in addition to the 
NT5C2(P414A) clone. These NT5C2(R39Q) mutant cells expanded 
(0.0224%) in a serial sample obtained during a second complete remis-
sion 60 days later, while the NT5C2(P414A) mutant clone decreased, 
becoming clonal at the time of second relapse 50 days later (Extended 
Data Table 1). These results suggest that NT5C2 mutations can be 
detected in complete-remission samples before relapse, yet, if present 
in the clonal repertoire at the time of diagnosis, they represent quan-
titatively minor populations below the sensitivity of molecular assays.
Resistance-driving mutations have been linked to enhanced 
 leukaemia growth and proliferation, clonal expansion at early stages 
of tumour development and increased leukaemia stem-cell activity20–22. 
However, studies of resistance to bacterial antibiotics have uncovered 
frequent examples of evolutionary trade-offs in which the acquisition 
of drug resistance is coupled with a reduced-fitness phenotype23. In this 
context, we noted that in the absence of chemotherapy, Nt5c2+/R367Q 
mouse tumour cells showed decreased proliferation in vitro, a delayed 
entry into the S phase of the cell cycle (Fig. 2a, b) and delayed tumour 
progression in vivo compared with wild-type Nt5c2+/co-R367Q isogenic 
controls (Fig. 2c). Moreover, limiting dilution transplantation assays 
demonstrated a 17-fold reduction of leukaemia-initiating cell activity 
in mutant Nt5c2+/R367Q tumour cells (Fig. 2d–e and Extended Data 
Table 2). Of note, allele expression analysis of tumours recovered from 
mice transplanted with Nt5c2+/R367Q leukaemia lymphoblasts showed 
decreased expression of the mutant Nt5c2 transcripts, suggesting 
downregulation of the mutant allele encoding Nt5c2(R367Q) during 
tumour progression in the absence of 6-MP (Extended Data Fig. 3). 
These results support the hypothesis that Nt5c2(R367Q) imposes a 
notable fitness cost to leukaemia lymphoblasts.
Given the role of NT5C2 in the degradation and export of purine 
nucleotides15, we examined whether imbalances in the  intracellular 
purine-nucleotide pool could mediate the loss-of-fitness pheno-
type observed in Nt5c2+/R367Q mutant leukaemia cells. Broad-based 
metabo lomic analysis showed that NT5C2 activation in Nt5c2+/R367Q 
ALL lymphoblasts leads to decreased intracellular levels of NT5C2 sub-
strates (inosine monophosphate, xanthine monophosphate and guano-
sine monophosphate) and accumulation of downstream nucleo tide 
products and their metabolites (inosine, hypoxanthine, xanthosine, 
xanthine, guanine and uric acid) in conditioned media (Fig. 3 and 
Supplementary Tables 1, 2). Similarly, expression of NT5C2(R367Q) 
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Figure 1 | Expression of Nt5c2(R367Q) in 
a NOTCH1-induced mouse model of ALL 
induces resistance to 6-MP. a, cDNA sequencing 
chromatograms of Nt5c2+/co-R367Q wild-type 
and Nt5c2+/R367Q isogenic T-ALL cells. Data are 
representative of results from more than two 
experiments. b, Cell viability of isogenic  
Nt5c2+/co-R367Q and Nt5c2+/R367Q T-ALL cells 
treated with increasing concentrations of 6-MP 
(n = 3 biological replicates). c, Change in the 
percentage of Nt5c2+/R367Q T-ALL cells over  
time in a mixed culture with isogenic  
Nt5c2+/co-R367Q cells treated with 6-MP (n = 3 
biological replicates). DMSO, dimethylsulfoxide. 
d, e, Tumour burden in mice allografted with 
Nt5c2+/co-R367Q (d) or isogenic Nt5c2+/R367Q (e) 
leukaemia cells and treated with 6-MP. Data for 
the vehicle groups are from 6 (d) or 5 (e) mice 
and from 5 mice for the treatment groups.  
* * P ≤ 0.01, * * * P ≤ 0.001, two-tailed Student’s  











































P = 6.74 × 10–6
CI for 1/(stem-cell frequency)
Group Lower Estimate Upper
Nt5c2+/co-R367Q 1,109 459 190
Nt5c2+/R367Q 19,538 7,817 3,127






























































Figure 2 | Nt5c2(R367Q) expression impairs proliferation and 
leukaemia-initiating cell activity in ALL. a, In vitro growth (fold change) 
of isogenic Nt5c2+/co-R367Q wild-type and Nt5c2+/R367Q mutant mouse 
T-ALL cells. b, Cell cycle progression of Nt5c2+/co-R367Q and Nt5c2+/R367Q 
mouse T-ALL cells. c, Kaplan–Meier survival curve of mice harbouring 
Nt5c2+/co-R367Q and Nt5c2+/R367Q isogenic leukaemias (n = 6 per group).  
d, Leukaemia-initiating cell analysis in mice bearing Nt5c2+/co-R367Q  
or isogenic Nt5c2+/R367Q leukaemia cells (n = 6 mice per group).  
e, Confidence intervals (CI) showing 1/(stem-cell frequency) based on d. 
a, b, Data are from three biological replicates. * P ≤ 0.05, * * P ≤ 0.005,  
* * * P ≤ 0.001, two-tailed Student’s t-test (a, b) or two-sided log-rank  
test (c).
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in human T-ALL (CUTLL1) and B precursor ALL (REH) cell lines 
resulted in depletion of intracellular purine nucleotides and increased 
levels of purine metabolites in the culture media (Extended Data Fig. 4 
and Supplementary Tables 3, 4). Increased extracellular purine metabo-
lites are consistent with the described activity of NT5C2 in promoting 
the export of purine nucleotides15 and might result in potential non-cell 
autonomous satellite effects modulating nucleotide metabolism and the 
response to 6-MP in by-standing wild-type NT5C2 cells.
A corollary of these findings is that because of this metabolic 
imbalance, gain-of-function NT5C2 mutations could be negatively 
selected during ALL tumour initiation and early disease progression, 
a time when clonal evolution is driven primarily by competition for 
microenvironment resources with normal haematopoietic stem and 
progenitor cells first, and then between different leukaemia clones24. 
Consistent with this model, integrated sequential network (ISN)25 anal-
ysis of mutation dynamics from diagnostic and relapse mutation data 
identified NT5C2 mutations as late events in the clonal evolution of 
ALL (Extended Data Fig. 5).
We hypothesized that gain-of-function relapse-associated NT5C2 
mutations could result in increased leukaemia dependence on purine 
synthesis, rendering leukaemia lymphoblasts more sensitive to drugs tar-
geting this pathway. Indeed, acquired drug resistance in bacteria can be 
accompanied by collateral sensitivity to an alternative antibiotic agent23. 
To test this possibility, we analysed the response of Nt5c2+/co-R367Q  
wild-type and isogenic Nt5c2+/R367Q mutant ALL lymphoblasts to 
mizoribine, an inhibitor of inosine-5′-monophosphate dehydroge-
nase (IMPDH), a rate-limiting enzyme required for the synthesis of 
guanine nucleotides26. Notably, these experiments demonstrated sig-
nificantly increased sensitivity to mizoribine in Nt5c2+/R367Q mutant 
leukaemia cells in vitro compared to Nt5c2+/co-R367Q wild-type isogenic 
controls (Fig. 4a and Extended Data Fig. 6). Moreover, guanosine 
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Figure 3 | Nt5c2(R367Q) decreases the 
intracellular purine nucleoside pool 
and increases secretion of purines in 
ALL cells. Diagram of the purine de novo 
biosynthesis and salvage pathways, showing 
gas chromatography–mass spectrometry 
and liquid chromatography–tandem mass 
spectrometry metabolic profiles (mass 
spectrometry scaled intensity, arbitrary 
units) of wild-type Nt5c2+/co-R367Q (WT) 
and Nt5c2+/R367Q mutant (R367Q) isogenic 
primary mouse T-ALL cells and their 
corresponding conditioned media (n = 3 
biological replicates). Box plots represent the 
upper quartile to lower quartile distribution. 
Asterisks indicate mean values, horizontal 
lines indicate median values and whiskers 
indicate the maximum and minimum values.
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Figure 4 | Collateral sensitivity to IMPDH 
inhibition in NT5C2(R367Q) mutant  
tumour cells. a, Cell viability of isogenic 
Nt5c2+/co-R367Q and Nt5c2+/R367Q T-ALLs treated 
with mizoribine. b, Kaplan–Meier survival 
curve of mice harbouring Nt5c2+/co-R367Q and 
Nt5c2+/R367Q isogenic leukaemias (n = 10 
mice per group) after initial treatment with 
mizoribine or vehicle (green bar). c, f, DNA 
sequencing chromatograms corresponding to 
two matched primary human T-ALL xenografts 
obtained from samples taken at the time of 
diagnosis (wild-type NT5C2) and after relapse 
(NT5C2(R367Q)) (matched pairs are labelled 
as ALL-4 (c–e) and ALL-N1 (f–h)). d, g, Cell 
viability of samples evaluated in c and f showing 
resistance to 6-MP in relapsed T-ALL xenograft 
cells. e, h, Cell viability in samples analysed in 
c, f, d and g showing collateral sensitivity to 
mizoribine in relapsed T-ALL xenograft cells. 
Data in a, d, e, g and h are from three biological 
replicates and P values were calculated using 
two-tailed Student’s t-test. P value in b was 
calculated with a two-sided log-rank test.
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Nt5c2+/co-R367Q wild-type and Nt5c2+/R367Q mutant lymphoblasts, sup-
porting a mechanistic role for nucleotide depletion in the activity of this 
drug and its synthetic lethal interaction with the mutant allele encoding 
Nt5c2(R367Q) (Extended Data Fig. 6). Similar differential responses 
to mizoribine in wild-type Nt5c2+/co-R367Q cells and in Nt5c2+/R367Q 
mutant cells were observed in vivo in a subcutaneous lymphoma 
model (Extended Data Fig. 6). Furthermore, treatment of Nt5c2+/R367Q 
leukaemia-bearing mice with mizoribine induced a marked in vivo 
anti-leukaemic response, with significantly improved survival com-
pared with isogenic Nt5c2+/co-R367Q wild-type controls (P < 0.0001) 
(Fig. 4b). Similarly, expression of gain-of-function NT5C2 muta-
tions (R238W, K359Q, R367Q and D407A) associated with relapse in 
CUTLL1 and REH ALL cells induced resistance to 6-MP and increased 
their sensitivity to mizoribine (Extended Data Figs 7, 8). As before, 
guanosine supplementation ameliorated the anti-leukaemic effects of 
mizoribine in this experiment, providing evidence that depletion of 
nucleotides is the mechanism of action for this drug (Extended Data 
Figs 7, 8). Additionally, knockdown of IMPDH2, the gene encoding the 
main IMPDH isoform expressed in proliferating tissues and tumour 
cells, led to decreased growth in NT5C2(R367Q)-expressing REH and 
CUTLL1 cells compared to wild-type NT5C2-expressing lymphoblasts 
(Extended Data Figs 7, 8). We also observed resistance to 6-MP with 
increased sensitivity to mizoribine in leukaemia cells from two human 
primary xenografts harbouring the mutant NT5C2(R367Q)-encoding 
allele compared to matched wild-type NT5C2 ALL blasts derived 
from samples obtained at the time of diagnosis (Fig. 4c–h). Moreover, 
immunodeficient mice transplanted with an NT5C2(R367Q) xenograft 
derived from a relapsed patient showed decreased tumour burden and 
tumour infiltration following mizoribine treatment compared to mice 
transplanted with matched wild-type NT5C2 xenograft cells derived 
from samples taken at the time of diagnosis (Extended Data Fig. 6).
These results document fitness cost and acquired resistance to 6-MP 
as evolutionary forces that drive the clonal evolution  dynamics and 
selection of relapse-associated NT5C2 mutations in ALL,  highlight 
the relevance of nucleotide export in the control of nucleotide 
 homeostasis27 and in the context of antimetabolite therapy28, and 
 identify collateral sensitivity to IMPDH inhibition as a potentially 
 relevant vulnerability in NT5C2-mutant leukaemia.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Patient samples. DNA samples from leukaemic ALL blasts obtained at diag-
nosis and after relapse and matched remission lymphocytes were provided by 
the Hemato-Oncology Laboratory at University of Padua, Italy; the Children’s 
Oncology Group in the Department of Hematology/Oncology at Saitama 
Children’s Medical Center, Saitama, Japan and St Jude Children’s Research Hospital. 
Informed consent was obtained at study entry and samples were collected under 
the supervision of local Institutional Review Boards for participating institutions 
and analysed under the supervision of the Columbia University Medical Center 
Institutional Review Board (Protocol Number: IRB-AAAB3250). Research was 
conducted in compliance with ethical regulations.
Cell lines and cell culture procedures. We performed cell culture in a humidi-
fied atmosphere at 37 °C under 5% CO2. We harvested primary mouse tumour 
cells from the spleens of leukaemic mice by processing spleens through a 70-µ m 
mesh to obtain single-cell suspensions and incubated cells with red blood cell lysis 
buffer. Tumour cells were then placed in culture in Opti-MEM media supple-
mented with 10% fetal bovine serum (FBS), 100 U ml−1 penicillin G, 100 µ g ml−1 
streptomycin, 55 µ M β -mercaptoethanol, 10 ng ml−1 mouse IL-7 and 10 ng ml−1 
human IL-2. Subsequent passages of tumour cells did not include IL-2. We pas-
saged and harvested primary human xenograft T-ALL cells from the spleens of 
NRG (NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ, Jackson Laboratory) mice and  cultured 
them in RPMI media supplemented with 20% FBS, 100 U ml−1 penicillin G, 
100 µ g ml−1 streptomycin and 10 ng ml−1 human IL-7. We purchased HEK293T 
cells for viral production and REH cells from American Type Culture Collection. 
The CUTLL1 cell line, which was generated by continuous culture of T-cell lymph-
oblastic pleural effusion cells from a patient in relapse, has been characterized and 
reported previously29. We grew HEK293T cells in DMEM media supplemented 
with 10% FBS, 100 U ml−1 penicillin G and 100 µ g ml−1 streptomycin for up to two 
weeks. We cultured CUTLL1 and REH cells in RPMI-1640 media supplemented 
with 10% FBS, 100 U ml−1 penicillin G and 100 µ g ml−1 streptomycin. Cell lines 
were regularly authenticated and tested for mycoplasma contamination.
Drugs. We purchased tamoxifen, guanosine, 4-hydroxytamoxifen, 6-mercaptopurine 
(6-MP) and mizoribine from Sigma-Aldrich. For in vitro assays we dissolved 
4-hydroxytamoxifen in 100% ethanol, guanosine in DMSO, 6-MP in DMSO and 
mizoribine in PBS. For in vivo studies we resuspended 100 mg tamoxifen in 100 µ l 
of ethanol and added corn oil to reach a final concentration of 3 mg 100 µ l−1. We 
then rotated the tamoxifen suspension for 1 h at 55 °C and froze it in aliquots 
at − 20 °C. We administered tamoxifen as a single 100 µ l intraperitoneal injection 
per mouse. For intraperitoneal injections of 6-MP we prepared frozen aliquots of 
5 mg ml−1 6-MP in 0.1 M NaOH and immediately before each round of treatment 
we prepared fresh final solutions of 6-MP by buffering the stock solution down to 
pH 8 with 0.2 M NaH2PO4. This resulted in a 6-MP concentration of 3.48 mg ml−1, 
which we diluted to various final concentrations using a solution made from 0.05 M 
NaOH and 0.2 M NaH2PO4 adjusted to pH 8. We administered 6-MP as 25 mg kg−1. 
40 mg kg−1 and 50 mg kg−1 all twice a day. We prepared vehicle by dissolving 
0.254 g NaCl in 50 ml 0.05 M NaOH and adjusting the pH to 8 with 0.2 M 
NaH2PO4. For intraperitoneal injections we dissolved mizoribine (TCI America 
and Toronto Research Chemicals) in PBS at 10 mg ml−1 or 15 mg ml−1 and froze 
aliquots to be thawed before treatment. We adjusted injection volume to correct 
for any differences in weight between individual mice.
Plasmid and vectors. We obtained MigR1_∆ -E NOTCH1_GFP from R. Kopan, 
sh-TURBOGFP and pLKO.1_IMPDH2_shRNA (clone ID: NM_000884.1-
360s1c1) from Sigma Aldrich’s Mission shRNA library and FUW-mCherry-Puro-
Luc from ref. 30. We generated the NT5C2 R238W, K359Q, R367Q and D407A 
mutations in the pLOC-NT5C2 plasmid2 by site-directed mutagenesis using the 
QuikChange II XL Site-Directed Mutagenesis kit (Stratagene) according to the 
manufacturer’s instructions.
Retroviral and lentiviral infections. We transfected retroviral or lentiviral 
 plasmids together with gag-pol (pCMV ∆ R8.91) and V-SVG (pMD.G VSVG) 
expressing vectors into HEK293T cells using JetPEI transfection reagent (Polyplus). 
We collected viral supernatants after 48 h and used them to infect mouse bone 
marrow progenitors, human cell lines, or primary tumour cells by spinoculation 
with 4 µ g ml−1 Polybrene Infection/Transfection Reagent (Fisher Scientific). We 
selected infected primary mouse tumour cells or human cell lines with 1 mg ml−1 
blasticidin (InvivoGen) for 14 days.
Mice and animal procedures. We maintained all animals in specific pathogen-free 
facilities at the Irving Cancer Research Center at Columbia University Medical 
Campus. The Columbia University Institutional Animal Care and Use Committee 
(IACUC) approved all animal procedures. Animal experiments were conducted in 
compliance with all relevant ethical regulations. Animals were euthanized upon 
showing symptoms of clinically overt disease (do not feed, lack of  activity,  abnormal 
grooming behaviour, hunch back posture) or excessive weight loss (10–15% body 
weight loss over a week) and before reaching the maximum permitted tumour 
burden of 90% blasts in the bone marrow. To generate conditional Nt5c2(R367Q) 
knock-in mice we used homologous recombination in C57BL/6 embryonic stem 
cells to introduce a point mutation (AG→ CA) in exon 14 that caused the R367Q 
substitution (two nucleotide changes were introduced to replace the mouse R367 
codon (AGA) with a glutamine-coding codon (CAA)) as well as a loxP-flanked 
wild-type mini-gene cassette (1958 bp, inserted 233 bp upstream of exon 14) com-
posed of the fusion of exons 14–18 and flanking genomic sequences upstream of 
exon 14 and downstream of exon 18. Immediately downstream of the mini-gene 
we introduced a FRT-flanked neomycin selection cassette. We generated chimaeras 
in C57BL/6 albino blastocysts using three independent knock-in embryonic stem-
cell clones identified by PCR analysis and verified by Southern blot. We verified 
germ-line transmission in the offspring of highly chimaeric male mice crossed 
with C57BL/6 females. To remove the neomycin selection cassette we crossed 
mice harbouring the targeting construct with a Flp germ line deleter line (B6;SJL-
Tg(ACTFLPe)9205Dym/J, Jackson Laboratory) and crossed the resulting mice 
with wild-type C57BL/6 to breed out the Flp allele. To generate inducible knock-in 
mice we bred animals harbouring the Nt5c2co-R367Q allele with Rosa26+/creERT2  
mice, which express a tamoxifen-inducible form of the Cre recombinase from the 
ubiquitous Rosa26 locus31.
To generate NOTCH1-induced T-ALL tumours in mice, we performed ret-
roviral transduction of bone marrow cells (from Rosa26+/creERT2Nt5c2+/co-R367Q 
mice) enriched in lineage negative cells isolated using magnetic beads (Lineage 
Cell Depletion Kit, Miltenyi Biotec) with retroviruses expressing an activated form 
of the NOTCH1 oncogene (∆ E-NOTCH1)17 and the green fluorescent protein 
(GFP) and transplanted them via intravenous injection into lethally irradiated 
isogenic recipients (6–8-week-old C57BL/6 females, Taconic Farms) as previously 
described18,32.
We assessed T-ALL tumour development by monitoring CD4+CD8+GFP+ cells 
in peripheral blood by flow cytometry. In brief, we incubated blood samples with 
red blood cell lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 
5 min at room temperature three times before staining with APC–Cy7-conjugated 
antibodies against mouse CD4 (BD Pharmingen-552051) and PE–Cy7-conjugated 
antibodies against mouse CD8a (eBioscience-25-0081-82). Flow cytometry 
 analyses were performed in a FACSCanto flow cytometer (BD Biosciences) and 
analysed with Flowjo software (FlowJo LLC).
For all subsequent in vivo studies, we harvested fresh Rosa26+/creERT2Nt5c2+/co-R367Q 
T-ALL tumour cells from the spleens of donor mice and transplanted them into 
sublethally irradiated (4 Gy) secondary recipients (C57BL/6 females, 6–8 weeks old, 
Taconic Farms). Animals were randomly assigned to different treatment groups 
and no blinding was done. For survival and leukaemia-initiating cell experi ments, 
we treated mice with tamoxifen (3 mg via intraperitoneal injection) two days 
after transplantation to induce mini-gene-cassette deletion and expression of the 
Nt5c2 allele encoding the R367Q mutation in the leukaemic cells, or with corn oil 
vehicle in the control group (n = 6 mice per group). Mice were then observed for 
incidence and time of onset of leukaemia.
To detect tamoxifen-inducible mini-gene deletion, we purified DNA from 
primary Rosa26+/creERT2Nt5c2+/co-R367Q mouse tumour cells treated with 1 µ M 
4-hydroxytamoxifen or ethanol vehicle (in vitro experiments) and tamoxifen or 
corn oil vehicle (in vivo experiments) and then performed PCR-amplification with 
a three-primer reaction: (i) the minigene cassette (primer immediately upstream 
of proximal loxP site and reverse primer in exon 17) and (ii) the deleted mini-
gene and wild-type alleles (primer immediately upstream of proximal loxP site 
and reverse primer in intron 14). The deleted and wild-type alleles differ by the 
size of the remaining loxP site (49 bp). We visualized PCR products resolved by 
electrophoresis in a 1.5% agarose gel with ethidium bromide.
To detect tamoxifen-inducible expression of mRNA corresponding to the Nt5c2 
allele encoding the R367Q mutation, we purified total RNA from mouse tumour 
cells with the RNeasy kit (Qiagen), prepared complementary DNA (cDNA) by 
reverse transcription using the SuperScript First-Strand Synthesis System for 
RT–PCR (Invitrogen) and PCR amplified the Nt5c2 exon 14 cDNA region using 
primers spanning neighbouring exons following standard procedures. We analysed 
the resulting PCR products by dideoxy DNA sequencing to verify the expression 
of the engineered nucleotide substitutions in the Nt5c2 allele encoding the R367Q 
mutation.
For experimental therapeutics treatment studies, we used Rosa26+/creERT2 
Nt5c2+/co-R367Q T-ALL tumour cells infected with lentiviral particles expressing 
the red cherry fluorescent protein and luciferase (FUW-mCherry-Luc-puro). We 
transplanted luciferased Rosa26+/creERT2Nt5c2+/co-R367Q T-ALL tumour cells into 
C57BL/6 recipients by intravenous injection and monitored tumour develop-
ment by in vivo luminescence bioimaging with the In vivo Imaging System (IVIS, 
Xenogen) and by flow cytometry using analysis of GFP+ cells in peripheral blood. 
Once mice had 50% GFP positive cells in the peripheral blood and a  detectable 
baseline tumour burden by bioluminescence, we treated them with tamoxifen 




(3 mg, intraperitoneal injection) or corn oil vehicle as described above. Two days 
later we initiated treatment with a range of doses of 6-MP (0, 50, 80, 100 mg kg−1 
per day) via intraperitoneal injection for five consecutive days (n = 5 mice per 
group). We monitored disease progression and response to chemotherapy by 
bioluminescence imaging on days 0, 3 and 6 after the start of 6-MP treatment. We 
euthanized mice on day 6 and analysed GFP+ tumour infiltration in the spleen by 
flow cytometry. To assess mizoribine response in vivo we treated Rosa26+/creERT2 
Nt5c2+/co-R367Q leukaemia bearing mice 48 h following tamoxifen or corn oil vehicle 
treatment (as described above) with 40 mg kg−1 mizoribine or PBS vehicle (n = 10 
per group) via intraperitoneal injection for ten consecutive days. Mice were then 
observed for incidence and time of onset of leukaemia.
For experimental therapeutic treatment studies in a subcutaneous setting, 
Rosa26+/creERT2 Nt5c2+/co-R367Q T-ALL tumour cells infected with lentiviral parti-
cles expressing the red cherry fluorescent protein and luciferase (FUW-mCherry-
Luc-puro) were treated with 1 µ M 4-hydroxytamoxifen or ethanol vehicle in vitro, 
mixed with an equal volume of Corning Matrigel Membrane Matrix (Fisher 
Scientific) and injected (106 cells) into the flanks of female C57BL/6 mice. Upon 
detectable baseline tumour burden by bioluminescence, mice were treated intra-
peritoneally with PBS vehicle or mizoribine (20, 40, 75 or 100 mg kg−1 per day, 
n = 4 per dose) for 5 consecutive days. We monitored tumour progression and 
response to mizoribine by bioluminescence imaging on days 0 and 6 after the 
start of mizoribine treatment. Subcutaneous tumours were not allowed to exceed 
20 mm in diameter.
To evaluate the competitive selection of Nt5c2+/R367Q cells in vivo we mixed wild-
type Nt5c2+/co-R367Q and Nt5c2+/R367Q mutant mouse tumour cells at a 1:10, 1:100 
and 1:1,000 Nt5c2+/R367Q:Nt5c2+/co-R367Q ratios and transplanted into C57BL/6 
recipients by intravenous injection. Ten days after transplant, mice were treated 
with vehicle or 50 mg kg−1 6-MP per day for 5 days, then allowed to recover for ten 
days and given a second round of treatment for 1–3 days. Following this second 
cycle of treatment, mice were euthanized and lymphoblasts were recovered from 
spleen samples for quantitative evaluation of Nt5c2+/R367Q mutant cells.
We generated primary human leukaemia xenografts by intravenous injection 
of cryopreserved leukaemia lymphoblasts from diagnostic and relapsed acute 
lympho blastic leukaemia patient samples into immunodeficient NRG mice.
We infected primary leukaemia xenograft cells with lentiviral particles 
 expressing the red cherry fluorescent protein and luciferase (FUW-mCherry-Luc-
puro) and transplanted matched ALL-4 diagnosis and ALL-4 relapse tumour cells 
into NRG immunodeficient recipients by intravenous injection and monitored 
tumour development by in vivo luminescence bioimaging with the In vivo Imaging 
System (IVIS, Xenogen) and by analysis of human CD45+ cells in peripheral blood 
by flow cytometry with an APC conjugated antibody (eBioscience 17-0459-42). 
Upon tumour establishment, mice were treated intraperitoneally with PBS vehicle 
or mizoribine (100 mg kg−1 administered twice a day) for 3 consecutive days. Four 
animals in the relapse-xenograft mizoribine treatment group did not tolerate the 
full course of therapy presumably because of tumour lysis syndrome and were not 
included in the analysis. We euthanized mice on day 4 and analysed spleen weight 
and CD45+ tumour infiltration in the bone marrow by flow cytometry.
In vitro cell viability and chemotherapy response assays. We measured cell 
growth and chemotherapy responses of primary mouse tumours, patient-derived 
xenografts, and human ALL cell lines in vitro by measurement of the metabolic 
reduction of the tetrazolium salt MTT using the Cell Proliferation Kit I (Roche) 
following the manufacturer’s instructions. We analysed chemotherapy responses 
following 72-h incubation with increasing concentrations of 6-mercaptopurine 
or mizoribine.
For the mixed culture experiment of isogenic wild-type Nt5c2+/co-R367Q and 
Nt5c2+/R367Q mouse tumour cells, we treated uninfected tumour cells (expressing 
GFP) with vehicle and treated the same tumour cells previously infected with a 
mCherry-expressing vector (FUW-mCherry-Luc-puro) with 4-hydroxytamoxifen 
and quantified proportions of the two cell populations by FACS analysis using a 
Fortessa flow cytometer (BD Biosciences) and analysed data with FlowJo software 
(FlowJo LLC). All experiments were performed in triplicate.
Cell synchronization and cell cycle analysis. We synchronized isogenic wild-type 
Nt5c2+/co-R367Q and Nt5c2+/R367Q mouse tumour cells using a double thymidine 
block procedure. In brief, we incubated cells with 2 mM thymidine (Sigma Aldrich) 
for 16 h, allowed cells to recover for 14 h in regular media, and incubated a second 
time with 2 mM thymidine for 16 h. We harvested cells at 0, 3, 6 and 9 h time points 
and stained them with propidium iodide (Sigma Aldrich) for cell cycle  progression 
analysis. FACS analysis was performed using a FACSCanto flow cytometer 
(BD Biosciences) and we analysed data with FlowJo software (FlowJo LLC).
Quantitative allele-specific qPCR assay. We quantitatively assessed the presence 
of the allele encoding NT5C2(R367Q) in matching DNA specimens obtained at 
diagnosis and during remission using a custom Mutation Detection Competitive 
Allele-Specific TaqMan PCR (castPCR) Assay (Life Technologies) using 30 ng 
of DNA in a reaction volume of 20 µ l in a 7500 real-time PCR system (Applied 
Biosystems) following the manufacturer’s instructions and recommended cycling 
conditions. We determined a detection ∆ Ct cut-off value for the assay by running 
the wild-type and mutant NT5C2 assays on genomic DNA samples from three 
wild-type cell lines and calibrated both assays by spiking in increasing concentra-
tions of wild-type NT5C2 or of the plasmid containing the NT5C2 allele encoding 
the R367Q mutation. We determined the assay sensitivity for the allele encoding 
NT5C2(R367Q) by analysing NT5C2 wild-type genomic DNA samples spiked with 
decreasing concentrations of the plasmid containing the NT5C2 allele encoding 
the R367Q mutation. We analysed experimental data using the Mutation Detector 
Software (Life Technologies) to calculate the ∆ Ct value between the wild-type 
NT5C2 and the NT5C2(R367Q)-encoding allele assay reads for each sample, and 
comparing these to the predetermined ∆ Ct cut-off value.
To quantitatively assess the presence of Nt5c2+/R367Q mutant cells in mixed 
tumour populations of wild-type Nt5c2+/co-R367Q and Nt5c2+/R367Q mutant lympho-
blasts, we performed a quantitative analyses of mutant transcripts  normalizing 
tumour content by quantitative PCR with reverse transcription (RT–PCR) 
 analysis of GFP. In this experiment we isolated RNA from lymphoblasts with 
the RNeasy kit (Qiagen) and prepared complementary DNA (cDNA) by reverse 
transcription using the SuperScript First-Strand Synthesis System for RT–PCR 
(Invitrogen). Nt5c2 exon 14 was amplified using TaqMan Gene Expression 
Master Mix (TaqMan) and the allele encoding Nt5c2(R367Q) was detected using 
a mutant-specific TaqMan probe (5′ FAM-AGGGTGGCAGACTTT-MGBNFQ 3′ , 
ThermoFisher). Actb (β -actin) and GFP were amplified using FastStart Universal 
SYBR Green Master (ROX) (Roche) following standard protocols. Quantitative 
PCR reactions were run in a 7500 Real Time PCR System (Applied Biosystems). 
Ct values of the allele encoding Nt5c2(R367Q) and GFP were  normalized to Actb 
Ct values and a ratio was taken of Nt5c2(R367Q) expression over GFP expression 
to represent the percentage of Nt5c2+/R367Q mutant cells present in mixed tumour 
populations.
Digital droplet PCR. Targeted ultra-deep mutation screening was performed 
using the digital droplet PCR technique (RainDance Technologies) as described 
previously33. In brief, TaqMan assay primers and probes were custom designed 
for the allele encoding NT5C2(P414A) using PrimerExpress 3.0 (Thermo 
Fisher Scientific). Primers and probes for the allele encoding NT5C2(R39Q) 
were designed through the Custom TaqMan Assay Design Tool (CADT) (Life 
Technologies) with the support of RainDance Technologies. Probes matching 
the wild-type allele were labelled with VIC fluorescent reporter dye and probes 
 matching the mutant allele were labelled with FAM dye. Amplicon sizes ranged 
from 75 bp to 120 bp. Genomic DNA was sheared to 3 kb using the M220 instru-
ment (Covaris) and a total of 500–1,000 ng of fragmented DNA was used in 
each 50 µ l ddPCR reaction. The digital droplet PCR reaction further contained 
1×  TaqMan Genotyping Master Mix (Applied Biosystems), 1×  digital PCR droplet 
stabilizer (RainDance Techonologies), and 1×  TaqMan primers and probes mix 
(Integrated DNA Technologies). In line with the manufacturer’s instructions, an 
average of 7 ×  106 droplets were generated by the RainDrop Source instrument and 
emulsion PCR was performed using the C1000 Thermal Cycler (BioRad). Droplet 
fluorescence of the amplified product was detected by the RainDrop Sense instru-
ment and data analysis was carried out using the RainDrop Analyst II Software 
(RainDance Techonolgies).
To determine the detection limit of the assays, we constructed dilution curves 
of patient tumour cells and cells from the REH cell line. The REH cell line was 
 confirmed to be wild type after Sanger sequencing for the locations targeted in 
the digital droplet PCR. We collected pure populations of tumour cells by flow 
cytometric sorting of the relapse samples of patients SJBALL192 (containing cells 
heterozygous for the allele encoding NT5C2(R39Q)). We made serial dilutions 
of tumour cells with wild-type cells (REH cell line) to generate final mutant allele 
frequency (MAF) levels of 50%, 5%, 0.5%, 0.05%, 0.005%, and 0.0005% and  isolated 
DNA using phenol–chloroform. With an input of 500 ng DNA in the digital  droplet 
PCR assay the MAFs correspond to 70,000, 7,000, 700, 70, 7, and 0.7 copies, 
 respectively. A frequency of > 0.005% (> 7 copies) could be consistently detected.
Duplex sequencing of diagnostic patient samples. Duplex sequencing was  carried 
out by TwinStrand Biosciences under fully blinded conditions using methods 
 previously described34,35. In brief, 400 ng of extracted genomic DNA was ultrasoni-
cally sheared, A-tailed and ligated to degenerate tag-containing Duplex adapters. 
The library was amplified and subjected to two successive rounds of hybrid capture 
with 120 bp biotinylated oligonucleotide probes tiled across exons 9, 11, 13, 15, 16 
and 17 of the human NT5C2 gene and flanking sequences. Indexed libraries were 
pooled and sequenced on an Illumina NextSeq 500. Duplex consensus sequences 
were generated after alignment to hg38 using the requirement that error-corrected 
bases be supported by at least three independent reads from each original strand. 
The variant calls for each sample were filtered against known single nucleotide 
polymorphisms in the Phase 3 build of the 1000 genomes database and tabulated 




versus all reference base calls at the eight codons of interest. Variant allele frequency 
was calculated as the number of variants per total number of error-corrected bases 
at each nucleotide position. The average error-corrected molecular depth at codons 
of interest was approximately 4,100× (1,840–8,530× ), yielding an average power 
for detecting variants at a level of 1/1,000 of ∼ 98%.
Metabolomic analyses. To analyse metabolic differences between Nt5c2+/co-R367Q 
and Nt5c2+/R367Q primary mouse tumours, we treated tumour cells in triplicate 
with 1 µ M 4-hydroxytamoxifen for 48 h in vitro to induce expression of the allele 
 encoding Nt5c2(R367Q) or with vehicle for wild-type controls, after which 
we diluted out the 4-hydroxytamoxifen or vehicle with media. After 72 h, we 
 harvested cells into packed 50–100-µ l size pellets and collected conditioned 
media for analyses (n = 3, cell pellets and media). We flash-froze cell pellet and 
media samples, which were then extracted using standard solvent extraction 
methods and analysed on the gas chromatography–mass spectrometry and liquid 
 chromatography–tandem mass spectrometry platforms by Metabolon. Analysed 
metabolites consisted of a total of 459 named biochemicals in cells and 252 named 
biochemicals in media. We first normalized results to protein concentration, log 
transformed and imputed any missing values with the minimum observed value for 
each compound. We then used Welch’s two-sample t-test to identify  biochemicals 
that differed significantly between experimental groups. To account for the  multiple 
comparisons that occur in metabolomics studies we also calculated an estimate 
of the false discovery rate (q-value), which indicates the fraction of biochemicals 
that would meet a given P-value cut-off by random chance. Similar processing and 
analyses were performed on CUTLL1 and REH ALL cell lines expressing wild-type 
NT5C2 or NT5C2(R367Q). Analysed metabolites in these cell lines consisted of a 
total of 596 named biochemicals in cells and 347 in media.
ISN of relapsed ALL. We illustrated the sequential order of somatic mutations 
in relapsed ALL using the ISN25 that pools evolutionary paths across all patients. 
We selected recurrently mutated genes that were previously defined as drivers of 
paediatric ALL36–38 and relapse-genes10,11. Only non-synonymous single nucleotide 
variants were used in analysis. For each patient, we generated a sequential network 
that defined early events as mutations observed in both the primary tumour and 
the relapsed tumour, whereas late events were mutations only observed in the 
relapsed tumour. Each node represented a gene, and each arrow pointed from a 
gene with an early event to a gene with a late event. The ISN then pooled sequential 
networks across all patients. To test whether a gene within the ISN was significantly 
early or late, we used the binomial test based on the in-degree and out-degree of 
each node. Somatic mutation data used to generate ISN were aggregated from 
previously published studies (refs 9–11).
Statistical analyses. We performed statistical analysis by Student’s t-test. We 
 considered results with P < 0.05 as statistically significant. Survival in mouse 
experiments was represented with Kaplan–Meier curves and significance was 
estimated with the log-rank test (GraphPad Prism). We analysed serial limited 
dilution leukaemia-initiating cell data using the ELDA software39. No outlier data 
points were excluded in the analyses.
Data availability. All data generated or analysed during this study are included in 
this published article and its Supplementary Information.
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Extended Data Figure 1 | Schematic representation of 6-MP activation 
and mechanism of action. The hypoxanthine-guanine phosphoribosyl 
transferase enzyme (HPRT) processes 6-MP to thio-IMP, which is then 
converted to thio-XMP and thio-GMP. Subsequent metabolism of thio-
GMP by kinases and reductases yields thio-dGTP which is incorporated 
into replicating DNA strands and triggers the DNA mismatch-repair 
machinery, leading to cell cycle arrest and apoptosis. The anti-leukaemic 
effects of 6-MP are in part also attributed to a second metabolic pathway 
in which thiopurine S-methyl transferase (TPMT) methylates thio-
IMP to form methylthio-IMP (MeTIMP), which is a potent inhibitor 
of amidophosphoribosyltransferase (ATase), an enzyme catalysing the 
committed step of de novo purine biosynthesis.
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Extended Data Figure 2 | See next page for caption.
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Extended Data Figure 2 | Conditional knock-in targeting of Nt5c2, 
generation and analysis of a Nt5c2(R367Q) conditional inducible 
T-ALL model. a, Schematic representation of the targeting strategy for 
the generation of Nt5c2+/co-R367Q conditional knock-in ice. b, Southern 
blot analysis of DNA samples from Nt5c2+/+ and targeted Nt5c2+/co-R367Q 
embryonic stem cells after digestions with BamHI restriction enzyme 
and hybridization of a DNA probe external to the long arm. c, Southern 
blot analysis of DNA samples from Nt5c2+/+ and targeted Nt5c2+/co-R367Q 
embryonic stem cells after digestion with ApaI restriction enzyme and 
hybridization of a DNA probe to the short arm. d, Schematic depiction of 
the strategy for developing conditional inducible Nt5c2+/co-R367Q primary 
mouse T-ALL tumours and for assessing the role of Nt5c2+/R367Q on 
leukaemia progression and response to chemotherapy. e, Representative 
FACS plot of a Rosa26+/creERT2Nt5c2+/co-R367Q ∆ E-NOTCH1-induced 
primary T-ALL tumour with a CD4+CD8+ immunophenotype.  
f, Representative genotyping PCR results from genomic DNA of a 
Rosa26+/CreERT2 Nt5c2+/co-R367Q ∆ E-NOTCH1-induced primary T-ALL 
tumour treated with 4-hydroxytamoxifen (TMX) or vehicle only (ethanol, 
ETOH) in vitro showing Cre-mediated deletion of the exon 14–18 Nt5c2 
wild-type mini-gene. g, Tumour burden assessed in the spleen (percentage 
of GFP+ cells) in mice allografted with NOTCH1-induced Nt5c2+/co-R367Q 
and isogenic Nt5c2+/R367Q primary leukaemia cells treated with a range of 
6-MP doses (n = 5 per group). h, Analysis of selection for the mutant allele 
encoding Nt5c2(R367Q) by qPCR in mice allografted with Nt5c2+/co-R367Q 
and Nt5c2+/R367Q primary mouse T-ALL cells at a 1:10, 1:100 and 1:1,000 
Nt5c2+/R367Q:Nt5c2+/co-R367Q dilution and treated with vehicle or 6-MP 
(n = 5 mice per group and n = 3 technical replicates for the controls). The 
horizontal bar represents mean values. P values were calculated using two-
tailed Student’s t-test (g) or a one-tailed Student’s t-test (h). Data in e and f 
show representative results from more than two experiments.
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Extended Data Figure 3 | Decreased expression of the allele encoding 
Nt5c2(R367Q) allele upon leukaemia progression in vivo. Sanger 
sequencing chromatograms of cDNA from tumours in Fig. 2c show 
decreased expression of the Nt5c2(R367Q)-encoding allele over the 
wild-type Nt5c2 allele compared with recently 4-hydroxytamoxifen 
treated Rosa26+/creERT2Nt5c2+/co-R367Q cells (Fig. 1a). Mutant-allele 
deoxynucleotides are indicated in red.
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Extended Data Figure 4 | NT5C2(R367Q) expression leads to  
increased purine export in T-ALL and B-ALL cell lines. Diagram  
of the purine de novo biosynthesis and salvage pathways, showing gas  
chromatography–mass spectrometry and liquid chromatography–tandem  
mass spectrometry metabolic profiles (mass spectrometry scaled  
intensity, arbitrary units) of CUTLL1 and REH cell lines expressing  
wild-type NT5C2 or NT5C2(R367Q) and their corresponding conditioned 
media (n = 3 biological replicates per sample). Box plots represent the 
upper quartile to lower quartile distribution. Plus signs indicate mean 
values, horizontal lines indicate median values and whiskers indicate the 
maximum and minimum values of the distributions.
































Extended Data Figure 5 | NT5C2 mutations are late events in ALL. ISN 
illustrating the sequential order of somatic mutations in relapsed ALL by 
pooling evolutionary paths across patients. Each node represents a gene 
and each arrow points from a gene with an early event to a gene with a late 
event. To test whether a gene within the ISN was significantly early or late, 
we used a one-sided binomial test based on the in-degree and out-degree 
of each node.
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Extended Data Figure 6 | Guanosine rescue of mizoribine sensitivity 
in vitro and mizoribine activity against NT5C2(R367Q) mutant cells 
in vivo. a, b, Cell viability assays showing drug responses of wild-type 
Nt5c2+/co-R367Q primary mouse T-ALL cells (a) or mutant Nt5c2+/R367Q 
mouse T-ALL lymphoblasts (b) to increasing doses of mizoribine in the 
presence of 20 µ M guanosine (n = 3 biological replicates). c, Analysis of 
tumour burden assessed by bioimaging in mice transplanted with wild-
type Nt5c2+/co-R367Q leukaemia cells (left flank) or mutant Nt5c2+/R367Q 
leukaemia cells (right flank) treated with a range of mizoribine doses 
(n = 8 mice for the vehicle group and n = 4 mice per treated group).  
d, Quantification of data from c. e, Analysis of tumour burden assessed  
by spleen weight in mice allografted with wild-type NT5C2 ALL-4 
diagnosis or NT5C2(R367Q) ALL-4 relapsed-patient derived leukaemia 
cells treated with 100 mg kg−1 mizoribine twice a day (n = 6 for diagnosis 
vehicle group, n = 3 for relapse treated group and n = 7 for diagnosis 
treated and relapse vehicle groups). f, Analysis of tumour burden assessed 
by percentage of CD45+ cells in the bone marrow of mice allografted with 
NT5C2 wild-type ALL-4 diagnosis or NT5C2(R367Q) ALL-4 relapsed-
patient derived leukaemia cells treated with 100 mg kg−1 mizoribine twice 
daily. (n = 3–7 mice per group). Horizontal bars in a, b, d–f indicate mean 
values. P values were calculated using a two-tailed Student’s t-test.
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Extended Data Figure 7 | 6-MP and IMPDH inhibition response in 
CUTLL1 cells. a, Cell viability assays showing drug responses of the 
CUTLL1 cell line infected with wild-type or mutant NT5C2-expressing 
lentiviruses to increasing doses of 6-MP. b, Cell viability assays as in a 
documenting the response to mizoribine. c, d, Cell viability assay showing 
drug responses of wild-type (c) or NT5C2(R367Q) (d) CUTLL1 cells 
to increasing doses of mizoribine in the presence of 20 µ M guanosine. 
e, Growth curve of CUTLL1 cells infected with a control short hairpin 
RNA (shRNA) targeting GFP or an shRNA targeting IMPDH2. f, Growth 
curve of wild-type or NT5C2(R367Q) CUTLL1 cells and infected with a 
shRNA targeting IMPDH2. a–f, Data are from three biological replicates. 
Horizontal bars in c and d indicate mean values. P values were calculated 
using a two-tailed Student’s t-test. * P ≤ 0.05.
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Extended Data Figure 8 | 6-MP and IMPDH inhibition response in REH 
B-ALL cells. a, Cell viability assay showing drug responses of the REH cell 
line infected with wild-type or mutant NT5C2-expressing lentiviruses to 
increasing doses of 6-MP. b, Cell viability assays as in a documenting the 
response to mizoribine. c, d, Cell viability assay showing drug responses 
of wild-type (c) or NT5C2(R367Q) (d) REH cells to increasing doses of 
mizoribine in the presence of 20 µ M guanosine. e, Growth curve of REH 
cells infected with a control shRNA targeting GFP or shRNA targeting 
IMPDH2. f, Growth curve of wild-type or NT5C2(R367Q) REH cells 
and infected with an shRNA targeting IMPDH2. a–f, n = 3 biological 
replicates. Horizontal bars in c and d indicate mean values. P values were 
calculated using a two-tailed Student’s t-test. * P ≤ 0.05.



















Sample Allele load at diagnosis
T-ALL 4 Not detected
T-ALL 17 Not detected
T-ALL 35 Not detected
T-ALL C4 Not detected
T-ALL C7 Not detected
T-ALL C11 Not detected
T-ALL C17 Not detected
T-ALL C18 Not detected








SJBALL192 D 0 0.005 P414A 0.00000
SJBALL192 R1 170 0.005 P414A 37.73843
SJBALL192 CR 204 0.005 P414A 0.20425
SJBALL192 CR 230 0.005 P414A 0.15196
SJBALL192 R2 280 0.005 P414A 0.00064
SJBALL192 D 0 0.005 R39Q 0.00256
SJBALL192 R1 170 0.005 R39Q 0.00584
SJBALL192 CR 230 0.005 R39Q 0.02241
SJBALL192 R2 280 0.005 R39Q 48.57407
SJTALL001 D 0 0.005 R39Q 0.00238
SJTALL001 D 0 0.005 R39Q 0.00307
SJTALL001 CR 53 0.005 R39Q 0.00576
SJTALL001 CR 53 0.005 R39Q 0.00762
SJTALL001 CR 218 0.005 R39Q 0.00333
SJTALL001 CR 218 0.005 R39Q 0.00579
SJTALL001 CR 362 0.005 R39Q 0.01952
SJTALL001 R1 399 0.005 R39Q 3.70027
SJTALL001 R1 412 0.005 R39Q 3.57648
SJTALL001 CR 434 0.005 R39Q 0.00931
SJTALL001 R2 751 0.005 R39Q 37.58709
SJTALL001 R2 751 0.005 R39Q 39.23768
D = Diagnosis, CR=complete remission, R1=First Relapse, R2=Second Relapse
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Extended Data Table 1 | Deep sequencing, allele-specific PCR and droplet PCR analyses of matched diagnostic and remission 
DNA from patients with NT5C2 mutations at relapse
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Rosa26+/CreERT2 Nt5c2 R367Q +/co-R367Q – Vehicle treated
Rosa26+/CreERT2 Nt5c2 R367Q +/R367Q  – Tamoxifen treated
Extended Data Table 2  | Leukaemia-initiating cell activity of isogenic Nt5c2+/co-R367Q  
wild-type and Nt5c2+/R367Q primary mouse T-ALL tumours
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5’ Cytosolic nucleotidase II (NT5C2) is a ubiquitously expressed cytosolic enzyme that 
dephosphorylates 6-hydroxypurine monophosphates IMP, GMP, XMP, dGMP, and dIMP 
so that their purine precursors can be exported from the cell (Brouwer, Vogels-Mentink 
et al. 2005). Regulating nucleotide levels within the cell is a very important process as 
shown by the multitude of diseases associated with altered nucleotide availability such 
as Lesch-Nyhan syndrome and adenylosuccinate lyase deficiency (Pesi, Micheli et al. 
2000, Jinnah, Sabina et al. 2013). The importance of NT5C2 activity is particularly 
apparent in hereditary spastic paraplegia, a rare neurodegenerative disease, which has 
been associated with loss of function mutations in NT5C2 (Darvish, Azcona et al. 2017, 
Elsaid, Ibrahim et al. 2017). 
 
In addition to regulating endogenous purine levels, NT5C2 also regulates metabolism of 
6-mercaptopurine and 6-thioguanine, two chemotherapies commonly used in the 
treatment of acute lymphoblastic leukemia (ALL). NT5C2 dephosphorylates and 
inactivates the cytotoxic thiopurine monophosphate nucleotides 6-thioinosine 
monophosphate (thio-IMP), 6-thioxanthine monophosphate (thio-XMP) and 6-
thioguanosine monophosphate (thio-GMP) into thiopurine nucleosides, which are then 
exported from the cell (Brouwer, Vogels-Mentink et al. 2005). Thus, NT5C2 plays a 
crucial role in regulating the efficacy of thiopurine therapy. In this context, gain of 
function NT5C2 mutations have been found in 20% of relapsed T-ALL and 3-10% of 
relapsed B-ALL cases and drive thiopurine chemotherapy resistance (Tzoneva, Perez-
Garcia et al. 2013, Tzoneva, Dieck et al. 2018). Additionally increased expression of 
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NT5C2 is associated with worse outcome in AML patients treated with cytarabine 
(Galmarini, Cros et al. 2005, Mitra, Crews et al. 2011). 
 
Activation and regulatory mechanisms controlling NT5C2 activity have been elucidated 
through extensive structure function analyses of NT5C2 WT and gain-of-function relapse 
ALL associated NT5C2 mutant proteins in basal and active configurations (Wallden, 
Stenmark et al. 2007, Wallden and Nordlund 2011, Hnizda, Skerlova et al. 2016, Dieck, 
Tzoneva et al. 2018, Hnizda, Fabry et al. 2018). Structurally, NT5C2 is a member of the 
haloacid dehalogenase (HAD) superfamily of Mg2+-dependent intracellular 5’-
nucleotidases (Koonin and Tatusov 1994) and functions as a homotetramer made up of 
a dimer of two tightly-associated dimers with the dimer being the smallest functional unit 
with enzymatic activity (Wallden, Stenmark et al. 2007). NT5C2 is inactive in basal 
conditions and is allosterically activated by ATP, dATP and diadenosine tetraphosphate 
(Ap4A) (Pinto, Canales et al. 1986, Spychala, Madrid-Marina et al. 1988, Marques, 
Teixeira et al. 1998). NT5C2 activation and inactivation is regulated by three structural 
regulatory elements; (i) the helix A allosteric response element (Gly355-Gln364) which is 
disordered in basal conditions, becomes ordered into an alpha helix (helix A) upon 
allosteric activation allowing for substrate binding and subsequent catalysis to occur 
(Wallden, Stenmark et al. 2007, Wallden and Nordlund 2011). Catalysis of the substrate 
proceeds via formation of a phosphoenzyme intermediate at Asp52 mediated by three 
conserved HAD motifs in the catalytic center (Collet, Stroobant et al. 1998, Allegrini, 
Scaloni et al. 2001). (ii) The second regulatory element consists of an intramolecular 
interaction between the tip of the arm region and inter-monomeric positively charged 
pocket, which work together to switch-off the enzyme: upon allosteric activation and 
substrate binding, the tip region of the flexible arm region of NT5C2 Glu373-Tyr434 
disengages from the neighboring monomer, travels down the intermonomeric cavity, 
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interacts with Lys361 and disrupts the stabilization of the helixA region returning the 
enzyme to an inactive, off, configuration. (iii) The third regulatory element is the stretch 
of 13 acidic amino acids at the C-terminus of NT5C2. These negatively charged residues 
sit in the positively charged intermonomeric space in the basal configuration and act as a 
blockade against allosteric activation (Dieck, Tzoneva et al. 2018).   
 
All three of these critical regulatory elements are coopted by relapse ALL associated 
NT5C2 mutant proteins to create gain-of-function enzymes that contribute to 
chemotherapy resistance. Class I NT5C2 mutations (NT5C2 K359Q and L375F) lock the 
allosterically activated helixA in a constitutively active configuration leading to continuous 
activation and substrate processing. Class II mutations which account for >95% of 
mutations (NT5C2 R39Q, R238W/L/G/Q, R367Q, S445F_R446Q, R478S, K404N, 404-
405insD, D407A/Y/E/H, S408R, P414S/A and D415G) lie in the intermonomeric pocket 
or arm region of NT5C2 and disrupt this intramolecular NT5C2 switch-off mechanism. 
Additionally, a single Class III C-terminus truncating mutant, NT5C2 Q523*, favors 
allosteric activation of NT5C2 due to the loss of a C-terminal acidic tail (Dieck, Tzoneva 
et al. 2018).  
 
As NT5C2 plays an important role in physiologic purine regulation as well as thiopurine 
metabolism and efficacy, it is a strong candidate for inhibitor development. Several 
groups have begun the process of identifying an inhibitor of NT5C2 using docking 
studies, virtual screening of chemical databases, and fragment based drug design 
(Nguyen, Devidas et al. 2008, Gallier, Lallemand et al. 2011, Jordheim, Marton et al. 
2013, Meurillon, Marton et al. 2014, Marton, Guillon et al. 2015), but none have yet 
shown efficacy in preclinical models. Recent studies have shown that the majority of 
relapse associated NT5C2 mutations which drive chemotherapy resistance retain the 
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ability to respond to allosteric activation, pointing to the allosteric effector site as a 
potentially attractive target for the design of small molecule NT5C2 inhibitors for the 
reversal of 6-MP resistance in relapsed ALL (Dieck, Tzoneva et al. 2018). Here we show 
the first stages of the development of a targeted inhibitor of NT5C2 for the reversal of 6-
MP resistance in NT5C2 mutant relapsed ALL. 
 
Results 
High-throughput inhibitor screen and HTP_2 validation 
To assess NT5C2 activity and screen for small molecule inhibitors in a high throughput 
manner, we developed a high throughput malachite green based nucleotidase assay. 
Assays were performed using NT5C2 R367Q recombinant protein as it represents the 
most frequent relapse ALL associated NT5C2 mutation (Tzoneva, Dieck et al. 2018). 
Briefly, purified recombinant NT5C2 R367Q is incubated with inosine monophosphate 
(IMP) as substrate for 15 minutes at 37ºC to allow the nucleotidase reaction to occur. 
The enzymatic reaction (IMPà Pi +inosine) is terminated by the addition of malachite 
green reagent. Colorimetric analysis of the malachite green reagent reaction with free 
phosphate (Pi) is measured after 15 minutes. The malachite green assay was optimized 
to meet NIH high throughput enzyme assay guidelines (Brooks, Geeganage et al. 2004) 
ensuring the assay is run at a linear initial velocity with substrate concentrations at or 





Figure 4.1 – Optimization of malachite green assay measuring NT5C2 R367Q conversion of 
inosine monophosphate (IMP) to inosine and phosphate. (a) Reaction progress curve of 
NT5C2 R367Q recombinant protein at five protein concentrations (b) Initial velocity versus 
substrate concentration of 0.02 µM NT5C2 R367Q recombinant protein with IMP as substrate. 
Vmax= 610 µM IMP/min, Km = 308 uM IMP. 
 
 
Using this optimized high throughput assay, we analyzed a diversity library of 60,640 
compounds curated by the Columbia University’s High Throughput Screen Facility in 
collaboration with Brent Stockwell. From the primary screen, 3 standard deviations away 
from the mean was used as a cutoff to select 225 compounds that had 33.21% inhibitory 
activity or higher. Following confirmatory assays and dose dependent curves, we 
identified a single lead compound with dose dependent NT5C2 R367Q low micromolar 
inhibitory activity, compound HTP_2 (Figure 4.2 a,b). To confirm the inhibitory activity of 
small molecule inhibitor, HTP_2 we resynthesized the compound at the Columbia 
University Probe Synthesis Facility and repeated malachite green nucleotidase assay 
analysis (Figure 4.2 c). Molecular docking analyses predict that HTP_2 binds to the 
active site of NT5C2 (Figure 4.2 d) and Biacore surface plasmon resonance binding 
studies confirm a dose dependent binding interaction of HTP_2 with NT5C2 R367Q 






Figure 4.2 – HTP_2 binds and inhibits NT5C2 R367Q. (a) Structure of HTP_2 (b) Malachite 
green assay of NT5C2 R367Q recombinant protein incubated with increasing concentrations of 
HTP_2 (c) Malachite green assay analysis of HTP_2 provided by Enamine or synthesized in 
house at the Columbia Probe Synthesis facility incubated with recombinant NT5C2 R367Q 
protein (d) Molecular docking of HPT_2 in the active site of the NT5C2 D52N R39Q crystal 
structure (e) Representative sensorgram for HTP_2 binding NT5C2 R367Q recombinant protein 
generated with Biacore surface plasmon resonance technology. Kd = 54.5 µM HTP_2. 
 
HTP_2 reverses 6-MP resistance in ALL lymphoblasts 
Activating relapse ALL associated NT5C2 mutations lead to increased 6-MP resistance 
due to increased processing and export of thiopurine cytotoxic metabolites resulting in 
less thioguanine nucleotide incorporation into DNA. We hypothesized that NT5C2 
inhibition should reverse this resistance mechanism and make 6-MP therapy more 
effective in NT5C2 mutant cells. Indeed when we treat NT5C2 R29Q mutant PEER and 
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BE13 human ALL cell lines with 6-MP and increasing doses of small molecule NT5C2 
inhibitor HTP_2, we see increased sensitivity to 6-MP chemotherapy (Figure 4.3 a). 
Interestingly, we also see similar increased 6-MP cytotoxicity in NT5C2 wild-type 
JURKAT and CUTLL1 human ALL cell lines suggesting inhibition of wild type NT5C2 as 
well as mutant NT5C2 may improve 6-MP cytotoxicity and be a useful therapy in the 
treatment of all ALLs, not just those harboring activating NT5C2 mutations (Figure 4.3 
b). This increased sensitivity to 6-MP in the presence of NT5C2 inhibitor HTP_2 was 
also evaluated in Nt5c2 WT (Nt5c2+/co-R367Q) and Nt5c2 mutant (Nt5c2+/R367Q) murine 
NOTCH1 driven ALL lymphoblasts and human cell lines overexpressing relapse 
associated NT5C2 mutations (Figure 4.3 c and d). Isobologram analyses further show 
combination therapy with 6-MP and small molecule NT5C2 inhibitor HTP_2 is synergistic 
in both Nt5c2 WT (Nt5c2+/co-R367Q) and Nt5c2 mutant (Nt5c2+/R367Q) mouse lymphoblasts 






Figure 4.3 – NT5C2 inhibitor HTP_2 sensitizes human and murine NT5C2 wildtype and 
mutant lymphoblasts to 6-MP chemotherapy. (a, b, c, d) Cell viability of (a) PEER and BE13 
NT5C2 mutant human ALL cell lines (b) JURKAT and CUTLL1 NT5C2 WT human ALL cell lines 
(c) Nt5c2 WT (Nt5c2+/co-R367Q) and Nt5c2 mutant (Nt5c2+/R367Q) mouse lymphoblasts and (d) 
CUTLL1 cell lines expressing NT5C2 WT and NT5C2 relapse associated NT5C2 mutations 
treated with 6-MP and increasing doses of HTP_2. (e) Isobologram analysis of Nt5c2 WT 
(Nt5c2+/co-R367Q) and Nt5c2 mutant (Nt5c2+/R367Q) mouse lymphoblasts treated with 6-MP, HTP_2, 
or a combination of 6-MP and HTP_2.  
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We repeated drug combination studies in NT5C2 knockout CUTLL1 cell lines generated 
using CRISPR/CAS9 technology (Figure 4.4 a). Consistent with the small molecule 
inhibition of NT5C2 studies, NT5C2 knockout cells showed increased sensitivity to 6-MP 
therapy (Figure 4.4 b). Additionally, NT5C2 knockout cells did not show further 
sensitization to 6-MP therapy upon addition of HTP_2 suggesting that this phenotype is 
directly related to NT5C2 activity and that HTP_2 is a specific inhibitor of NT5C2 (Figure 
4.4 b). Additional studies still need to be performed to assess whether HTP_2 binds to 




Figure 4.4 – NT5C2 Knockout cells show increased sensitivity to 6-MP. (a) Western blot 
analysis of CUTLL1 cells infected with NT5C2 gRNA CAS9 targeting constructs (NT5C2 KO) or 
CAS9 empty vector controls (NT5C2 WT). (b) Cell viability of CUTLL1 NT5C2 WT (left) and 
NT5C2 knockout (right) clones treated with increasing doses of 6-MP and 20 µM HTP_2. 
 
Toxicity evaluation of NT5C2 inhibition 
In developing a new inhibitor, it is necessary to consider potential therapeutic toxicities 
that may occur. In particular, NT5C2 loss of function mutations have been associated 
with a hereditary neurodegenerative disease, spastic paraplegia (SPG45) (Darvish, 
Azcona et al. 2017, Elsaid, Ibrahim et al. 2017), thus it is important to check the potential 
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toxicity of systemic NT5C2 inhibition. In efforts to assess NT5C2 inhibitor toxicity, we 
have generated NT5C2 knockout clones in the CUTLL1 T-ALL cell line using CRISPR 
Cas9 technology (Figure 4.4 a). NT5C2 wild-type and NT5C2 KO cells show no 
apparent growth or proliferation disparities suggesting that systemic administration of 
NT5C2 inhibitors could be fairly well tolerated. To further examine the potential toxicity of 
NT5C2 inhibitors, we have also generated an Nt5c2 knockout mouse line using CRISPR 
Cas9 technology (Figure 4.5). Nt5c2 knockout mice are viable, fertile, and have no 
apparent developmental delays in agreement with previously published work using a 




Figure 4.5 – NT5C2 knockout mouse generation and characterization. (a) Genomic map of 
Nt5c2 gRNA targeting in chromosome 19 of the mouse genome (b) Genotyping of Nt5c2 +/+, 
Nt5c2 +/- and Nt5c2 -/- mice. 
 
Discussion 
Thiopurine chemotherapy is the critical agent in a 2-3 year anti-metabolite maintenance 
regimen consisting of daily, oral 6-MP, given to ALL patients upon remission to prevent 
further leukemic growth (Pui and Evans 2006, Conter, Arico et al. 2010, Gaynon, 
Angiolillo et al. 2010, Schmiegelow, Forestier et al. 2010). Multiple studies have shown 
that patients with higher dose intensity of 6-MP have better event free survival and 
patients with <95% adherence to maintenance therapy are 2.5 times more likely to 
 101 
relapse (Relling, Hancock et al. 1999, Bhatia, Landier et al. 2012). Thus, 6-MP 
maintenance therapy is critical for improving event free survival in patients with ALL and 
this is dependent on chronic and continuous exposure to the drug over a long period of 
time. 
 
Although maintenance therapy has proven to be very successful, some patients do 
relapse during therapy suggesting mechanisms of resistance to 6-MP treatment. 
Deletions and decreased expression of MSH6 (MutS homolog 6) as well as mutations in 
PRPS1 have been associated with 6-MP resistance, yet the most frequent mechanism 
of thiopurine resistance in relapsed ALL cases is the presence of activating mutations in 
NT5C2 (Yang, Bhojwani et al. 2008, Meyer, Wang et al. 2013, Tzoneva, Perez-Garcia et 
al. 2013, Li, Li et al. 2015, Evensen, Madhusoodhan et al. 2018). Activating mutations in 
the NT5C2 gene are found in 20% of relapsed T-ALLs and 3-10% of relapsed B-ALLs 
and are particularly common amongst early relapse accounting for 35-45% of cases. As 
relapse associated NT5C2 mutations act as gain-of-function alleles with increased 
nucleotidase activity that lead to chemotherapy resistance, NT5C2 stands as a clear 
therapeutic target to prevent the emergence of these thiopurine resistant clones in 
relapsed ALL. 
 
Here we describe the identification of HTP_2, a small molecule inhibitor of NT5C2.  
HTP_2 shows low millimolar inhibitory activity against NT5C2 R367Q recombinant 
protein and reverses 6-MP resistance in mutant NT5C2 lymphoblasts. Additionally, we 
show that small molecule NT5C2 inhibitor HTP_2 also sensitizes NT5C2 wild-type cells 
to 6-MP chemotherapy. This data is consistent with unpublished work from Koichi 
Oshima identifying NT5C2 as one of the top CRISPR knockout sensitizing genes for 6-
MP sensitivity. This screen and the data shown here suggest that pan NT5C2 inhibition 
 102 
may be effective to reverse 6-MP resistance even in the absence of NT5C2 activating 
mutations and thus NT5C2 inhibitors may be useful in treating all leukemias that are at 
risk of developing thiopurine resistance.  
 
We have shown promising preliminary results with small molecule NT5C2 inhibitor 
HTP_2 here, yet HTP_2 is fairly insoluble and therefore very difficult to move forward 
into in vivo and clinical studies. Further testing and screening of HTP_2 analogues is 
necessary to identify NT5C2 inhibitors with increased solubility and increased potency 
against NT5C2. Upon identifying more soluble and potent inhibitors, co-crystallization 
studies will be critical for understanding the mechanism of inhibition and ways to further 
improve NT5C2 specificity and targeting. Additionally, HTP_2 and other inhibitors will 
need to be screened against other nucleotidase family member proteins to select for 
compounds with minimal off target effects.  
 
NT5C2 mutations are particularly common amongst early relapse patients still 
undergoing therapy suggesting that 6-MP based maintenance treatment creates an 
immense selective pressure towards the emergence of these mutations and subsequent 
relapse. The development of NT5C2 inhibitors and improved, personalized therapy 
regimens has the potential to improve the efficacy of ALL maintenance therapy by 
curtailing the emergence of NT5C2 mutant clones responsible for relapse. 
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Materials and Methods 
Drugs and Small-Molecule Compounds 
We purchased 6-mercaptopurine (6-MP), inosine 5’-monophosphate disodium salt 
hydrate and ATP from Sigma-Aldrich. For in vitro assays we dissolved 6-MP in DMSO 
and ATP in Tris gel filtration buffer (50 mM Tris-HCl, 100 mM NaCl, 10% Glycerol, 5 mM 
β-mercaptoethanol). HTP_2 was purchased from Enamine (cat# Z27358589) and 
dissolved in DMSO. 
Cell Culture 
We performed cell culture in a humidified atmosphere at 37ºC under 5% CO2. We 
purchased 293T cells for viral production from American Type Culture Collection (ATCC) 
and grew them in DMEM media supplemented with 10% fetal bovine serum (FBS), 100 
U ml–1 penicillin G and 100 µg ml–1 streptomycin for up to two weeks. The CUTLL1 cell 
line, which was generated by continuous culture of a T-cell lymphoblastic pleural 
effusion cells from a patient at relapse, has been characterized and reported before 
(Palomero, Barnes et al. 2006). We obtained REH and JURKAT cells from American 
Type Culture Collection (ATCC) and BE13 and PEER cells from Deutsche Sammlung 
von Mikroorganismen und Zellkulturen (DSMZ). We cultured CUTLL1 and REH cells in 
RPMI-1640 media supplemented with 10% FBS, 100 U ml–1 penicillin G and 100 µg ml–1 
streptomycin and BE13 and PEER cells in RPMI-1640 media supplemented with 20% 
FBS, 100 U ml–1 penicillin G and 100 µg ml–1 streptomycin. Cell lines were regularly 
authenticated and tested for mycoplasma contamination. Mouse Rosa26+/CreERT2 
Nt5c2+/co-R367Q T-ALL tumor cells were previously described (Tzoneva, Dieck et al. 2018), 
and were culture in OptiMEM media supplemented with 10% fetal bovine serum (FBS), 
100 U ml–1 penicillin G, 100 µg ml–1 streptomycin, 55 µM β-mercaptoethanol, and 10 ng 
ml-1 mouse IL7. 
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Plasmids and vectors 
We obtained the pET28aLIC (Plasmid #26094) and pL-CRISPR.efs.gfp (Plasmid 
#57818) plasmids from Addgene. We amplified the coding sequence of the NT5C2 
cDNA from pLOC-NT5C2 (Tzoneva, Perez-Garcia et al. 2013) and cloned it into the 
pET28aLIC vector using In-fusion cloning using the In-Fusion HD Cloning Kit (Clontech) 
following manufacturer guidelines. We generated lentiviral vectors expressing CAS9 and 
gRNAs targeting the exon 3 of murine Nt5c2 by cloning the corresponding gRNA 
oligonucleotides (Sigma-Aldrich) into pL-CRISPR.efs.gfp as reported (Shalem, Sanjana 
et al. 2014). NT5C2 R238W, K359Q, L375F, R367Q, and D407A mutations were cloned 
into the pLOC-NT5C2 plasmid (Tzoneva, Perez-Garcia et al. 2013) by site directed 
mutagenesis using the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene) 
according to manufacturer’s guidelines. 
Lentiviral production and infection 
We transfected lentiviral plasmids together with gag-pol (pCMV ΔR8.91) and V-SVG 
(pMD.G VSVG) expressing vectors into 293T cells using JetPEI transfection reagent 
(Polyplus). We collected viral supernatants after 48 h and used them to infect the 
CUTLL1 human cell line by spinoculation with 4 µg mL-1 Polybrene 
Infection/Transfection Reagent (Fisher Scientific). pLOC infected cells were selected 
with 10 days of Blasticidin treatment. 
Malachite green assay 
The malachite green enzymatic assay was adapted from a previously published protocol 
(Gallier, Lallemand et al. 2011) and optimized for NT5C2 R367Q enzyme kinetics. To 
optimize the assay, initial velocity and linear reaction conditions were performed 
following NIH enzyme assay guidelines (Brooks, Geeganage et al. 2004).   
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Briefly, 0.02 µM or 2.6 ng/mL purified recombinant NT5C2 R367Q protein was incubated 
with 100 µM inosine monophosphate (IMP) as substrate for 15 minutes at 37ºC. 
Enzymatic reaction (IMPà Pi +inosine) was terminated by addition of the malachite 
green reagent (Sigma Aldrich, MAK307). Colorimetric analysis of malachite green 
reaction with free phosphate (Pi) was measured after 15 minutes at 600 nM. Assays 
were performed in Tris gel filtration buffer (50 mM Tris-HCl, 100 mM NaCl, 10% 
Glycerol, 5 mM β-mercaptoethanol) with a final concentration of 10 mM MgCl2+. For 
assays with inhibitors or small molecule compounds, compounds dissolved in DMSO 
were added to the protein and incubated for 10 minutes at room temperature prior to 
adding IMP substrate.  
High-throughput inhibitor screen 
Screening procedure was performed on Cell:Explorer robotic station (Perkin Elmer) 
using the following modules: Janus liquid handling platform with NanoHead, FlexDrop 
liquid dispenser, Liconic microplate hotel, Liconic 500 microplate incubator (+37C), 
Envision plate reader. Briefly, 20 µL of 0.4 µM NT5C2 R367Q recombinant protein in 
Tris Gel Filtration Buffer or buffer alone controls were plated in clear bottom low binding 
black 384 well microplates (Greiner, Cat No 781906). Compounds from the Enamine 
library (see below) were then delivered to the plates by the NanoHead from 10mM stock 
library microplates to a final concentration of 100 nM. Plates were then incubated at 
room temperature in the Liconic hotel for 10 minutes. 20 µL of 200 mM Inosine 
monophosphate (IMP), substrate, were added to the wells with the Flexdrop and plates 
were incubated at 37oC in the Liconic incubator for 15 minutes. Following incubation, 5 
µL of the malachite green reagent (Sigma, Cat No MAK-307) was added to all of the 
wells. Plates were incubated in the Liconic hotel for 15 minutes and then read on an 
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Envision plate reader at 650 nM. MgCl2+ was added to all buffers for a final concentration 
of 10 mM in the assay. 
Enamine Library 
The Enamine Library consists of 60,640 compounds filtered for traditional 
physicochemical descriptors such as the rule of five, rotatable bond count, topological 
polar surface, and suitable aqueous solubility. The Enamine library was curated by 
assigning a score for each compound relative to the calculated value in relationship to a 
standard value using a method similar to Bickerton et al (Bickerton, Paolini et al. 2012). 
For example the number of rotatable bonds was calculated for each compound, then 
using a standard value of 6, deviations from that value are penalized based on distance 
from 6. After all criteria are calculated, the distribution of scores is then used to stratify 
the population with the highest scoring compounds being eliminated. The resulting 
compounds were clustered and two compounds from each cluster were selected for 
purchase. 
Analysis 
In screening the Enamine library, each plate had two columns for a non-treatment 
control containing all elements of the assay without the addition of library compounds 
and two columns serving as negative controls that had neither substrate nor drugs 
added. The raw data for all compound containing wells were normalized to the average 
of all the wells screened. From the primary screen, 3 standard deviations away from the 
mean was used as a cutoff to select 225 compounds that had 33.21% inhibitory activity 
or higher. Next, those 225 compounds were subject to confirmatory assay by cherry-
picking them from the original library and testing again in the same assay. Out of 225 
compounds 28 were confirmed. Next, we chose 6 compounds, which showed best 
inhibition and tested them in dose-response curves.  
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HTP_2 synthesis 
HTP_2 was synthesized as shown in the Scheme. Compound 1 was treated with thionyl 
chloride in toluene at 100oC to give the corresponding acid chloride 2. Reaction of 2 with 
the amine 3 in DMF in the presence of Hunig’s base gave HTP_2 after purification by 




NT5C2 recombinant protein purification 
For 5’-nucleotidase assays in the absence and presence of allosteric activators we 
cloned, expressed and purified recombinant wild-type and mutant NT5C2 proteins as 
previously described (Dieck, Tzoneva et al. 2018). Briefly, we cloned full-length NT5C2 
cDNA constructs with an N-terminal hexahistidine (His6) tag in the pET28a-LIC 
expression vector. We expressed recombinant proteins from Rosetta 2(DE3) 
Escherichia coli cells by induction with 0.5 mM isopropyl-β-D-thiogalactopyranoside 
overnight at 16 °C. We resuspended harvested cells in lysis buffer (50 mM Tris-HCl pH 
7.4, 500 mM sodium chloride, 10% glycerol, 0.5 mM TCEP, 20 mM imidazole) 
supplemented with Complete EDTA-free protease inhibitor (Roche) and lysed cells by 
sonication. We purified recombinant proteins using an ӒKTA fast protein liquid 
chromatography system (GE Healthcare) using a 2-step protocol adapted from one 
previously described (Wallden, Stenmark et al. 2007). We first performed affinity 
chromatography using a 1 ml Ni2+-charged His-Trap HP column (GE Healthcare) 
equilibrated in lysis buffer. We eluted NT5C2 proteins from the His-Trap column in a 
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the buffer ratio to 25% elution buffer for 8 column volumes and then switching to a linear 
gradient to 100% elution buffer over 10 column volumes. We pooled NT5C2-containing 
fractions and purified further by size exclusion chromatography using a HiLoad 16/60 
Superdex 200 gel filtration column (GE Healthcare) equilibrated in 50 mM Tris-HCl, pH 
7.4, 100 mM NaCl, 10% glycerol and 0.5 mM TCEP. 
In vitro cell viability and chemotherapy response assays 
We analyzed chemotherapy responses of human leukemia cell lines or murine mouse 
lymphoblasts following 72-hour incubation with increasing concentrations of 6-
mercaptopurine or HTP_2 by measurement of the metabolic reduction of the tetrazolium 
salt MTT using the Cell Proliferation Kit I (Roche) following the manufacturer’s 
instructions. Isobologram synergy assays where performed as above with 6-MP, HTP_2 
or the combination of 6-MP and HTP_2 at a consistent ratio. 
Nt5c2 KO mouse generation 
Nt5c2 knockout mice were generated using CRISPR-Cas9 technology (Wang, Yang et 
al. 2013). Single guide RNAs (sgRNAs) were designed in exon 13 and intron 11-12 of 
the murine Nt5c2 on chromosome 19 (Figure 4.5), evaluated for potential off-targets 
using E-CRISPR (Deutsches Krebsforschungszentrum) (Heigwer, Kerr et al. 2014), and 
purchased (Synthego, Redwood City, CA). Fertilized eggs were collected from the 
oviducts of superovulated B6CBAF1 female mice that had mated with B6CBAF1 stud 
males. 100 ng/µL of Cas9 mRNA (TriLink Biotechnologies L-6125) and 50 ng/µL of 
sgRNA were mixed and injected into zygotes at the pronuclei stage in M2 medium 
(Sigma M7167). After injection, eggs were transferred into the oviducts of Swiss Webster 
foster females. Genotyping of newly generated mice was performed by Nt5c2 PCR 
amplification using KAPA HiFi HotStart ReadyMix and running PCR products on a 1.5% 
agarose gel. The wild-type band is detected at ~1000bp and the deletion band is 
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detected at ~500bp (Forward primer: CTCTGGGATGAGCTGAGAGG; Reverse primer: 
CCACCAAAGGTACCATGACC). We maintained all animals in specific pathogen-free 
facilities at the Irving Cancer Research Center at Columbia University Medical Campus. 
The Columbia University Institutional Animal Care and Use Committee (IACUC) 
approved all animal procedures. Animal experiments were conducted in compliance with 
all relevant ethical regulations. 
CRISPR/CAS9 NT5C2 Knockout in ALL cell lines 
CUTLL1 cells were infected with pL-CRISPR.efs.gfp lentiviral particles containing an 
Nt5c2 exon 3 targeted sgRNA (GCAAAGCTGAGCAACTCCTG) or empty vector 
controls. We sorted infected cells based on GFP expression using a SONY SH800S cell 
sorter (SONY) and subsequently grew single cell clones. NT5C2 knockout was 
confirmed per clone via western blot analysis. 
Western blot analysis 
Cells were lysed in RIPA buffer, cleared of cell debris and boiled with 1x SDS-loading 
buffer. BCA protein quantification was performed according to manufacturer guidelines 
(BCA Protein Assay Kit, Fisher Scientific) and equal amounts of lysate were loaded onto 
a 7% Tris-acetate gel (Life technologies), separated by SDS PAGE, and transferred to a 
nitrocellulose membrane for western blot analysis. We detected NT5C2 with a mouse 
anti-NT5C2 antibody (Sigma Aldrich # WH0022978M2) and β-actin with a mouse 
monoclonal anti-β-actin antibody (Sigma Aldrich # A5441). 
HTP_2 Docking 
Schrodinger Maestro was used for docking HTP_2 into the ligand binding site of NT5C2 
R39Q (PDB: 6DDQ). LigPrep was used to generate energy minimized 3D molecular 
ligands of HTP_2 optimized for docking using Glide. The OPLS3 force field was used 
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and ionization states at pH 7.0 +/- 2.0 were generated as well as tautomers. Protein 
Preparation Wizard was used to convert the PDB structure NT5C2 R39Q (PDB: 6DDQ) 
to an all-atom, fully prepared protein models for use in Glide. HET states were generated 
using Epik at pH 7.0 +/- 2.0. Hydrogen bonds were assigned using PROPKA at pH 7.0. 
A restrained protein minimization was run using the OPLS3 force field. A receptor grid 
was generated in the prepared protein centered on the ligand binding site of NT5C2. 
Computation docking was done with Schrodinger Glide using the ligand structures from 
LigPrep and the receptor grid generated on the protein optimized using Protein 
Preparation Wizard. Standard precision docking was used with flexible ligand sampling. 
GlideScores were generated for each ligand-receptor docking. GlideScore is an 
empirical scoring function indicative of binding affinity and comprised of terms that 
account for lipophilic-lipophilic interactions, hydrogen bonds, rotatable bond penalties, 
and contributions from protein-ligand coulomb-vdW energies. Lower GlideScores 
indicate stronger binding. 
Biacore Assay 
A Biacore X100 surface plasmon resonance system (GE Healthcare) was used to test 
the binding kinetics of small molecule inhibitor HTP_2 with NT5C2 R367Q recombinant 
protein. NT5C2 R367Q protein was immobilized by covalent binding via amino group on 
a sensor chip, CM-5, at concentration 100 µg/ml with a final binding of 111136 RU 
(Response Units). Each small molecule compound was diluted in running buffer to 100 
µM. Rmax was calculated based on the molecular weight of the protein and compounds, 
and the amount of protein we used for the binding analysis.  
 
Rmax  =  the amount of protein immobilized in RU 
            MW of protein * MW of small molecule 
 
 111 
Evaluation software was used to calculate the Kd for the small molecule: protein binding 
affinity.  
Quantification and statistical analyses 
We performed statistical analysis by Student’s t-test. We considered results with P < 




Chapter 5: Conclusions  
  
 
Despite improved therapy regimens, 20% of pediatric and 50% of adult ALL patients fail 
to achieve remission and end up relapsing. Here we show an in-depth analysis of the 
role of NT5C2 mutations in chemotherapy resistance and emergence of therapy 
resistant clones in relapsed ALL. 
 
With extensive structure-function analyses of NT5C2 wild-type and relapse associated 
NT5C2 mutant proteins, we identified three critical regulatory elements that control 
NT5C2 activation and inactivation: (i) the helix A allosteric response element, (ii) an 
intramolecular, arm region mediated, switch off mechanism, and (iii) the c-terminus 
allosteric activation blockade. Each of these regulatory elements is disrupted in relapse 
associated NT5C2 mutations leading to increased nucleotidase activity and subsequent 
chemotherapy resistance when expressed in ALL cells. Importantly, these analyses 
identified that the majority of NT5C2 relapse associated mutant proteins, retain the 
ability to bind and respond to allosteric activators identifying a potential therapeutic 
target for the development of NT5C2 inhibitors.   
 
Moving forward, it will be important to continue to further our understanding of how 
NT5C2 is regulated to identify additional mechanisms of chemotherapy resistance. In 
addition to looking at direct structure-function relationships, it may be interesting to look 
at levels of NT5C2 regulation at transcriptional and post-translational levels.  
Unpublished work has identified four post-translation modifications present on NT5C2.  
Additional studies are needed to explore the regulatory capacity of these modifications, 
but preliminary results suggest that a phosphorylation at Ser502 of NT5C2 leads to 
increased nucleotidase activity (Appendix 1.1). This identifies an additional activation 
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mechanism that may be altered to induce thiopurine resistance in relapsed ALL and thus 
should be further explored. 
 
In addition to understanding the role of NT5C2 mutations on a structural level, we also 
present here data on the clonal evolution of NT5C2 relapse associated mutations in 
relapsed ALL. We generated a knock-in mouse model (Nt5c2+/co-R367Q) with conditional 
expression of Nt5c2R367Q, the most common NT5C2 mutation found in relapsed ALL, and 
generated primary NOTCH1-induced Rosa26+/CreERT2 Nt5c2+/co-R367Q T-ALL tumors. Using 
this model, we saw overt resistance to 6-MP in Nt5c2+/R367Q mutant leukemias, and were 
surprised to find that this chemotherapy resistance phenotype came at the cost of 
impaired cell fitness and leukemia initiating cell activity. Nt5c2+/R367Q mutant cells show 
increased export of purines to the extracellular space and depletion of the intracellular 
purine nucleotide pool, resulting in delayed cell growth and proliferation. Despite this 
impaired fitness, Nt5c2+/R367Q mutant cells are positively selected over isogenic Nt5c2+/co-
R367Q wild type cells in mixed tumor populations in response to 6-MP chemotherapy in 
vitro and in vivo (Tzoneva, Dieck et al. 2018). Thus, thiopurine treatment selects for 
NT5C2 gain of function mutations as key evolutionary drivers shaping the clonal 
evolution of relapsed ALL. This data along with the fact that 6-MP is a major component 
of maintenance therapy for ALL patients, that NT5C2 mutations frequently occur in early 
relapse and the recent identification of NT5C2 mutations in relapsed APL patients 
treated with 6-MP (Lehmann-Che, Bally et al. 2018) suggest that thiopurine therapy 
creates an immense selective pressure towards the emergence of these mutations and 
subsequent relapse. 
 
Improving the outcomes of patients with relapsed ALL will involve further understanding 
of the genetic variants and mechanisms by which relapse clones acquire therapy 
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resistance. In discovering the fitness cost associated with relapse associated NT5C2 
mutations, we revealed a weak point in relapsed NT5C2 mutant ALL we could use to 
further target mutant cells. Given their increased dependence on purine synthesis, 
NT5C2 mutant cells are particularly sensitive to the inosine monophosphate 
dehydrogenase (IMPDH) inhibitor, mizoribine, which further blocks guanosine production 
in the cells leading to selective cytotoxicity in NT5C2 mutant lymphoblasts (Tzoneva, 
Dieck et al. 2018). Identifying further synthetic lethalities in NT5C2 mutant cells and 
other drug resistant ALL populations will aid in developing multi-agent chemotherapy 
regimens to target relapse ALL with specific genetic vulnerabilities.  
 
In addition to finding collateral sensitivities to continue to target NT5C2 mutations in 
relapsed ALL, the development of potent NT5C2 inhibitors may provide useful 
therapeutic options for the treatment of relapsed ALL and other diseases associated with 
increased nucleotidase activity such as Lesch-Nyhan syndrome (Pesi, Micheli et al. 
2000). Here we identify a small molecule inhibitor of NT5C2, HTP_2, which shows low 
millimolar inhibitory activity in in vitro enzymatic assays on NT5C2 R367Q recombinant 
protein. Importantly HTP_2 synergizes with 6-MP chemotherapy working to reverse 6-
MP resistance in NT5C2 mutant cell lines. NT5C2 small molecule inhibitor HTP_2 also 
yields increased sensitivity to 6-MP in NT5C2 wild-type cells suggesting that NT5C2 
inhibition may prove to be a useful therapeutic for the treatment of all ALLs and not just 
those harboring NT5C2 mutations. HTP_2 requires additional optimization to improve 
target potency and solubility to move forward in preclinical in vivo models.  
 
Continued studies to identify drivers of chemotherapy resistance are integral to our 
understanding of relapsed ALL. Along with NT5C2 mutations, other groups have 
identified mutations in CREBBP and PRPS1 as relapse specific variants that drive 
 115 
glucocorticoid and thiopurine resistance respectively (Mullighan, Zhang et al. 2011, Mar, 
Bullinger et al. 2014, Li, Li et al. 2015). Additional mechanistic analyses and further 
understanding of the role of NT5C2 and these other genes in relapsed leukemia will be 
critical for improving the outcome of patients with relapsed ALL. Additionally, further 
development of the small molecule NT5C2 inhibitor HTP_2 may prove useful in treating 
relapse ALL patients harboring NT5C2 mutant alleles. Many targeted and personalized 
therapies have shown to be successful in the treatment of diseases over the past few 
decades and further development of targeted NT5C2 therapeutics has the potential to 
improve the efficacy of ALL maintenance therapy by curtailing the emergence of NT5C2 
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Appendix 1.1 – NT5C2 S502phosphorylation displays resistance to 6-MP and increased 
nucleotidase activity. (a) Post-translational modifications identified with mass spectrometry 
analysis of a tandem affinity pulldown from FLAG-HA NT5C2 expressing cells. (b) Cell viability 
assays of JURKAT T-ALL cell lines expressing NT5C2 Ser502 phospho-mimic or phospho-
resistant proteins or wild type controls with increasing amounts of 6-MP. (c) In vitro nucleotidase 
activity of NT5C2 WT or NT5C2 S502D phospho-mimic or NT5C2 S502A phospho-resistant 
recombinant protein. 
 
